<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC2019_S02_C20_IDX_p517_550_9P</title>
		<link href="BCSC2019_S02_C20_IDX_p517_550_9P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC2019_S02_C20_IDX_p517_550_9P" lang="en-US">
		<div id="_idContainer000" class="Basic-Text-Frame">
			<p class="em-only_endmatter-title ParaOverride-1">Index</p>
			<p class="em-only_endmatter-idx1">(<span class="endmatter-idx1_italic">f</span> <span class="endmatter-idx1_symbol">=</span> figure; <span class="endmatter-idx1_italic">t</span> <span class="endmatter-idx1_symbol">=</span> &#173;table)</p>
			<p class="em-only_endmatter-idx1">A-&#173;scan ultrasound/ultrasonography, 463<span class="endmatter-idx1_italic">t,</span> 463<span class="endmatter-idx1_italic">f,</span> 463–464</p>
			<p class="em-only_endmatter-idx1">AAO Task Force on Ge&#173;ne&#173;tic Testing, 240–241</p>
			<p class="em-only_endmatter-idx1">Abatacept, 406<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">ABCA4, 308, 326, 328</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">ABCR</span> gene, 328</p>
			<p class="em-only_endmatter-idx1">Abducens nerve</p>
			<p class="em-only_endmatter-idx2">anatomy of, 107<span class="endmatter-idx2_italic">f,</span> 133</p>
			<p class="em-only_endmatter-idx2">palsy of, 475<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Abetalipoproteinemia, 236</p>
			<p class="em-only_endmatter-idx1">ACAID. <span class="endmatter-idx1_italic">See</span> Anterior chamber–&#173;associated immune deviation</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Acanthamoeba</span> infections, 437</p>
			<p class="em-only_endmatter-idx1">Accessory ophthalmic artery, 23<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Accommodation</p>
			<p class="em-only_endmatter-idx2">in &#173;children, 79</p>
			<p class="em-only_endmatter-idx2">direct-&#173;acting cholinergic agonists’ effect on, 375</p>
			<p class="em-only_endmatter-idx1">Accommodative esotropia, 379</p>
			<p class="em-only_endmatter-idx1">Accommodative power, 79</p>
			<p class="em-only_endmatter-idx1">Acetazolamide, 362, 391<span class="endmatter-idx1_italic">t,</span> 392</p>
			<p class="em-only_endmatter-idx1">Acetazolamide sodium, 391<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Acetylcholine</p>
			<p class="em-only_endmatter-idx2">degradation of, 377<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">intracameral use of, 360<span class="endmatter-idx2_italic">t,</span> 375–376</p>
			<p class="em-only_endmatter-idx2">synthesis of, 377<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Acetylcholine receptors, 374, 374<span class="endmatter-idx1_italic">f,</span> 375<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Acetylcholinesterase, 375–376, 377<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Acetylcysteine, 371<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Acetyltransferase, 233</p>
			<p class="em-only_endmatter-idx1">Achromatopsia, 229</p>
			<p class="em-only_endmatter-idx1">Actin, 285</p>
			<p class="em-only_endmatter-idx1">Acular. <span class="endmatter-idx1_italic">See</span> Ketorolac tromethamine</p>
			<p class="em-only_endmatter-idx1">Acular&#160;LS.&#160;<span class="endmatter-idx1_italic">See</span> Ketorolac tromethamine</p>
			<p class="em-only_endmatter-idx1">Acular&#160;PF.&#160;<span class="endmatter-idx1_italic">See</span> Ketorolac tromethamine</p>
			<p class="em-only_endmatter-idx1">Acuvail. <span class="endmatter-idx1_italic">See</span> Ketorolac tromethamine</p>
			<p class="em-only_endmatter-idx1">Acyclovir sodium, 432<span class="endmatter-idx1_italic">t,</span> 433–434</p>
			<p class="em-only_endmatter-idx1">Adalimumab, 405<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Adenine, 176</p>
			<p class="em-only_endmatter-idx1">Adeno-&#173;associated virus vectors, 194, 196</p>
			<p class="em-only_endmatter-idx1">Adenosine triphosphate, 287, 290<span class="endmatter-idx1_italic">f,</span> 311</p>
			<p class="em-only_endmatter-idx1">Adenoviral conjunctivitis, 38</p>
			<p class="em-only_endmatter-idx1">Adenylate cyclase, 385</p>
			<p class="em-only_endmatter-idx1">Adie tonic pupil, pilocarpine for diagnosis of, 377</p>
			<p class="em-only_endmatter-idx1">Adrenergic agonists</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_greek">α</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">1</span>-&#173;, direct-&#173;acting, 384</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_greek">α</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">2</span>-&#173;, 385–386</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_accent">β</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">2</span>-&#173;, 385<span class="endmatter-idx2_italic">t,</span> 387–389</p>
			<p class="em-only_endmatter-idx2">indirect-&#173;acting, 387</p>
			<p class="em-only_endmatter-idx1">Adrenergic drugs</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_accent">β</span>-&#173;, 387–390, 389<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">overview of, 382, 384</p>
			<p class="em-only_endmatter-idx1">Adrenergic receptors</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_greek">α</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">1</span>, 382</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_greek">α</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">2</span>, 382</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_accent">β</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">1</span>, 382</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_accent">β</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">2</span>, 382</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_accent">β</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">3</span>, 382</p>
			<p class="em-only_endmatter-idx2">categories of, 382</p>
			<p class="em-only_endmatter-idx2">sites of, 382, 384</p>
			<p class="em-only_endmatter-idx1">Advanced glycation end products (AGEs), 345</p>
			<p class="em-only_endmatter-idx1">Aflibercept, 449</p>
			<p class="em-only_endmatter-idx1">Age-&#173;Related Eye Disease Study (AREDS), 340, 346</p>
			<p class="em-only_endmatter-idx1">Age-&#173;related macular degeneration (AMD)</p>
			<p class="em-only_endmatter-idx2">genome-&#173;wide association studies for, 193</p>
			<p class="em-only_endmatter-idx2">indocyanine green applications in, 444</p>
			<p class="em-only_endmatter-idx2">Manhattan plot for, 193<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">neovascular, 449</p>
			<p class="em-only_endmatter-idx2">oxidative stress in, 345</p>
			<p class="em-only_endmatter-idx2">vascular endothelial growth &#173;factor inhibitors for, <br />449</p>
			<p class="em-only_endmatter-idx1">AGEs. <span class="endmatter-idx1_italic">See</span> Advanced glycation end products</p>
			<p class="em-only_endmatter-idx1">Agonists</p>
			<p class="em-only_endmatter-idx2">definition of, 367</p>
			<p class="em-only_endmatter-idx2">direct-&#173;acting</p>
			<p class="em-only_endmatter-idx3">acetylcholine, 375–377</p>
			<p class="em-only_endmatter-idx3">actions of, 375</p>
			<p class="em-only_endmatter-idx3">adverse effects of, 378</p>
			<p class="em-only_endmatter-idx3">indications for, 378</p>
			<p class="em-only_endmatter-idx3">pilocarpine, 377–378</p>
			<p class="em-only_endmatter-idx2">indirect-&#173;acting, 379</p>
			<p class="em-only_endmatter-idx2">mechanism of action, 374–375</p>
			<p class="em-only_endmatter-idx2">muscarinic</p>
			<p class="em-only_endmatter-idx3">adverse effects of, 378</p>
			<p class="em-only_endmatter-idx3">direct-&#173;acting, 375–379, 376–377<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">indirect-&#173;acting, 379</p>
			<p class="em-only_endmatter-idx2">types of, 376<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Aicardi syndrome, 210</p>
			<p class="em-only_endmatter-idx1">Air–&#173;eye interface, 249, 249<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ak-&#173;Cide. <span class="endmatter-idx1_italic">See</span> Prednisolone sodium phosphate/sulfacetamide sodium</p>
			<p class="em-only_endmatter-idx1">Ak-&#173;Con. <span class="endmatter-idx1_italic">See</span> Naphazoline hydrochloride</p>
			<p class="em-only_endmatter-idx1">AK-&#173;Dilate. <span class="endmatter-idx1_italic">See</span> Phenylephrine hydrochloride</p>
			<p class="em-only_endmatter-idx1">AK-&#173;Pentolate. <span class="endmatter-idx1_italic">See</span> Cyclopentolate hydrochloride</p>
			<p class="em-only_endmatter-idx1">Ak-&#173;Poly-&#173;Bac. <span class="endmatter-idx1_italic">See</span> Polymyxin B sulfate/bacitracin zinc</p>
			<p class="em-only_endmatter-idx1">Ak-&#173;Spore. <span class="endmatter-idx1_italic">See</span> Hydrocortisone/neomycin sulfate/polymyxin B sulfate/bacitracin zinc</p>
			<p class="em-only_endmatter-idx1">Ak-&#173;Tob. <span class="endmatter-idx1_italic">See</span> Tobramycin sulfate</p>
			<p class="em-only_endmatter-idx1">Ak-&#173;Tracin. <span class="endmatter-idx1_italic">See</span> Bacitracin zinc</p>
			<p class="em-only_endmatter-idx1">Ak-&#173;Trol. <span class="endmatter-idx1_italic">See</span> Dexamethasone/neomycin sulfate/polymyxin B sulfate</p>
			<p class="em-only_endmatter-idx1">Alamast. <span class="endmatter-idx1_italic">See</span> Pemirolast potassium</p>
			<p class="em-only_endmatter-idx1">Alaway. <span class="endmatter-idx1_italic">See</span> Ketotifen fumarate</p>
			<p class="em-only_endmatter-idx1">Albalon. <span class="endmatter-idx1_italic">See</span> Naphazoline hydrochloride</p>
			<p class="em-only_endmatter-idx1">Albinism</p>
			<p class="em-only_endmatter-idx2">description of, 205</p>
			<p class="em-only_endmatter-idx2">enzymes that cause, 204<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">oculocutaneous, 78, 215, 229</p>
			<p class="em-only_endmatter-idx1">Albumin, serum, 298</p>
			<p class="em-only_endmatter-idx1">Alcaftadine, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Alcaine. <span class="endmatter-idx1_italic">See</span> Proparacaine</p>
			<p class="em-only_endmatter-idx1">Aldehyde dehydrogenase, 260</p>
			<p class="em-only_endmatter-idx1">Aldose reductase, 289–290</p>
			<p class="em-only_endmatter-idx1">Alkaptonuria, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Alkylating agents, 404<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">All-<span class="endmatter-idx1_italic">trans</span>-retinal, 308, 326</p>
			<p class="em-only_endmatter-idx1">All-&#173;<span class="endmatter-idx1_italic">trans</span>-&#173;retinaldehyde, 308, 326</p>
			<p class="em-only_endmatter-idx1">Allele-&#173;specific marking, 180</p>
			<p class="em-only_endmatter-idx1">Alleles</p>
			<p class="em-only_endmatter-idx2">definition of, 214</p>
			<p class="em-only_endmatter-idx2">in&#173;de&#173;pen&#173;dent assortment of, 175</p>
			<p class="em-only_endmatter-idx1">Allergic conjunctivitis, 411–412, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Alocril. <span class="endmatter-idx1_italic">See</span> Nedocromil sodium</p>
			<p class="em-only_endmatter-idx1">Alomide. <span class="endmatter-idx1_italic">See</span> Lodoxamide tromethamine</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">α</span>-&#173;Adrenergic drugs</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_greek">α</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">2</span>-&#173;adrenergic agonists, 385–386</p>
			<p class="em-only_endmatter-idx2">direct-&#173;acting <span class="endmatter-idx2_greek">α</span><span class="endmatter-idx1_subscript _idGenCharOverride-1">1</span>-&#173;adrenergic agonists, 384</p>
			<p class="em-only_endmatter-idx2">indirect-&#173;acting, 387</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">α</span><span class="endmatter-idx1_subscript _idGenCharOverride-1">1</span>-&#173;Adrenergic receptors, 382</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">α</span><span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span>-&#173;Adrenergic receptors</p>
			<p class="em-only_endmatter-idx2">description of, 382</p>
			<p class="em-only_endmatter-idx2">ligand binding to, 385</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">α</span><span class="endmatter-idx1_subscript _idGenCharOverride-1">1</span>-&#173;Antitrypsin, 276</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">α</span>-&#173;<span class="SC">L</span>-&#173;iduronidase, 214</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">α</span><span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span>-&#173;Macroglobulin, 276</p>
			<p class="em-only_endmatter-idx1">Alphagan&#160;P.&#160;<span class="endmatter-idx1_italic">See</span> Brimonidine tartrate</p>
			<p class="em-only_endmatter-idx1">Alport syndrome, pleiotropism in, 220</p>
			<p class="em-only_endmatter-idx1">Alrex. <span class="endmatter-idx1_italic">See</span> Loteprednol etabonate</p>
			<p class="em-only_endmatter-idx1">Altacaine. <span class="endmatter-idx1_italic">See</span> Tetracaine</p>
			<p class="em-only_endmatter-idx1">Altafrin. <span class="endmatter-idx1_italic">See</span> Phenylephrine hydrochloride</p>
			<p class="em-only_endmatter-idx1">Alternative splicing, 179</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Alu</span> sequence, 177</p>
			<p class="em-only_endmatter-idx1">Amacrine cells, 316</p>
			<p class="em-only_endmatter-idx1">Amaurosis fugax, 474<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">AMD.&#160;<span class="endmatter-idx1_italic">See</span> Age-&#173;related macular degeneration</p>
			<p class="em-only_endmatter-idx1">Amikacin, 425</p>
			<p class="em-only_endmatter-idx1">Amikacin sulfate, 418<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Aminoglycosides, 425–426</p>
			<p class="em-only_endmatter-idx1">Amniocentesis, 239</p>
			<p class="em-only_endmatter-idx1">Amoxicillin, 419</p>
			<p class="em-only_endmatter-idx1">Amphotericin&#160;B, 429, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ampicillin sodium, 418<span class="endmatter-idx1_italic">t,</span> 419</p>
			<p class="em-only_endmatter-idx1">Anaphase, 174, 174<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anaphylactoid reactions, 417</p>
			<p class="em-only_endmatter-idx1">Ancobon. <span class="endmatter-idx1_italic">See</span> Flucytosine</p>
			<p class="em-only_endmatter-idx1">Anestacaine. <span class="endmatter-idx1_italic">See</span> Lidocaine</p>
			<p class="em-only_endmatter-idx1">Anesthetics, local</p>
			<p class="em-only_endmatter-idx2">composition of, 438</p>
			<p class="em-only_endmatter-idx2">intraocular surgery use of, 441–442</p>
			<p class="em-only_endmatter-idx2">mechanism of action, 439</p>
			<p class="em-only_endmatter-idx2">overview of, 437–440</p>
			<p class="em-only_endmatter-idx2">peribulbar anesthesia, 442</p>
			<p class="em-only_endmatter-idx2">regional anesthetics, 438<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">retrobulbar anesthesia, 442</p>
			<p class="em-only_endmatter-idx2">topical, 439<span class="endmatter-idx2_italic">t,</span> 439–440, 441–442</p>
			<p class="em-only_endmatter-idx2">toxic manifestations of, 439</p>
			<p class="em-only_endmatter-idx2">types of, 440–441</p>
			<p class="em-only_endmatter-idx1">Aneuploidy, of autosomes, 222–224</p>
			<p class="em-only_endmatter-idx1">Angelman syndrome, 180–181</p>
			<p class="em-only_endmatter-idx1">Angiogenesis, vitreous effects on, 301</p>
			<p class="em-only_endmatter-idx1">Angular artery, 23<span class="endmatter-idx1_italic">f,</span> 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Angular vein, 26<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anidulafungin, 431, 431<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Aniridia, 206, 225</p>
			<p class="em-only_endmatter-idx1">Annulus of Zinn, 11, 17–18<span class="endmatter-idx1_italic">f,</span> 18, 20<span class="endmatter-idx1_italic">f,</span> 113–114, 125<span class="endmatter-idx1_italic">f,</span> 128</p>
			<p class="em-only_endmatter-idx1">Antagonists</p>
			<p class="em-only_endmatter-idx2">cholinergic, 380–381</p>
			<p class="em-only_endmatter-idx2">definition of, 367</p>
			<p class="em-only_endmatter-idx2">muscarinic, 380–381</p>
			<p class="em-only_endmatter-idx2">nicotinic, 382, 383<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Anterior ce&#173;re&#173;bral artery, 139<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior chamber</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48<span class="endmatter-idx2_italic">f,</span> 59–62<span class="endmatter-idx2_italic">f,</span> 59–63</p>
			<p class="em-only_endmatter-idx2">aqueous humor of, 59</p>
			<p class="em-only_endmatter-idx2">depth of, 48, 59</p>
			<p class="em-only_endmatter-idx2">development of, 161, 161<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">dimensions of, 49<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">dysgenesis of, 161</p>
			<p class="em-only_endmatter-idx2">structures of, 59–62<span class="endmatter-idx2_italic">f,</span> 59–63</p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 60<span class="endmatter-idx2_italic">f,</span> 471–472<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">volume of, 48</p>
			<p class="em-only_endmatter-idx1">Anterior chamber &#173;angle</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48<span class="endmatter-idx2_italic">f,</span> 56<span class="endmatter-idx2_italic">f,</span> 59–62<span class="endmatter-idx2_italic">f,</span> 59–63, 62<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">development of, 161</p>
			<p class="em-only_endmatter-idx2">structures of, 59–62<span class="endmatter-idx2_italic">f,</span> 59–63</p>
			<p class="em-only_endmatter-idx1">Anterior chamber–&#173;associated immune deviation, 299</p>
			<p class="em-only_endmatter-idx1">Anterior ciliary arteries, 22, 24<span class="endmatter-idx1_italic">f,</span> 43</p>
			<p class="em-only_endmatter-idx1">Anterior clinoid, 106<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior clinoid pro&#173;cess, 10<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior colobomas, 153</p>
			<p class="em-only_endmatter-idx1">Anterior communicating artery, 106<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior cranial fossa, 459<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Anterior ethmoidal artery, 23<span class="endmatter-idx1_italic">f,</span> 25<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior ethmoidal foramen, 6<span class="endmatter-idx1_italic">f,</span> 11</p>
			<p class="em-only_endmatter-idx1">Anterior facial vein, 26<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior hyaloid face, 472<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior lacrimal crest, 6<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior lens capsule, 80</p>
			<p class="em-only_endmatter-idx1">Anterior pigmented epithelium, 70–71, 71<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anterior segment, 459<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Anterior uveitis, muscarinic antagonists for, 380–381</p>
			<p class="em-only_endmatter-idx1">Anti-&#173;inflammatory drugs</p>
			<p class="em-only_endmatter-idx2">glucocorticoids. <span class="endmatter-idx2_italic">See</span> Glucocorticoids</p>
			<p class="em-only_endmatter-idx2">types of, 400<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Antiallergic drugs, 411–413</p>
			<p class="em-only_endmatter-idx1">Anticipation, 218–219</p>
			<p class="em-only_endmatter-idx1">Antifibrinolytic agents, 446–447</p>
			<p class="em-only_endmatter-idx1">Antifibrotic drugs, 413–414</p>
			<p class="em-only_endmatter-idx1">Antifungal drugs, 429–431, 430–431<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Antiglaucoma agents, 385<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Antihistamines</p>
			<p class="em-only_endmatter-idx2">description of, 411–412</p>
			<p class="em-only_endmatter-idx2">mast-&#173;cell stabilizers and, 413</p>
			<p class="em-only_endmatter-idx1">Antimetabolites, 404<span class="endmatter-idx1_italic">t,</span> 413–414</p>
			<p class="em-only_endmatter-idx1">Antimicrobial drugs</p>
			<p class="em-only_endmatter-idx2">aminoglycosides, 425–426</p>
			<p class="em-only_endmatter-idx2">antifungal drugs, 429–431, 430–431<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">cephalosporins, 417, 419–420</p>
			<p class="em-only_endmatter-idx2">chloramphenicol, 425</p>
			<p class="em-only_endmatter-idx2">fluoroquinolones, 420, 422–423</p>
			<p class="em-only_endmatter-idx2">macrolide antibiotics, 427</p>
			<p class="em-only_endmatter-idx2">penicillins, 417–419</p>
			<p class="em-only_endmatter-idx2">sulfonamides, 423–424</p>
			<p class="em-only_endmatter-idx2">tetracyclines, 424–425</p>
			<p class="em-only_endmatter-idx2">types of, 418<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">vancomycin, 426–427</p>
			<p class="em-only_endmatter-idx1">Antioncogenes, 183</p>
			<p class="em-only_endmatter-idx1">Antioxidants</p>
			<p class="em-only_endmatter-idx2">age-&#173;related macular degeneration and, 346</p>
			<p class="em-only_endmatter-idx2">ascorbate, 342–343</p>
			<p class="em-only_endmatter-idx2">carotenoids, 343</p>
			<p class="em-only_endmatter-idx2">catalase, 342</p>
			<p class="em-only_endmatter-idx2">description of, 447</p>
			<p class="em-only_endmatter-idx2">glutathione. <span class="endmatter-idx2_italic">See</span> Glutathione</p>
			<p class="em-only_endmatter-idx2">glutathione peroxidase, 341</p>
			<p class="em-only_endmatter-idx2">macula localization of, 344<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">pathways of, 337<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in ret&#173;i&#173;nal pigment epithelium, 341–343</p>
			<p class="em-only_endmatter-idx2">selenium, 341</p>
			<p class="em-only_endmatter-idx2">superoxide dismutase, 342</p>
			<p class="em-only_endmatter-idx2">vitamin E, 340, 342, 344<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Antiporters, 271</p>
			<p class="em-only_endmatter-idx1">Antiretroviral drugs, 436–437</p>
			<p class="em-only_endmatter-idx1">Antiretroviral therapy (ART), 437</p>
			<p class="em-only_endmatter-idx1">Antisense oligonucleotides, 197<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Anti–&#173;vascular endothelial growth &#173;factor, 360<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Antiviral drugs</p>
			<p class="em-only_endmatter-idx2">description of, 431, 433–434</p>
			<p class="em-only_endmatter-idx2">systemic, 434–437</p>
			<p class="em-only_endmatter-idx2">topical, 433–434</p>
			<p class="em-only_endmatter-idx2">types of, 432–433<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Aplastic anemia, 393</p>
			<p class="em-only_endmatter-idx1">Apolipoprotein&#160;D, 276</p>
			<p class="em-only_endmatter-idx1">Apoptosis</p>
			<p class="em-only_endmatter-idx2">atrophy caused by, 182</p>
			<p class="em-only_endmatter-idx2">definition of, 171, 182</p>
			<p class="em-only_endmatter-idx2">in embryogenesis, 182</p>
			<p class="em-only_endmatter-idx1">Apparent diffusion coefficient, 461<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Apraclonidine hydrochloride, 385<span class="endmatter-idx1_italic">t,</span> 385–386</p>
			<p class="em-only_endmatter-idx1">Aquaporin, 285</p>
			<p class="em-only_endmatter-idx1">Aquaporin channels, 294<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Aqueous humor</p>
			<p class="em-only_endmatter-idx2">ascorbate levels in, 274</p>
			<p class="em-only_endmatter-idx2">blood–&#173;aqueous barrier, 270, 279</p>
			<p class="em-only_endmatter-idx2">calcium in, 274</p>
			<p class="em-only_endmatter-idx2">carbohydrates in, 274–275</p>
			<p class="em-only_endmatter-idx2">carbon dioxide in, 278–279</p>
			<p class="em-only_endmatter-idx2">composition of, 273<span class="endmatter-idx2_italic">t,</span> 273–279</p>
			<p class="em-only_endmatter-idx2">dynamics of, 270–273</p>
			<p class="em-only_endmatter-idx2">enzymes in, 276</p>
			<p class="em-only_endmatter-idx2">formation of, 270–273, 272<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">glucose concentration in, 274–275</p>
			<p class="em-only_endmatter-idx2">glutathione in, 275</p>
			<p class="em-only_endmatter-idx2">growth-&#173;modulatory &#173;factors in, 277</p>
			<p class="em-only_endmatter-idx2">inorganic ions in, 274</p>
			<p class="em-only_endmatter-idx2">inositol in, 275</p>
			<p class="em-only_endmatter-idx2">insulin-&#173;like growth &#173;factor binding proteins in, 277</p>
			<p class="em-only_endmatter-idx2">in iris stroma, 68</p>
			<p class="em-only_endmatter-idx2">lactate in, 274</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 459<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">neuroendocrine proteins in, 276</p>
			<p class="em-only_endmatter-idx2">neurotrophic proteins in, 276</p>
			<p class="em-only_endmatter-idx2">nonpigmented epithelium secretion of, 271</p>
			<p class="em-only_endmatter-idx2">organic anions in, 274</p>
			<p class="em-only_endmatter-idx2">oxygen in, 278</p>
			<p class="em-only_endmatter-idx2">pH of, 279</p>
			<p class="em-only_endmatter-idx2">phosphate in, 274</p>
			<p class="em-only_endmatter-idx2">production of, 59, 269, 272<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">proteinase inhibitors in, 276</p>
			<p class="em-only_endmatter-idx2">proteinases in, 276</p>
			<p class="em-only_endmatter-idx2">proteins in, 275–276</p>
			<p class="em-only_endmatter-idx2">secretion of, 270–273, 272<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">urea in, 275</p>
			<p class="em-only_endmatter-idx2">vascular endothelial growth &#173;factors in, 277–278</p>
			<p class="em-only_endmatter-idx1">Aqueous misdirection, 378</p>
			<p class="em-only_endmatter-idx1">Aqueous vein, 67<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Arachidonic acid</p>
			<p class="em-only_endmatter-idx2">derivatives of, 407</p>
			<p class="em-only_endmatter-idx2">description of, 399</p>
			<p class="em-only_endmatter-idx2">prostaglandin synthesis from, 408<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Arachnoid sheath, 114, 114<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">AREDS. <span class="endmatter-idx1_italic">See</span> Age-&#173;Related Eye Disease Study</p>
			<p class="em-only_endmatter-idx1">Arrestin, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">ART.&#160;<span class="endmatter-idx1_italic">See</span> Antiretroviral therapy</p>
			<p class="em-only_endmatter-idx1">Artificial insemination, 238</p>
			<p class="em-only_endmatter-idx1">Artificial tears, 415</p>
			<p class="em-only_endmatter-idx1">Ascorbate</p>
			<p class="em-only_endmatter-idx2">in aqueous humor, 274</p>
			<p class="em-only_endmatter-idx2">description of, 340, 342–343</p>
			<p class="em-only_endmatter-idx2">in vitreous cavity, 302, 303<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Aspirin, 409<span class="endmatter-idx1_italic">t,</span> 409–410</p>
			<p class="em-only_endmatter-idx1">Astrocytes, 111, 113</p>
			<p class="em-only_endmatter-idx1">Ataxia-&#173;telangiectasia, 181</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">ATM</span> gene, 181</p>
			<p class="em-only_endmatter-idx1">ATP.&#160;<span class="endmatter-idx1_italic">See</span> Adenosine triphosphate</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">ATPase-6</span> gene, 186</p>
			<p class="em-only_endmatter-idx1">Atropine-&#173;Care. <span class="endmatter-idx1_italic">See</span> Atropine sulfate</p>
			<p class="em-only_endmatter-idx1">Atropine sulfate, 354, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Auto-&#173;oxidation, 337</p>
			<p class="em-only_endmatter-idx1">Autophagy</p>
			<p class="em-only_endmatter-idx2">description of, 283</p>
			<p class="em-only_endmatter-idx2">in ret&#173;i&#173;nal pigment epithelium, 332</p>
			<p class="em-only_endmatter-idx1">Autosomal dominant inheritance, 206–208, 207<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Autosomal dominant retinitis pigmentosa, <br />312</p>
			<p class="em-only_endmatter-idx1">Autosomal recessive inheritance</p>
			<p class="em-only_endmatter-idx2">carrier heterozygotes, 205</p>
			<p class="em-only_endmatter-idx2">characteristics of, 207<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">consanguinity, 206</p>
			<p class="em-only_endmatter-idx2">description of, 203</p>
			<p class="em-only_endmatter-idx2">enzyme defects as cause of, 203, 205</p>
			<p class="em-only_endmatter-idx2">pseudodominance, 206</p>
			<p class="em-only_endmatter-idx1">Autosomal recessive retinitis pigmentosa, 312</p>
			<p class="em-only_endmatter-idx1">Autosomes</p>
			<p class="em-only_endmatter-idx2">aneuploidy of, 222–224</p>
			<p class="em-only_endmatter-idx2">definition of, 213–214</p>
			<p class="em-only_endmatter-idx1">Axenfeld loops, 58, 58<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Axenfeld-&#173;Rieger syndrome, 236</p>
			<p class="em-only_endmatter-idx1">Axial hyperopia, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Axial proptosis, 110</p>
			<p class="em-only_endmatter-idx1">Axial scans</p>
			<p class="em-only_endmatter-idx2">B-&#173;scan ultrasound, 464–465, 464–465<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">computed tomography, 454, 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy, 468, 471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">AzaSite. <span class="endmatter-idx1_italic">See</span> Azithromycin</p>
			<p class="em-only_endmatter-idx1">Azathioprine, 404<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Azelastine hydrochloride, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Azithromycin, 421<span class="endmatter-idx1_italic">t,</span> 427</p>
			<p class="em-only_endmatter-idx1">Azlocillin, 419</p>
			<p class="em-only_endmatter-idx1">Azopt. <span class="endmatter-idx1_italic">See</span> Brinzolamide</p>
			<p class="em-only_endmatter-idx1">B-&#173;scan ultrasound/ultrasonography</p>
			<p class="em-only_endmatter-idx2">axial scans, 464–465, 464–465<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">dynamic, 467–468, 469<span class="endmatter-idx2_italic">t,</span> 470–471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">longitudinal scans, 464, 466<span class="endmatter-idx2_italic">f,</span> 468–469<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">probe for, 463<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">tissue-&#173;specific gain setting for, 469<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">transverse scans, 464–467, 466–467<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">types of, 464, 465<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Bacampicillin hydrochloride, 419</p>
			<p class="em-only_endmatter-idx1">Bacitracin zinc, 418<span class="endmatter-idx1_italic">t,</span> 421<span class="endmatter-idx1_italic">t,</span> 428</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Bacteroides</span> spp, 419</p>
			<p class="em-only_endmatter-idx1">Balanced salt solution, 360<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Bardet-&#173;Biedl syndrome, 220</p>
			<p class="em-only_endmatter-idx1">Baroreceptors, 384</p>
			<p class="em-only_endmatter-idx1">Basal cells, of corneal epithelium, 261</p>
			<p class="em-only_endmatter-idx1">Basal lamina, of cornea, 51, 52<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Base pairs</p>
			<p class="em-only_endmatter-idx2">definition of, 182</p>
			<p class="em-only_endmatter-idx2">mutations of, 183</p>
			<p class="em-only_endmatter-idx1">Basic fibroblast growth &#173;factor, 448</p>
			<p class="em-only_endmatter-idx1">Basilar artery, 106<span class="endmatter-idx1_italic">f,</span> 124, 139</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">BAX</span> gene, 181</p>
			<p class="em-only_endmatter-idx1">BBG.&#160;<span class="endmatter-idx1_italic">See</span> Brilliant blue G</p>
			<p class="em-only_endmatter-idx1">Benoxinate, 441</p>
			<p class="em-only_endmatter-idx1">Benzalkonium chloride, 351</p>
			<p class="em-only_endmatter-idx1">Bepotastine besilate, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Bepreve. <span class="endmatter-idx1_italic">See</span> Bepotastine besilate</p>
			<p class="em-only_endmatter-idx1">Besifloxacin, 421<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Besivance. <span class="endmatter-idx1_italic">See</span> Besifloxacin</p>
			<p class="em-only_endmatter-idx1">Bestrophin, 333<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx2_accent">β</span>-&#173;Adrenergic antagonists, 389<span class="endmatter-idx1_italic">t,</span> 389–390</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx2_accent">β</span><span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span>-&#173;Adrenergic agonists, 385<span class="endmatter-idx1_italic">t,</span> 387–389</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx2_accent">β</span><span class="endmatter-idx1_subscript _idGenCharOverride-1">1</span>-&#173;Adrenergic receptors, 382, 383<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx2_accent">β</span><span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span>-&#173;Adrenergic receptors, 382, 383<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx2_accent">β</span><span class="endmatter-idx1_subscript _idGenCharOverride-1">3</span>-&#173;Adrenergic receptors, 382</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx2_accent">β</span>-&#173;Blockers. <span class="endmatter-idx1_italic">See</span> <span class="endmatter-idx2_accent">β</span>-&#173;Adrenergic antagonists</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx2_accent">β</span>-&#173;Lactamases, 417</p>
			<p class="em-only_endmatter-idx1">Betagan. <span class="endmatter-idx1_italic">See</span> Levobunolol hydrochloride</p>
			<p class="em-only_endmatter-idx1">Betaxolol hydrochloride, 389<span class="endmatter-idx1_italic">t,</span> 390</p>
			<p class="em-only_endmatter-idx1">Betimol. <span class="endmatter-idx1_italic">See</span> Timolol hemihydrate</p>
			<p class="em-only_endmatter-idx1">Betoptic&#160;S.&#160;<span class="endmatter-idx1_italic">See</span> Betaxolol hydrochloride</p>
			<p class="em-only_endmatter-idx1">Bevacizumab, 371<span class="endmatter-idx1_italic">t,</span> 449</p>
			<p class="em-only_endmatter-idx1">Bicarbonate</p>
			<p class="em-only_endmatter-idx2">from carbonic anhydrase inhibitors, 391–392</p>
			<p class="em-only_endmatter-idx2">in tear film, 251</p>
			<p class="em-only_endmatter-idx1">Bimatoprost, 394<span class="endmatter-idx1_italic">t,</span> 395</p>
			<p class="em-only_endmatter-idx1">Bimatoprost/timolol maleate, 394<span class="endmatter-idx1_italic">t,</span> 397<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Bioavailability, 349</p>
			<p class="em-only_endmatter-idx1">Bioinformatics, 194</p>
			<p class="em-only_endmatter-idx1">Biologic agent, 349</p>
			<p class="em-only_endmatter-idx1">Biologic response modifiers, 405–406<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Bipolar cells, 87, 315–318, 316<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Bipolar dendrites, 87</p>
			<p class="em-only_endmatter-idx1">Bitemporal hemianopia, 474<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Bleph-10. <span class="endmatter-idx1_italic">See</span> Sulfacetamide sodium</p>
			<p class="em-only_endmatter-idx1">Blephamide. <span class="endmatter-idx1_italic">See</span> Prednisolone acetate/sulfacetamide sodium</p>
			<p class="em-only_endmatter-idx1">Blepharospasm, 359</p>
			<p class="em-only_endmatter-idx1">Blessig-&#173;Iwanoff cysts, 101</p>
			<p class="em-only_endmatter-idx1">Blinking, 354</p>
			<p class="em-only_endmatter-idx1">Bloch-&#173;Sulzberger syndrome, 209</p>
			<p class="em-only_endmatter-idx1">Blood pressure, phenylephrine hydrochloride effects on, 384</p>
			<p class="em-only_endmatter-idx1">Blood–&#173;aqueous barrier</p>
			<p class="em-only_endmatter-idx2">breakdown of, 279</p>
			<p class="em-only_endmatter-idx2">description of, 270</p>
			<p class="em-only_endmatter-idx2">functions of, 275</p>
			<p class="em-only_endmatter-idx1">Blood–&#173;ocular barrier, 448</p>
			<p class="em-only_endmatter-idx1">Blood–&#173;retina barrier, 88, 90<span class="endmatter-idx1_italic">f,</span> 270, 321</p>
			<p class="em-only_endmatter-idx1">Blue-&#173;cone monochromatism, 232<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Blue zone, 55</p>
			<p class="em-only_endmatter-idx1">Bony orbit, 6<span class="endmatter-idx1_italic">f,</span> 6–7</p>
			<p class="em-only_endmatter-idx1">Botulinum toxin, 359</p>
			<p class="em-only_endmatter-idx1">Botulinum toxin type A, 443</p>
			<p class="em-only_endmatter-idx1">Bowman layer</p>
			<p class="em-only_endmatter-idx2">anatomy of, 50<span class="endmatter-idx2_italic">f,</span> 51, 262–263</p>
			<p class="em-only_endmatter-idx2">Descemet membrane versus, 51</p>
			<p class="em-only_endmatter-idx1">Brainstem, 108<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Brilliant blue G (BBG), 444</p>
			<p class="em-only_endmatter-idx1">Brimonidine tartrate</p>
			<p class="em-only_endmatter-idx2">characteristics of, 385<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">in infants, 387</p>
			<p class="em-only_endmatter-idx2">intraocular pressure reductions using, 386</p>
			<p class="em-only_endmatter-idx2">neuroprotective effects of, 386</p>
			<p class="em-only_endmatter-idx1">Brimonidine tartrate/timolol maleate, 385<span class="endmatter-idx1_italic">t,</span> 389<span class="endmatter-idx1_italic">t,</span> 397<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Brinzolamide, 356, 391<span class="endmatter-idx1_italic">t,</span> 393</p>
			<p class="em-only_endmatter-idx1">Brinzolamide/brimonidine tartrate suspension, 397<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">British anti-&#173;Lewisite, 235</p>
			<p class="em-only_endmatter-idx1">Broad-&#173;spectrum penicillins, 419</p>
			<p class="em-only_endmatter-idx1">Brodmann area, 115</p>
			<p class="em-only_endmatter-idx1">Bromday. <span class="endmatter-idx1_italic">See</span> Bromfenac sodium</p>
			<p class="em-only_endmatter-idx1">Bromfenac sodium, 400<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Bruch membrane, 97, 99, 100<span class="endmatter-idx1_italic">f,</span> 322<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Bulbar conjunctiva, 28<span class="endmatter-idx1_italic">f,</span> 43</p>
			<p class="em-only_endmatter-idx1">Bupivacaine, 438<span class="endmatter-idx1_italic">t,</span> 440</p>
			<p class="em-only_endmatter-idx1">Butyrylcholinesterase, 379</p>
			<p class="em-only_endmatter-idx1">C4, 276</p>
			<p class="em-only_endmatter-idx1">CAIs. <span class="endmatter-idx1_italic">See</span> Carbonic anhydrase inhibitors</p>
			<p class="em-only_endmatter-idx1">Calcarine fissure, 119</p>
			<p class="em-only_endmatter-idx1">Calcarine sulcus, 119</p>
			<p class="em-only_endmatter-idx1">Calcitonin gene–&#173;related peptide (CGRP), 62, 251</p>
			<p class="em-only_endmatter-idx1">Calcium, in aqueous humor, 274</p>
			<p class="em-only_endmatter-idx1">CALT. <span class="endmatter-idx1_italic">See</span> Conjunctiva-&#173;associated lymphoid tissue</p>
			<p class="em-only_endmatter-idx1">Canaliculus, punctum of, 27</p>
			<p class="em-only_endmatter-idx1">Cancer, 183–184</p>
			<p class="em-only_endmatter-idx1">Candidate gene screening, 188–189</p>
			<p class="em-only_endmatter-idx1">Capsulopalpebral fascia, 35</p>
			<p class="em-only_endmatter-idx1">Capsulopalpebral head, 28<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Carbachol</p>
			<p class="em-only_endmatter-idx2">characteristics of, 378<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">intracameral use of, 360<span class="endmatter-idx2_italic">t,</span> 375–376</p>
			<p class="em-only_endmatter-idx2">intraocular pressure affected by, 377</p>
			<p class="em-only_endmatter-idx1">Carbenicillin, 419</p>
			<p class="em-only_endmatter-idx1">Carbenicillin sodium, 418<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Carbocaine. <span class="endmatter-idx1_italic">See</span> Mepivacaine</p>
			<p class="em-only_endmatter-idx1">Carbohydrate cataracts, 289–291</p>
			<p class="em-only_endmatter-idx1">Carbohydrates, in aqueous humor, 274–275</p>
			<p class="em-only_endmatter-idx1">Carbon dioxide, in aqueous humor, 278–279</p>
			<p class="em-only_endmatter-idx1">Carbonic anhydrase, 271, 367</p>
			<p class="em-only_endmatter-idx1">Carbonic anhydrase inhibitors (CAIs), 391–393</p>
			<p class="em-only_endmatter-idx1">Carotenoids, 343</p>
			<p class="em-only_endmatter-idx1">Carotid canal, 106<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Carotid cavernous sinus, 476<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Carteolol hydrochloride, 389<span class="endmatter-idx1_italic">t,</span> 390</p>
			<p class="em-only_endmatter-idx1">Caruncle, 27<span class="endmatter-idx1_italic">f,</span> 44</p>
			<p class="em-only_endmatter-idx1">Caspofungin, 431, 431<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Catalase, 342</p>
			<p class="em-only_endmatter-idx1">Cataracts</p>
			<p class="em-only_endmatter-idx2">carbohydrate, 289–291</p>
			<p class="em-only_endmatter-idx2">cortical, 235</p>
			<p class="em-only_endmatter-idx2">galactose metabolism defects as cause of, 289</p>
			<p class="em-only_endmatter-idx2">posterior subcapsular, 283</p>
			<p class="em-only_endmatter-idx2">sugar, 289–291</p>
			<p class="em-only_endmatter-idx2">ultrasonographic findings in, 470<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cathepsin&#160;D, 276</p>
			<p class="em-only_endmatter-idx1">Cavernous sinus, 133, 135–136, 138<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cavernous sinus syndrome, 475<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">CDKs. <span class="endmatter-idx1_italic">See</span> Cyclin-&#173;dependent kinases</p>
			<p class="em-only_endmatter-idx1">Cefadroxil, 419</p>
			<p class="em-only_endmatter-idx1">Cefamandole, 419</p>
			<p class="em-only_endmatter-idx1">Cefazidime, 418<span class="endmatter-idx1_italic">t,</span> 426</p>
			<p class="em-only_endmatter-idx1">Cefazolin sodium, 418<span class="endmatter-idx1_italic">t,</span> 419</p>
			<p class="em-only_endmatter-idx1">Cefepime hydrochloride, 420</p>
			<p class="em-only_endmatter-idx1">Cefoperazone, 420</p>
			<p class="em-only_endmatter-idx1">Cefotaxime, 420</p>
			<p class="em-only_endmatter-idx1">Cefoxitin, 419</p>
			<p class="em-only_endmatter-idx1">Cefpirome, 420</p>
			<p class="em-only_endmatter-idx1">Ceftazidime, 420</p>
			<p class="em-only_endmatter-idx1">Ceftriaxone sodium, 418<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cefuroxime, 360<span class="endmatter-idx1_italic">t,</span> 419</p>
			<p class="em-only_endmatter-idx1">Celecoxib, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cell cycle</p>
			<p class="em-only_endmatter-idx2">checkpoints in, 175–176, 183</p>
			<p class="em-only_endmatter-idx2">cytokinesis, 173–174</p>
			<p class="em-only_endmatter-idx2">meiosis, 174–175</p>
			<p class="em-only_endmatter-idx2">mitosis, 173</p>
			<p class="em-only_endmatter-idx2">phases of, 173–174, 174<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">regulation of, 175–176</p>
			<p class="em-only_endmatter-idx1">Cell-&#173;free fetal DNA, 239</p>
			<p class="em-only_endmatter-idx1">Cellophane maculopathy, 300</p>
			<p class="em-only_endmatter-idx1">Cellular retinol-&#173;binding protein 1, 326</p>
			<p class="em-only_endmatter-idx1">Central colobomas, 153</p>
			<p class="em-only_endmatter-idx1">Central cornea, 51</p>
			<p class="em-only_endmatter-idx1">Central ret&#173;i&#173;nal artery</p>
			<p class="em-only_endmatter-idx2">description of, 111</p>
			<p class="em-only_endmatter-idx2">lumen of, 119</p>
			<p class="em-only_endmatter-idx1">Central ret&#173;i&#173;nal vein, 26<span class="endmatter-idx1_italic">f,</span> 111, 120</p>
			<p class="em-only_endmatter-idx1">Central supporting connective tissue strand, 112<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cephalexin, 419</p>
			<p class="em-only_endmatter-idx1">Cephalosporins, 417, 419–420</p>
			<p class="em-only_endmatter-idx1">Cephalothin, 420</p>
			<p class="em-only_endmatter-idx1">Cephradine, 419</p>
			<p class="em-only_endmatter-idx1">Ceramide trihexoside, 235</p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral aqueduct, 107<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral arterial circle, 139, 139<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral peduncle, 107<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ce&#173;re&#173;bral vascular system</p>
			<p class="em-only_endmatter-idx2">cavernous sinus, 135–136, 138<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 135</p>
			<p class="em-only_endmatter-idx2">venous sinuses, 136, 138, 138<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cerebrospinal fluid, magnetic resonance imaging of, 459<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">CFH</span> gene, 183</p>
			<p class="em-only_endmatter-idx1">CGRP. <span class="endmatter-idx1_italic">See</span> Calcitonin gene–&#173;related peptide</p>
			<p class="em-only_endmatter-idx1">Chaperone-&#173;mediated autophagy, 283</p>
			<p class="em-only_endmatter-idx1">Checkpoints, in cell cycle, 175–176</p>
			<p class="em-only_endmatter-idx1">&#173;Children</p>
			<p class="em-only_endmatter-idx2">accommodation in, 79</p>
			<p class="em-only_endmatter-idx2">aspirin in, 410</p>
			<p class="em-only_endmatter-idx2">tetracycline contraindications in, 424–425</p>
			<p class="em-only_endmatter-idx1">Chlorambucil, 404<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Chloramphenicol, 421<span class="endmatter-idx1_italic">t,</span> 425</p>
			<p class="em-only_endmatter-idx1">Chlortetracycline, 424</p>
			<p class="em-only_endmatter-idx1">Cholesterol, 284</p>
			<p class="em-only_endmatter-idx1">Cholinergic agents</p>
			<p class="em-only_endmatter-idx2">agonists</p>
			<p class="em-only_endmatter-idx3">direct-&#173;acting</p>
			<p class="em-only_endmatter-idx4">acetylcholine, 375–377</p>
			<p class="em-only_endmatter-idx4">actions of, 375</p>
			<p class="em-only_endmatter-idx4">adverse effects of, 378</p>
			<p class="em-only_endmatter-idx4">indications for, 378</p>
			<p class="em-only_endmatter-idx4">pilocarpine, 377–378</p>
			<p class="em-only_endmatter-idx3">indirect-&#173;acting, 379</p>
			<p class="em-only_endmatter-idx3">mechanism of action, 374–375</p>
			<p class="em-only_endmatter-idx3">types of, 376<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">antagonists, 380–381</p>
			<p class="em-only_endmatter-idx2">nicotinic</p>
			<p class="em-only_endmatter-idx3">antagonists, 382</p>
			<p class="em-only_endmatter-idx3">indirect-&#173;acting agonists, 381</p>
			<p class="em-only_endmatter-idx1">Cholinergic receptors, 374, 374<span class="endmatter-idx1_italic">f,</span> 375<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cholinesterase inhibitors</p>
			<p class="em-only_endmatter-idx2">characteristics of, 378<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">irreversible, 379</p>
			<p class="em-only_endmatter-idx2">pralidoxime reversal of, 379</p>
			<p class="em-only_endmatter-idx2">reversible, 379</p>
			<p class="em-only_endmatter-idx1">Chondroitin sulfate, 297</p>
			<p class="em-only_endmatter-idx1">Choriocapillaris</p>
			<p class="em-only_endmatter-idx2">anatomy of, 76, 77–78<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">development of, 160–161</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium and, 322<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Choroid</p>
			<p class="em-only_endmatter-idx2">blood flow in, 76</p>
			<p class="em-only_endmatter-idx2">choriocapillaris, 76, 77–78<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">development of, 160–161</p>
			<p class="em-only_endmatter-idx2">edema of, 378</p>
			<p class="em-only_endmatter-idx2">functions of, 76</p>
			<p class="em-only_endmatter-idx2">gyrate atrophy of, 204<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">innervation of, 76</p>
			<p class="em-only_endmatter-idx2">layers of, 76</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 459<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">melanoma of, 471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">neovascularization of, 99, 449</p>
			<p class="em-only_endmatter-idx2">perfusion of, 76</p>
			<p class="em-only_endmatter-idx2">stroma of, 77</p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 472<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">vessels of, 76–77</p>
			<p class="em-only_endmatter-idx1">Choroideremia, 232<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Chromosomal crossing over, 175</p>
			<p class="em-only_endmatter-idx1">Chromosomal defects, 221</p>
			<p class="em-only_endmatter-idx1">Chromosomal nondisjunction, 216<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chromosome(s)</p>
			<p class="em-only_endmatter-idx2">abnormalities of, in aniridia, 225–226</p>
			<p class="em-only_endmatter-idx2">description of, 213</p>
			<p class="em-only_endmatter-idx2">gene assignments, 187</p>
			<p class="em-only_endmatter-idx2">homologous, 215–216</p>
			<p class="em-only_endmatter-idx2">nonhomologous, 216</p>
			<p class="em-only_endmatter-idx2">numbering of, 176</p>
			<p class="em-only_endmatter-idx2">sex</p>
			<p class="em-only_endmatter-idx3">aneuploidy of, 223</p>
			<p class="em-only_endmatter-idx3">mosaicism, 225</p>
			<p class="em-only_endmatter-idx2">structure of, 177<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chromosome analy&#173;sis</p>
			<p class="em-only_endmatter-idx2">aneuploidy of autosomes, 222–224</p>
			<p class="em-only_endmatter-idx2">chromosome arm painting, 221–222, 222<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 221</p>
			<p class="em-only_endmatter-idx2">fluorescence in situ hybridization for, 221–222</p>
			<p class="em-only_endmatter-idx2">indications for, 221</p>
			<p class="em-only_endmatter-idx2">mosaicism, 224–225</p>
			<p class="em-only_endmatter-idx2">types of, 221–222</p>
			<p class="em-only_endmatter-idx1">Chromosome arm painting, 221–222, 222<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Chronic progressive external ophthalmoplegia</p>
			<p class="em-only_endmatter-idx2">description of, 185</p>
			<p class="em-only_endmatter-idx2">mitochondrial DNA mutations in, 185</p>
			<p class="em-only_endmatter-idx1">Cidofovir, 432<span class="endmatter-idx1_italic">t,</span> 436</p>
			<p class="em-only_endmatter-idx1">Ciliary arteries</p>
			<p class="em-only_endmatter-idx2">anatomy of, 22</p>
			<p class="em-only_endmatter-idx2">anterior, 22, 24<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior, 23–24<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ciliary body</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">apex of, 72</p>
			<p class="em-only_endmatter-idx2">aqueous humor production by, 269</p>
			<p class="em-only_endmatter-idx2">arterial supply to, 75</p>
			<p class="em-only_endmatter-idx2">cytochrome P450, 270</p>
			<p class="em-only_endmatter-idx2">definition of, 72</p>
			<p class="em-only_endmatter-idx2">development of, 157, 159<span class="endmatter-idx2_italic">f,</span> 160</p>
			<p class="em-only_endmatter-idx2">drug targeting of, for glaucoma, 269</p>
			<p class="em-only_endmatter-idx2">epithelial cells of, 72, 73f</p>
			<p class="em-only_endmatter-idx2">functions of, 72, 269</p>
			<p class="em-only_endmatter-idx2">neuroendocrine peptides in, 276</p>
			<p class="em-only_endmatter-idx2">oxidation-&#173;reduction enzymes in, 270</p>
			<p class="em-only_endmatter-idx2">oxidative stress and, 269</p>
			<p class="em-only_endmatter-idx2">pars plana of, 72</p>
			<p class="em-only_endmatter-idx2">pars plicata of, 72, 73<span class="endmatter-idx2_italic">f,</span> 100<span class="endmatter-idx2_italic">f,</span> 472<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">physiology of, 269–270</p>
			<p class="em-only_endmatter-idx2">pigmented epithelium of, 73</p>
			<p class="em-only_endmatter-idx2">protein synthesis in, 275</p>
			<p class="em-only_endmatter-idx2">smooth muscle fibers in, 75<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">stroma of, 73</p>
			<p class="em-only_endmatter-idx2">supraciliary space, 76</p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 471–472<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ciliary epithelium</p>
			<p class="em-only_endmatter-idx2">description of, 270, 273</p>
			<p class="em-only_endmatter-idx2">neuroendocrine properties of, 274, 276</p>
			<p class="em-only_endmatter-idx2">secretory properties of, 273</p>
			<p class="em-only_endmatter-idx1">Ciliary ganglion</p>
			<p class="em-only_endmatter-idx2">anatomy of, 16<span class="endmatter-idx2_italic">f,</span> 107<span class="endmatter-idx2_italic">f,</span> 128<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">branches of, 15–16</p>
			<p class="em-only_endmatter-idx2">motor root of, 15, 16<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">parasympathetic fibers in, 15</p>
			<p class="em-only_endmatter-idx2">roots of, 15, 16<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">sensory root of, 15, 16<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">sympathetic fibers in, 15</p>
			<p class="em-only_endmatter-idx2">sympathetic root of, 15, 16<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ciliary muscle</p>
			<p class="em-only_endmatter-idx2">contraction of, 79</p>
			<p class="em-only_endmatter-idx2">development of, 160</p>
			<p class="em-only_endmatter-idx2">direct-&#173;acting cholinergic agonists’ effect on, 375</p>
			<p class="em-only_endmatter-idx2">fibers of, 75–76, 375</p>
			<p class="em-only_endmatter-idx2">layers of, 75–76</p>
			<p class="em-only_endmatter-idx2">muscarinic antagonists’ effect on, 380–381</p>
			<p class="em-only_endmatter-idx2">stimulation of, for accommodative esotropia, 379</p>
			<p class="em-only_endmatter-idx1">Ciliary nerves</p>
			<p class="em-only_endmatter-idx2">branches of, 58</p>
			<p class="em-only_endmatter-idx2">long, 254<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">short, 16</p>
			<p class="em-only_endmatter-idx1">Ciliary neurotrophic &#173;factor, 332</p>
			<p class="em-only_endmatter-idx1">Ciliary pro&#173;cess</p>
			<p class="em-only_endmatter-idx2">description of, 72</p>
			<p class="em-only_endmatter-idx2">development of, 159<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ciliary sulcus, 60<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ciloxan. <span class="endmatter-idx1_italic">See</span> Ciprofloxacin hydrochloride</p>
			<p class="em-only_endmatter-idx1">Ciprofloxacin hydrochloride, 421<span class="endmatter-idx1_italic">t,</span> 422</p>
			<p class="em-only_endmatter-idx1">Circle of Willis, 138–139, 139<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Circle of Zinn-&#173;Haller, 120, 122<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Circular ciliary muscle, 25<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">11-<span class="endmatter-idx1_italic">cis</span>-retinal, 307, 326, 333<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">11-&#173;<span class="endmatter-idx1_italic">cis</span>-&#173;retinaldehyde, 307, 326, 333<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">CL.&#160;<span class="endmatter-idx1_italic">See</span> Contact lenses</p>
			<p class="em-only_endmatter-idx1">Clarithromycin, 427</p>
			<p class="em-only_endmatter-idx1">Clindamycin, 418<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Clinical ge&#173;ne&#173;tics</p>
			<p class="em-only_endmatter-idx2">chromosome analy&#173;sis. <span class="endmatter-idx2_italic">See</span> Chromosome analy&#173;sis</p>
			<p class="em-only_endmatter-idx2">chromosomes, 213–217</p>
			<p class="em-only_endmatter-idx2">expressivity, 220</p>
			<p class="em-only_endmatter-idx2">genes, 213–217</p>
			<p class="em-only_endmatter-idx2">inheritance patterns. <span class="endmatter-idx2_italic">See</span> Inheritance</p>
			<p class="em-only_endmatter-idx2">lyonization, 230–231, 231<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">meiosis, 215, 216<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">mitosis, 215</p>
			<p class="em-only_endmatter-idx2">mutations, 217–220. <span class="endmatter-idx2_italic">See also</span> Mutations</p>
			<p class="em-only_endmatter-idx2">overview of, 199–200</p>
			<p class="em-only_endmatter-idx2">pedigree analy&#173;sis in, 200–201, 201<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">penetrance, 219</p>
			<p class="em-only_endmatter-idx2">pleiotropism, 220</p>
			<p class="em-only_endmatter-idx2">terminology associated with, 210–212</p>
			<p class="em-only_endmatter-idx1">Clinical Laboratories Improvement Amendments, 241</p>
			<p class="em-only_endmatter-idx1">Cloquet canal, 157</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Clostridium botulinum,</span> 443</p>
			<p class="em-only_endmatter-idx1">CME.&#160;<span class="endmatter-idx1_italic">See</span> Cystoid macular edema</p>
			<p class="em-only_endmatter-idx1">Coats disease, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cocaine, 439<span class="endmatter-idx1_italic">t,</span> 441</p>
			<p class="em-only_endmatter-idx1">Cohesive ophthalmic viscosurgical devices, 445</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">COL2A1,</span> 302</p>
			<p class="em-only_endmatter-idx1">Colistimethate sodium, 418<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Collagen corneal shields, 365</p>
			<p class="em-only_endmatter-idx1">Collagen fibers</p>
			<p class="em-only_endmatter-idx2">in Bowman layer, 262</p>
			<p class="em-only_endmatter-idx2">in corneal stroma, 263, 264–265<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in Descemet membrane, 266</p>
			<p class="em-only_endmatter-idx2">scleral, 58–59</p>
			<p class="em-only_endmatter-idx2">in vitreous</p>
			<p class="em-only_endmatter-idx3">age-&#173;related breakdown of, 300</p>
			<p class="em-only_endmatter-idx3">description of, 101, 294–297, 295–296<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">proteins associated with, 298</p>
			<p class="em-only_endmatter-idx1">Collector channels, 64, 67<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Colobomas, 153</p>
			<p class="em-only_endmatter-idx1">Color vision defects, 312</p>
			<p class="em-only_endmatter-idx1">Combigan. <span class="endmatter-idx1_italic">See</span> Brimonidine tartrate/timolol maleate</p>
			<p class="em-only_endmatter-idx1">Complementary&#160;DNA, 189</p>
			<p class="em-only_endmatter-idx1">Compliance, 373</p>
			<p class="em-only_endmatter-idx1">Compounded phar&#173;ma&#173;ceu&#173;ti&#173;cals, 372–373</p>
			<p class="em-only_endmatter-idx1">Compounding, 372</p>
			<p class="em-only_endmatter-idx1">Computed tomography (CT)</p>
			<p class="em-only_endmatter-idx2">axial scans, 454, 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">contrast agents with, 457</p>
			<p class="em-only_endmatter-idx2">coronal scans, 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 453–454</p>
			<p class="em-only_endmatter-idx2">disadvantages of, 456–457</p>
			<p class="em-only_endmatter-idx2">indications for, 454, 473<span class="endmatter-idx2_italic">t,</span> 476<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">iodinated contrast agents with, 457</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging versus, 455<span class="endmatter-idx2_italic">t,</span> 457</p>
			<p class="em-only_endmatter-idx2">periorbital sinuses, 14<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior fossa on, 456</p>
			<p class="em-only_endmatter-idx2">radiation exposure from, 456</p>
			<p class="em-only_endmatter-idx1">Computed tomography (CT) angiography, 454, 455<span class="endmatter-idx1_italic">t,</span> 458</p>
			<p class="em-only_endmatter-idx1">Computed tomography (CT) venography, 454, 455<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cones</p>
			<p class="em-only_endmatter-idx2">anatomy of, 86<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">bipolar cells, 315–316, 315–316<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">cells of, 315–316, 315–316<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">circuitry of, 316<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">foveal, 95</p>
			<p class="em-only_endmatter-idx2">gene defects associated with, 314<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">L, 312, 315, 317</p>
			<p class="em-only_endmatter-idx2">light effects on, 318, 318<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">M, 312, 315, 318</p>
			<p class="em-only_endmatter-idx2">neurally mediated negative feedback of, 311</p>
			<p class="em-only_endmatter-idx2">neuronal ele&#173;ments of, 88</p>
			<p class="em-only_endmatter-idx2">number of, 84</p>
			<p class="em-only_endmatter-idx2">pedicle of, 87</p>
			<p class="em-only_endmatter-idx2">phototransduction of, 311</p>
			<p class="em-only_endmatter-idx2">rods versus, 306</p>
			<p class="em-only_endmatter-idx2">S, 312</p>
			<p class="em-only_endmatter-idx2">synaptic body of, 87</p>
			<p class="em-only_endmatter-idx2">trivariant color vision, 312</p>
			<p class="em-only_endmatter-idx1">Congenital, 210</p>
			<p class="em-only_endmatter-idx1">Congenital hypertrophy of ret&#173;i&#173;nal pigment epithelium, in familial adenomatous polyposis, 201, 202<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Congenital stationary night blindness with myopia, 232<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Conjunctiva</p>
			<p class="em-only_endmatter-idx2">anatomy of, 36, 37<span class="endmatter-idx2_italic">f,</span> 43–44</p>
			<p class="em-only_endmatter-idx2">bulbar, 28<span class="endmatter-idx2_italic">f,</span> 43</p>
			<p class="em-only_endmatter-idx2">epithelium of, 44</p>
			<p class="em-only_endmatter-idx2">fornices of, 28<span class="endmatter-idx2_italic">f,</span> 36, 37<span class="endmatter-idx2_italic">f,</span> 43</p>
			<p class="em-only_endmatter-idx2">innervation of, 43</p>
			<p class="em-only_endmatter-idx2">palpebral, 36, 37<span class="endmatter-idx2_italic">f,</span> 43</p>
			<p class="em-only_endmatter-idx2">topical agent absorption in, 355</p>
			<p class="em-only_endmatter-idx1">Conjunctiva-&#173;associated lymphoid tissue, 43</p>
			<p class="em-only_endmatter-idx1">Conjunctival artery, 24<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Conjunctival intraepithelial neoplasia, 414</p>
			<p class="em-only_endmatter-idx1">Conjunctivitis, allergic, 411–412, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Consanguinity, 206, 237</p>
			<p class="em-only_endmatter-idx1">Contact lenses (CL), 365–366</p>
			<p class="em-only_endmatter-idx1">Contiguous gene-&#173;deletion syndrome, 225</p>
			<p class="em-only_endmatter-idx1">Contrast agents</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 458</p>
			<p class="em-only_endmatter-idx2">gadolinium-&#173;based, for magnetic resonance imaging, 458</p>
			<p class="em-only_endmatter-idx2">iodinated, for computed tomography, 457</p>
			<p class="em-only_endmatter-idx1">Copper, in aqueous humor, 274</p>
			<p class="em-only_endmatter-idx1">Copper-&#173;zinc superoxide dismutase (CuZnSOD), 342</p>
			<p class="em-only_endmatter-idx1">Cornea</p>
			<p class="em-only_endmatter-idx2">air–&#173;tear film interface, 49</p>
			<p class="em-only_endmatter-idx2">aldehyde dehydrogenase in, 260</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48, 48<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">avascularity of, 259</p>
			<p class="em-only_endmatter-idx2">basal lamina of, 51, 52<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">biochemistry of, 259–260</p>
			<p class="em-only_endmatter-idx2">Bowman layer of. <span class="endmatter-idx2_italic">See</span> Bowman layer</p>
			<p class="em-only_endmatter-idx2">central, 51</p>
			<p class="em-only_endmatter-idx2">collagen fibrils of, 53</p>
			<p class="em-only_endmatter-idx2">Descemet membrane of. <span class="endmatter-idx2_italic">See</span> Descemet membrane</p>
			<p class="em-only_endmatter-idx2">development of, 161–162<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">edema of, 251</p>
			<p class="em-only_endmatter-idx2">epithelial cells of, 261–262, 262<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">epithelium of, 51, 52<span class="endmatter-idx2_italic">f,</span> 260–262, 261–262<span class="endmatter-idx2_italic">f,</span> 375</p>
			<p class="em-only_endmatter-idx2">glucose metabolism by, 259</p>
			<p class="em-only_endmatter-idx2">glycosaminoglycans in, 263</p>
			<p class="em-only_endmatter-idx2">ground substance of, 53</p>
			<p class="em-only_endmatter-idx2">keratocytes of, 53</p>
			<p class="em-only_endmatter-idx2">lactic acid accumulation in, 260</p>
			<p class="em-only_endmatter-idx2">layers of, 50<span class="endmatter-idx2_italic">f,</span> 50–55, 52–54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">matrix metalloproteinases in, 264</p>
			<p class="em-only_endmatter-idx2">peripheral, 51</p>
			<p class="em-only_endmatter-idx2">physiology of, 259–260</p>
			<p class="em-only_endmatter-idx2">posterior, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">precorneal tear film of, 49–50, 259</p>
			<p class="em-only_endmatter-idx2">proteinase inhibitors of, 264</p>
			<p class="em-only_endmatter-idx2">proteoglycans in, 53</p>
			<p class="em-only_endmatter-idx2">radius of curvature of, 50</p>
			<p class="em-only_endmatter-idx2">refractive index of, 50</p>
			<p class="em-only_endmatter-idx2">stroma of</p>
			<p class="em-only_endmatter-idx3">anatomy of, 53</p>
			<p class="em-only_endmatter-idx3">collagen fibers in, 263, 264–265<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">composition of, 53, 58</p>
			<p class="em-only_endmatter-idx3">keratocytes, 263</p>
			<p class="em-only_endmatter-idx2">tight junctions of, 51</p>
			<p class="em-only_endmatter-idx2">transketolase in, 260</p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Corneal endothelium</p>
			<p class="em-only_endmatter-idx2">anatomy of, 54–55<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">cells of, 54, 266–267, 267<span class="endmatter-idx2_italic">t,</span> 267<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 266</p>
			<p class="em-only_endmatter-idx1">Corneal haze, 263</p>
			<p class="em-only_endmatter-idx1">Corneoscleral junction, 55</p>
			<p class="em-only_endmatter-idx1">Corneoscleral trabecular meshwork, 63–64</p>
			<p class="em-only_endmatter-idx1">Corrugator supercilii muscle, 31<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cortical vision loss, 475<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cortical vitreous, 296</p>
			<p class="em-only_endmatter-idx1">Corticosteroids</p>
			<p class="em-only_endmatter-idx2">intravitreal administration of, 360<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ocular allergies treated with, 411</p>
			<p class="em-only_endmatter-idx2">types of, 400<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cortisporin suspension. <span class="endmatter-idx1_italic">See</span> Hydrocortisone/neomycin sulfate/polymyxin B sulfate</p>
			<p class="em-only_endmatter-idx1">Cosopt Ocumeter Plus. <span class="endmatter-idx1_italic">See</span> Dorzolamide hydrochloride/timolol maleate</p>
			<p class="em-only_endmatter-idx1">Cotransport, 271</p>
			<p class="em-only_endmatter-idx1">COX. <span class="endmatter-idx1_italic">See</span> Cyclooxygenase</p>
			<p class="em-only_endmatter-idx1">CPEO. <span class="endmatter-idx1_italic">See</span> Chronic progressive external ophthalmoplegia</p>
			<p class="em-only_endmatter-idx1">Cranial nerve(s)</p>
			<p class="em-only_endmatter-idx2">anatomic relationships of, 106<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">anatomy of, 15</p>
			<p class="em-only_endmatter-idx2">cerebrovascular system effects on, 135</p>
			<p class="em-only_endmatter-idx2">I.&#160;<span class="endmatter-idx2_italic">See</span> Olfactory nerve</p>
			<p class="em-only_endmatter-idx2">II.&#160;<span class="endmatter-idx2_italic">See</span> Optic nerve</p>
			<p class="em-only_endmatter-idx2">III.&#160;<span class="endmatter-idx2_italic">See</span> Oculomotor nerve</p>
			<p class="em-only_endmatter-idx3">intracavernous course of, 137<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">IV.&#160;<span class="endmatter-idx2_italic">See</span> Trochlear nerve</p>
			<p class="em-only_endmatter-idx3">palsy of, 135, 475<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">V.&#160;<span class="endmatter-idx2_italic">See</span> Trigeminal nerve</p>
			<p class="em-only_endmatter-idx2">VI.&#160;<span class="endmatter-idx2_italic">See</span> Abducens nerve</p>
			<p class="em-only_endmatter-idx2">VII.&#160;<span class="endmatter-idx2_italic">See</span> Facial nerve</p>
			<p class="em-only_endmatter-idx1">Craniofacial development, 145<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">CRBP1. <span class="endmatter-idx1_italic">See</span> Cellular retinol-&#173;binding protein 1</p>
			<p class="em-only_endmatter-idx1">Crigler-&#173;Najjar syndrome, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">CRISPR–&#173;Cas9, 198</p>
			<p class="em-only_endmatter-idx1">Crolom. <span class="endmatter-idx1_italic">See</span> Cromolyn sodium</p>
			<p class="em-only_endmatter-idx1">Cromolyn sodium, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Crossing over, 175, 216–217</p>
			<p class="em-only_endmatter-idx1">Crystallins</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_greek">α</span>-&#173;, 284</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_accent">β</span>,<span class="endmatter-idx2_greek">γ</span>-&#173;, 284–285</p>
			<p class="em-only_endmatter-idx2">description of, 281, 284–285</p>
			<p class="em-only_endmatter-idx2">taxon-&#173;specific, 285</p>
			<p class="em-only_endmatter-idx1">CT.&#160;<span class="endmatter-idx1_italic">See</span> Computed tomography</p>
			<p class="em-only_endmatter-idx1">CT angiography. <span class="endmatter-idx1_italic">See</span> Computed tomography (CT) angiography</p>
			<p class="em-only_endmatter-idx1">CT venography. <span class="endmatter-idx1_italic">See</span> Computed tomography (CT) venography</p>
			<p class="em-only_endmatter-idx1">CuZnSOD. <span class="endmatter-idx1_italic">See</span> Copper-&#173;zinc superoxide dismutase</p>
			<p class="em-only_endmatter-idx1">Cyclic adenosine monophosphate (cAMP), 388</p>
			<p class="em-only_endmatter-idx1">Cyclic nucleotide-&#173;gated channels, 307, 309<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Cyclin-&#173;dependent kinases, 176</p>
			<p class="em-only_endmatter-idx1">Cyclins, 176</p>
			<p class="em-only_endmatter-idx1">Cyclogyl. <span class="endmatter-idx1_italic">See</span> Cyclopentolate hydrochloride</p>
			<p class="em-only_endmatter-idx1">Cyclomydril. <span class="endmatter-idx1_italic">See</span> Cyclopentolate hydrochloride/phenylephrine hydrochloride</p>
			<p class="em-only_endmatter-idx1">Cyclooxygenase (COX), 409</p>
			<p class="em-only_endmatter-idx1">Cyclopentolate hydrochloride, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cyclopentolate hydrochloride/phenylephrine hydrochloride, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cyclophosphamide, 404<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cycloplegia, 381</p>
			<p class="em-only_endmatter-idx1">Cycloplegics, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cyclosporine, 404<span class="endmatter-idx1_italic">t,</span> 415</p>
			<p class="em-only_endmatter-idx1">Cyclosporine&#160;A, 258, 371<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cylate. <span class="endmatter-idx1_italic">See</span> Cyclopentolate hydrochloride</p>
			<p class="em-only_endmatter-idx1">CYP2D6, 270</p>
			<p class="em-only_endmatter-idx1">Cystine, 235</p>
			<p class="em-only_endmatter-idx1">Cystinosis, 235</p>
			<p class="em-only_endmatter-idx1">Cystoid macular edema (CME), 359, 391, 394, 410</p>
			<p class="em-only_endmatter-idx1">Cytochrome P450, 351</p>
			<p class="em-only_endmatter-idx1">Cytoge&#173;ne&#173;tics, 221</p>
			<p class="em-only_endmatter-idx1">Cytokines, in tear film, 252</p>
			<p class="em-only_endmatter-idx1">Cytomegalovirus retinitis, 364, 435–436</p>
			<p class="em-only_endmatter-idx1">Cytosine, 176</p>
			<p class="em-only_endmatter-idx1">Cytoskeletal proteins, in lens, 285</p>
			<p class="em-only_endmatter-idx1">Cytotoxic edema, 461<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Cytovene&#160;IV.&#160;<span class="endmatter-idx1_italic">See</span> Ganciclovir sodium</p>
			<p class="em-only_endmatter-idx1">Daclizumab, 406<span class="endmatter-idx-alpha_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Dapiprazole hydrochloride, 387</p>
			<p class="em-only_endmatter-idx1">DCCT. <span class="endmatter-idx1_italic">See</span> Diabetes Control and Complications Trial</p>
			<p class="em-only_endmatter-idx1">Decamethonium, 382</p>
			<p class="em-only_endmatter-idx1">Decongestants, ocular, 416–417</p>
			<p class="em-only_endmatter-idx1">Deep plexus, 57</p>
			<p class="em-only_endmatter-idx1">Demyelination optic neuritis, 474<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Depolarizing agents, 382</p>
			<p class="em-only_endmatter-idx1">Depressor supercilii muscle, 31<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">DES.&#160;<span class="endmatter-idx1_italic">See</span> Dry eye syndrome</p>
			<p class="em-only_endmatter-idx1">Descemet membrane</p>
			<p class="em-only_endmatter-idx2">age-&#173;related thickening of, 266<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">anatomy of, 53, 54<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">Bowman layer versus, 51</p>
			<p class="em-only_endmatter-idx2">definition of, 266</p>
			<p class="em-only_endmatter-idx2">Hassall-&#173;Henle warts of, 53</p>
			<p class="em-only_endmatter-idx2">thickness of, 53</p>
			<p class="em-only_endmatter-idx1">Desmosomes, 51, 52<span class="endmatter-idx1_italic">f,</span> 73<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Dexacidin. <span class="endmatter-idx1_italic">See</span> Dexamethasone/neomycin sulfate/polymyxin B sulfate</p>
			<p class="em-only_endmatter-idx1">Dexamethasone implant, 364</p>
			<p class="em-only_endmatter-idx1">Dexamethasone/neomycin sulfate/polymyxin B sulfate, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Dexamethasone sodium phosphate, 400<span class="endmatter-idx1_italic">t,</span> 402<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Dexamethasone/tobramycin, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Dexasporin. <span class="endmatter-idx1_italic">See</span> Dexamethasone/neomycin sulfate/polymyxin B sulfate</p>
			<p class="em-only_endmatter-idx1">Diabetes Control and Complications Trial (DCCT), 345</p>
			<p class="em-only_endmatter-idx1">Diabetic retinopathy</p>
			<p class="em-only_endmatter-idx2">proliferative, 301</p>
			<p class="em-only_endmatter-idx2">reactive oxygen species in, 345</p>
			<p class="em-only_endmatter-idx1">Diamox Sequels. <span class="endmatter-idx1_italic">See</span> Acetazolamide</p>
			<p class="em-only_endmatter-idx1">Diclofenac sodium, 400<span class="endmatter-idx1_italic">t,</span> 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">DIDMOAD syndrome, 220</p>
			<p class="em-only_endmatter-idx1">Diet, ge&#173;ne&#173;tic diseases managed with, 235</p>
			<p class="em-only_endmatter-idx1">Diffusible ligands, 165–166</p>
			<p class="em-only_endmatter-idx1">Diffusion, 271</p>
			<p class="em-only_endmatter-idx1">Diffusion-&#173;weighted imaging (DWI), 458, 461<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Diflucan. <span class="endmatter-idx1_italic">See</span> Fluconazole</p>
			<p class="em-only_endmatter-idx1">Diflunisal, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Difluprednate, 356, 400<span class="endmatter-idx1_italic">t,</span> 403</p>
			<p class="em-only_endmatter-idx1">Diisopropyl phosphofluoridate, 379</p>
			<p class="em-only_endmatter-idx1">Dinitrophenol, 330</p>
			<p class="em-only_endmatter-idx1">Dipivefrin hydrochloride, 385<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Diquafosol tetrasodium, 416</p>
			<p class="em-only_endmatter-idx1">Direct-&#173;acting agonists</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_greek">α</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">1</span>-&#173;adrenergic agonists, 384</p>
			<p class="em-only_endmatter-idx2">cholinergic</p>
			<p class="em-only_endmatter-idx3">acetylcholine, 375–377</p>
			<p class="em-only_endmatter-idx3">actions of, 375</p>
			<p class="em-only_endmatter-idx3">adverse effects of, 378</p>
			<p class="em-only_endmatter-idx3">indications for, 378</p>
			<p class="em-only_endmatter-idx3">pilocarpine, 377–378</p>
			<p class="em-only_endmatter-idx1">Direct sequencing, 189</p>
			<p class="em-only_endmatter-idx1">Direct-&#173;to-&#173;consumer ge&#173;ne&#173;tic testing, 241</p>
			<p class="em-only_endmatter-idx1">Disciform macular degeneration, ultrasonographic findings in, 471<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Dispersive ophthalmic viscosurgical devices, 445</p>
			<p class="em-only_endmatter-idx1">DNA</p>
			<p class="em-only_endmatter-idx2">coding region of, 178</p>
			<p class="em-only_endmatter-idx2">damage to, 181–182</p>
			<p class="em-only_endmatter-idx2">direct sequencing of, 189</p>
			<p class="em-only_endmatter-idx2">methylation of, 180</p>
			<p class="em-only_endmatter-idx2">mutations in, 182–183</p>
			<p class="em-only_endmatter-idx2">noncoding, 177–178</p>
			<p class="em-only_endmatter-idx2">repair of, 181–182</p>
			<p class="em-only_endmatter-idx2">sequencing of, 189</p>
			<p class="em-only_endmatter-idx2">telomeric, 178</p>
			<p class="em-only_endmatter-idx1">DNA gyrase, 420</p>
			<p class="em-only_endmatter-idx1">Docosahexaenoic acid, 324</p>
			<p class="em-only_endmatter-idx1">Dominant diseases, gene therapy for, 197–198</p>
			<p class="em-only_endmatter-idx1">Dominant inheritance</p>
			<p class="em-only_endmatter-idx2">autosomal, 206–208, 207<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 202–203</p>
			<p class="em-only_endmatter-idx2">X-&#173;linked, 209, 210<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Dominant-&#173;negative effect, 197</p>
			<p class="em-only_endmatter-idx1">Dorello canal, 133</p>
			<p class="em-only_endmatter-idx1">Dorsal midbrain syndrome, 475<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Dorsal nasal artery, 23<span class="endmatter-idx1_italic">f,</span> 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Dorzolamide hydrochloride, 391<span class="endmatter-idx1_italic">t,</span> 393</p>
			<p class="em-only_endmatter-idx1">Dorzolamide hydrochloride/timolol maleate, 389<span class="endmatter-idx1_italic">t,</span> 391<span class="endmatter-idx1_italic">t,</span> 397<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Double heterozygotes, 215</p>
			<p class="em-only_endmatter-idx1">Down syndrome</p>
			<p class="em-only_endmatter-idx2">clinical features of, 223, 224<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic errors in, 223</p>
			<p class="em-only_endmatter-idx2">ocular features of, 224<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">pharmacoge&#173;ne&#173;tics and, 233–234</p>
			<p class="em-only_endmatter-idx1">Doxycycline</p>
			<p class="em-only_endmatter-idx2">description of, 371<span class="endmatter-idx2_italic">t,</span> 424</p>
			<p class="em-only_endmatter-idx2">ocular rosacea treated with, 370</p>
			<p class="em-only_endmatter-idx1">Drug(s). <span class="endmatter-idx1_italic">See also specific drug</span></p>
			<p class="em-only_endmatter-idx2">compliance with, 373</p>
			<p class="em-only_endmatter-idx2">compounding of, 372–373</p>
			<p class="em-only_endmatter-idx2">as diagnostic agents, 444–445</p>
			<p class="em-only_endmatter-idx2">dry eye treated with, 415–416</p>
			<p class="em-only_endmatter-idx2">noncompliance with, 373, 373<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">topical. <span class="endmatter-idx2_italic">See</span> Topical drugs</p>
			<p class="em-only_endmatter-idx1">Drug delivery</p>
			<p class="em-only_endmatter-idx2">collagen corneal shields for, 365</p>
			<p class="em-only_endmatter-idx2">contact lenses for, 365–366</p>
			<p class="em-only_endmatter-idx2">encapsulated cell technology for, 366</p>
			<p class="em-only_endmatter-idx2">gel-&#173;forming drops for, 366</p>
			<p class="em-only_endmatter-idx2">implants for, 364</p>
			<p class="em-only_endmatter-idx2">intracameral, 359–360, 360<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">intraocular, 359–361</p>
			<p class="em-only_endmatter-idx2">intraocular lenses for, 364–365</p>
			<p class="em-only_endmatter-idx2">intravitreal, 360<span class="endmatter-idx2_italic">t,</span> 361</p>
			<p class="em-only_endmatter-idx2">liposomes for, 366</p>
			<p class="em-only_endmatter-idx2">local administration, 359–361</p>
			<p class="em-only_endmatter-idx2">microelectromechanical systems for, 367</p>
			<p class="em-only_endmatter-idx2">nanotechnology for, 366–367</p>
			<p class="em-only_endmatter-idx2">ocular inserts for, 363–364</p>
			<p class="em-only_endmatter-idx2">periocular injections, 359</p>
			<p class="em-only_endmatter-idx2">punctal plug–&#173;mediated, 366</p>
			<p class="em-only_endmatter-idx2">routes for, 353<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">sustained-&#173;release, 363–365</p>
			<p class="em-only_endmatter-idx2">systemic administration, 361–362</p>
			<p class="em-only_endmatter-idx2">topical. <span class="endmatter-idx2_italic">See</span> Topical drugs</p>
			<p class="em-only_endmatter-idx1">Drug Quality and Security Act (2013), 372</p>
			<p class="em-only_endmatter-idx1">Dry eye syndrome (DES)</p>
			<p class="em-only_endmatter-idx2">cyclosporine A for, 258</p>
			<p class="em-only_endmatter-idx2">description of, 250, 253</p>
			<p class="em-only_endmatter-idx2">lifitegrast for, 258</p>
			<p class="em-only_endmatter-idx2">medi&#173;cations for, 415–416</p>
			<p class="em-only_endmatter-idx2">neural feedback loop in, 255<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ocular surface inflammation in, 257<span class="endmatter-idx2_italic">f,</span> 257–258</p>
			<p class="em-only_endmatter-idx2">tear substitutes for, 258</p>
			<p class="em-only_endmatter-idx2">vicious circle theory of, 254, 256<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Duchenne muscular dystrophy, 210</p>
			<p class="em-only_endmatter-idx1">DuoTrav. <span class="endmatter-idx1_italic">See</span> Travoprost/timolol maleate</p>
			<p class="em-only_endmatter-idx1">Dural fistula, 476<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Durezol. <span class="endmatter-idx1_italic">See</span> Difluprednate</p>
			<p class="em-only_endmatter-idx1">DWI.&#160;<span class="endmatter-idx1_italic">See</span> Diffusion-&#173;weighted imaging</p>
			<p class="em-only_endmatter-idx1">Dynamic B-&#173;scan ultrasonography, 467–468, 469<span class="endmatter-idx1_italic">t,</span> 470–471<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Dystrophin, 180</p>
			<p class="em-only_endmatter-idx1">Echinocandins, 431, 431<span class="endmatter-idx-alpha_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Echo time (TE), 457</p>
			<p class="em-only_endmatter-idx1">Echothiophate iodide, 378<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Econopred Plus. <span class="endmatter-idx1_italic">See</span> Prednisolone acetate</p>
			<p class="em-only_endmatter-idx1">Ectoderm</p>
			<p class="em-only_endmatter-idx2">derivatives of, 149<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 143–144, 145<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in embryologic development, 150<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ectomesenchymal cells, 161</p>
			<p class="em-only_endmatter-idx1">Ectomesenchyme, 149</p>
			<p class="em-only_endmatter-idx1">Ectropion, 72</p>
			<p class="em-only_endmatter-idx1">Ectropion uveae, 72</p>
			<p class="em-only_endmatter-idx1">Edetate disodium, 371<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Edinger-&#173;Westphal nucleus, 15, 71, 124, 126, 127<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Edrophonium, 381</p>
			<p class="em-only_endmatter-idx1">Efalizumab, 406<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">EFEMP1, 333<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ehlers-&#173;Danlos syndrome, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">El&#173;derly patients, pharmacologic princi&#173;ples in, <br />351–352</p>
			<p class="em-only_endmatter-idx1">Electro-&#173;oculogram, 330</p>
			<p class="em-only_endmatter-idx1">Electrolytes, in tear film, 251</p>
			<p class="em-only_endmatter-idx1">Electron transport chain, 336</p>
			<p class="em-only_endmatter-idx1">Electroretinogram, 318, 318<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">ELM.&#160;<span class="endmatter-idx1_italic">See</span> External limiting membrane</p>
			<p class="em-only_endmatter-idx1">Emadine. <span class="endmatter-idx1_italic">See</span> Epinastine hydrochloride</p>
			<p class="em-only_endmatter-idx1">Embryogenesis</p>
			<p class="em-only_endmatter-idx2">early stages of, 143, 144<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">steps involved in, 143</p>
			<p class="em-only_endmatter-idx1">Emedastine difumarate, 411, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Emissaria, 58</p>
			<p class="em-only_endmatter-idx1">Emotional lacrimation, 135</p>
			<p class="em-only_endmatter-idx1">Emulsion, 349, 356</p>
			<p class="em-only_endmatter-idx1">Encapsulated cell technology, for drug delivery, 366</p>
			<p class="em-only_endmatter-idx1">Endoderm, 143, 145<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Endoperoxides, 408</p>
			<p class="em-only_endmatter-idx1">Endophthalmitis, postoperative, 428</p>
			<p class="em-only_endmatter-idx1">Endothelial cells, of cornea, 54, 266–267, 267<span class="endmatter-idx1_italic">t,</span> 267<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Endothelial meshwork, 64, 65<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Endothelial nitric oxide synthase (eNOS), 394–395</p>
			<p class="em-only_endmatter-idx1">eNOS. <span class="endmatter-idx1_italic">See</span> Endothelial nitric oxide synthase</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Enterobacter aerogenes,</span> 419</p>
			<p class="em-only_endmatter-idx1">Enzyme(s)</p>
			<p class="em-only_endmatter-idx2">in aqueous humor, 276</p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment induced by, 304</p>
			<p class="em-only_endmatter-idx2">vitreolysis using, 304</p>
			<p class="em-only_endmatter-idx1">Enzyme replacement therapy, for ge&#173;ne&#173;tic diseases, 235</p>
			<p class="em-only_endmatter-idx1">EOG.&#160;<span class="endmatter-idx1_italic">See</span> Electro-&#173;oculogram</p>
			<p class="em-only_endmatter-idx1">Epidermal growth &#173;factor, 449</p>
			<p class="em-only_endmatter-idx1">Epigenet&#173;ics, 173, 179</p>
			<p class="em-only_endmatter-idx1">Epinastine hydrochloride, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Epinephrine hydrochloride</p>
			<p class="em-only_endmatter-idx2">description of, 385</p>
			<p class="em-only_endmatter-idx2">intracameral administration of, 360<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2"><span class="SC">L</span>-&#173;, 388</p>
			<p class="em-only_endmatter-idx1">Epiret&#173;i&#173;nal membranes, 300</p>
			<p class="em-only_endmatter-idx1">Episclera, 58</p>
			<p class="em-only_endmatter-idx1">Episcleral arterial circle, 24<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Episcleral vessels, 57, 57<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Epithelium, corneal, 51, 52<span class="endmatter-idx1_italic">f,</span> 260–262, 261–262<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_greek">ε</span>-&#173;Aminocaproic acid, 446–447</p>
			<p class="em-only_endmatter-idx1">Erythromycin, 418<span class="endmatter-idx1_italic">t,</span> 421<span class="endmatter-idx1_italic">t,</span> 427</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Escherichia coli,</span> 419</p>
			<p class="em-only_endmatter-idx1">Esotropia, accommodative, 379</p>
			<p class="em-only_endmatter-idx1">Etanercept, 405<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ethmoid bone, 6<span class="endmatter-idx1_italic">f,</span> 8</p>
			<p class="em-only_endmatter-idx1">Ethmoid sinus, 12, 14<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Etodolac, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Excision repair, 181</p>
			<p class="em-only_endmatter-idx1">Exons, 176–177</p>
			<p class="em-only_endmatter-idx1">Expiration dates on biologics, 372</p>
			<p class="em-only_endmatter-idx1">Expressivity, 220</p>
			<p class="em-only_endmatter-idx1">External limiting membrane (ELM)</p>
			<p class="em-only_endmatter-idx2">definition of, 91</p>
			<p class="em-only_endmatter-idx2">development of, 155</p>
			<p class="em-only_endmatter-idx1">Extraocular muscles. <span class="endmatter-idx1_italic">See also specific muscle</span></p>
			<p class="em-only_endmatter-idx2">anatomy of, 17–18<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">blood supply to, 21</p>
			<p class="em-only_endmatter-idx2">congenital cranial dysinnervation disorders <br />involving, 163</p>
			<p class="em-only_endmatter-idx2">development of, 162–163</p>
			<p class="em-only_endmatter-idx2">fine structure of, 22</p>
			<p class="em-only_endmatter-idx2">formation of, 162–163</p>
			<p class="em-only_endmatter-idx2">innervation of, 21</p>
			<p class="em-only_endmatter-idx2">insertions of, 20, 21<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 459<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">names of, 17</p>
			<p class="em-only_endmatter-idx2">orbital distribution of, 20</p>
			<p class="em-only_endmatter-idx2">origins of, 18, 20<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Eye. <span class="endmatter-idx1_italic">See also specific ocular entries</span></p>
			<p class="em-only_endmatter-idx2">compartments of, 48</p>
			<p class="em-only_endmatter-idx2">embryologic development of, 143–144, 144–146<span class="endmatter-idx2_italic">f,</span> 148<span class="endmatter-idx2_italic">f,</span> 152<span class="endmatter-idx2_italic">t</span>. <span class="endmatter-idx2_italic">See also</span> Ocular development</p>
			<p class="em-only_endmatter-idx2">fluid transport in, 294<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">glands of, 30<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Eyeball. <span class="endmatter-idx1_italic">See</span> Globe</p>
			<p class="em-only_endmatter-idx1">Eyelashes, 28</p>
			<p class="em-only_endmatter-idx1">Eyelid(s)</p>
			<p class="em-only_endmatter-idx2">anatomy of, 26–37, 28<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">arterial supply to, 38<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">blood supply to, 37–38, 38<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">lower</p>
			<p class="em-only_endmatter-idx3">anatomy of, 26</p>
			<p class="em-only_endmatter-idx3">development of, 163</p>
			<p class="em-only_endmatter-idx3">muscles of, 35</p>
			<p class="em-only_endmatter-idx3">punctum of, 42</p>
			<p class="em-only_endmatter-idx2">lymphatics of, 38, 39<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">margin of, 27, 30<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">movement of, 255</p>
			<p class="em-only_endmatter-idx2">muscles of, 28, 31<span class="endmatter-idx2_italic">f,</span> 33–35</p>
			<p class="em-only_endmatter-idx2">palpebral fissure of, 26, 27<span class="endmatter-idx2_italic">f,</span> 36<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">racial variations in, 27, 29<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">skin of, 27–29, 29–30<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">upper</p>
			<p class="em-only_endmatter-idx3">anatomy of, 26</p>
			<p class="em-only_endmatter-idx3">development of, 163, 164<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">muscles of, 33–35</p>
			<p class="em-only_endmatter-idx2">vascular supply of, 37–38, 38<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Eyelid–&#173;globe incongruity, 257</p>
			<p class="em-only_endmatter-idx1">Fabry disease, 204<span class="endmatter-idx-alpha_italic">t,</span> 232<span class="endmatter-idx-alpha_italic">t,</span> 235</p>
			<p class="em-only_endmatter-idx1">Facial angiofibromas, 229</p>
			<p class="em-only_endmatter-idx1">Facial artery, 23<span class="endmatter-idx1_italic">f,</span> 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Facial colliculus, 134</p>
			<p class="em-only_endmatter-idx1">Facial nerve</p>
			<p class="em-only_endmatter-idx2">anatomy of, 133–135</p>
			<p class="em-only_endmatter-idx2">branches of, 134</p>
			<p class="em-only_endmatter-idx2">motor nucleus of, 133</p>
			<p class="em-only_endmatter-idx2">temporal branch of, 134</p>
			<p class="em-only_endmatter-idx1">Famciclovir, 432<span class="endmatter-idx1_italic">t,</span> 435</p>
			<p class="em-only_endmatter-idx1">Familial adenomatous polyposis, congenital hypertrophy of ret&#173;i&#173;nal pigment epithelium in, 201, 202<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Familial cerebello ret&#173;i&#173;nal angiomatosis. <span class="endmatter-idx1_italic">See</span> von Hippel-<br />&#173;Lindau syndrome</p>
			<p class="em-only_endmatter-idx1">Familial disorder, 210</p>
			<p class="em-only_endmatter-idx1">Familial dysautonomia, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">&#173;Family history, in ge&#173;ne&#173;tic counseling, 237</p>
			<p class="em-only_endmatter-idx1">Famvir&#160;HZV.&#160;<span class="endmatter-idx1_italic">See</span> Famciclovir</p>
			<p class="em-only_endmatter-idx1">Fanconi syndrome, 425</p>
			<p class="em-only_endmatter-idx1">Fascia bulbi, 44</p>
			<p class="em-only_endmatter-idx1">FAZ.&#160;<span class="endmatter-idx1_italic">See</span> Foveal avascular zone</p>
			<p class="em-only_endmatter-idx1">FDA.&#160;<span class="endmatter-idx1_italic">See</span> Food and Drug Administration</p>
			<p class="em-only_endmatter-idx1">FDCA. <span class="endmatter-idx1_italic">See</span> Food, Drug, and Cosmetic Act</p>
			<p class="em-only_endmatter-idx1">Fenoprofen, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fibrillin, 298</p>
			<p class="em-only_endmatter-idx1">Fibrin sealant, 371<span class="endmatter-idx1_italic">t,</span> 446</p>
			<p class="em-only_endmatter-idx1">Fibrinolytic agents, 445–446</p>
			<p class="em-only_endmatter-idx1">Fibroblast growth &#173;factors, 166, 449</p>
			<p class="em-only_endmatter-idx1">Fibronectin, 304</p>
			<p class="em-only_endmatter-idx1">Filensin, 285</p>
			<p class="em-only_endmatter-idx1">First-&#173;generation cephalosporins, 419</p>
			<p class="em-only_endmatter-idx1">FISH. <span class="endmatter-idx1_italic">See</span> Fluorescence in situ hybridization</p>
			<p class="em-only_endmatter-idx1">5-&#173;Fluorocytosine, 431</p>
			<p class="em-only_endmatter-idx1">5-&#173;FU.&#160;<span class="endmatter-idx1_italic">See</span> Fluorouracil</p>
			<p class="em-only_endmatter-idx1">Fixed-&#173;combination medi&#173;cations, 397, 397<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Flarex. <span class="endmatter-idx1_italic">See</span> Fluorometholone acetate</p>
			<p class="em-only_endmatter-idx1">Flicker fusion threshold, 311</p>
			<p class="em-only_endmatter-idx1">Flucaine. <span class="endmatter-idx1_italic">See</span> Fluorescein sodium/proparacaine</p>
			<p class="em-only_endmatter-idx1">Fluconazole, 429, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Flucytosine, 431, 431<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fluocinolone acetonide, 403</p>
			<p class="em-only_endmatter-idx1">Fluocinolone acetonide implant, 364</p>
			<p class="em-only_endmatter-idx1">Fluor-&#173;Op. <span class="endmatter-idx1_italic">See</span> Fluorometholone</p>
			<p class="em-only_endmatter-idx1">Fluoracaine. <span class="endmatter-idx1_italic">See</span> Fluorescein sodium/proparacaine</p>
			<p class="em-only_endmatter-idx1">Fluorescein sodium/benoxinate, 439<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fluorescein sodium/proparacaine, 439<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fluorescence in situ hybridization, 221–222</p>
			<p class="em-only_endmatter-idx1">Fluo&#173;rescent polymerase chain reaction, 239</p>
			<p class="em-only_endmatter-idx1">Fluorometholone, 400<span class="endmatter-idx1_italic">t,</span> 402, 402<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fluorometholone acetate, 400<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fluorometholone/sulfacetamide, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fluoroquinolones, 420, 422–423</p>
			<p class="em-only_endmatter-idx1">Fluorouracil (5-&#173;FU), 359, 371<span class="endmatter-idx1_italic">t,</span> 413–414</p>
			<p class="em-only_endmatter-idx1">Flurbiprofen, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Flurbiprofen sodium, 400<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Fluress. <span class="endmatter-idx1_italic">See</span> Fluorescein sodium/benoxinate</p>
			<p class="em-only_endmatter-idx1">Flurox. <span class="endmatter-idx1_italic">See</span> Fluorescein sodium/benoxinate</p>
			<p class="em-only_endmatter-idx1">FML&#160;Forte Liquifilm. <span class="endmatter-idx1_italic">See</span> Fluorometholone</p>
			<p class="em-only_endmatter-idx1">FML&#160;Liquifilm. <span class="endmatter-idx1_italic">See</span> Fluorometholone</p>
			<p class="em-only_endmatter-idx1">FML-&#173;S.&#160;<span class="endmatter-idx1_italic">See</span> Fluorometholone/sulfacetamide</p>
			<p class="em-only_endmatter-idx1">FML S.O.P. <span class="endmatter-idx1_italic">See</span> Fluorometholone</p>
			<p class="em-only_endmatter-idx1">Food, Drug, and Cosmetic Act (FDCA), 372</p>
			<p class="em-only_endmatter-idx1">Food and Drug Administration (FDA)</p>
			<p class="em-only_endmatter-idx2">description of, 370</p>
			<p class="em-only_endmatter-idx2">expiration dates on biologics, 372</p>
			<p class="em-only_endmatter-idx1">Foramen rotundum, 106<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Foramina, orbital, 10–11</p>
			<p class="em-only_endmatter-idx1">Foscarnet sodium, 360<span class="endmatter-idx1_italic">t,</span> 432<span class="endmatter-idx1_italic">t,</span> 436</p>
			<p class="em-only_endmatter-idx1">Foscavir. <span class="endmatter-idx1_italic">See</span> Foscarnet sodium</p>
			<p class="em-only_endmatter-idx1">Fourth-&#173;generation cephalosporins, 419</p>
			<p class="em-only_endmatter-idx1">Fovea</p>
			<p class="em-only_endmatter-idx2">anatomy of, 83</p>
			<p class="em-only_endmatter-idx2">definition of, 94</p>
			<p class="em-only_endmatter-idx2">optical coherence tomography of, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">parafovea, 85</p>
			<p class="em-only_endmatter-idx2">perifovea, 97</p>
			<p class="em-only_endmatter-idx2">schematic section of, 93<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fovea ethmoidalis, 14, 14<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Foveal avascular zone (FAZ), 95, 97<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Foveal cones, 87</p>
			<p class="em-only_endmatter-idx1">Foveola</p>
			<p class="em-only_endmatter-idx2">borders of, 94</p>
			<p class="em-only_endmatter-idx2">definition of, 94</p>
			<p class="em-only_endmatter-idx2">photoreceptor layer of, 95</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">FOXC1</span> gene, 187</p>
			<p class="em-only_endmatter-idx1">&#173;Free iron, 339</p>
			<p class="em-only_endmatter-idx1">Frontal bone, 6–7<span class="endmatter-idx1_italic">f,</span> 9–10<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Frontal nerve, 12<span class="endmatter-idx1_italic">f,</span> 131</p>
			<p class="em-only_endmatter-idx1">Frontalis muscle, 28<span class="endmatter-idx1_italic">f,</span> 31<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Frontoethmoidal suture, 6<span class="endmatter-idx1_italic">f,</span> 9<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Frontosphenoid suture, 10<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Frontozygomatic suture, 10, 10<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fuchs endothelial corneal dystrophy, 54</p>
			<p class="em-only_endmatter-idx1">Fundus autofluorescence, 330<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fundus coloboma, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Fundus oculi, 83</p>
			<p class="em-only_endmatter-idx1">Fungizone. <span class="endmatter-idx1_italic">See</span> Amphotericin&#160;B</p>
			<p class="em-only_endmatter-idx1">G<span class="endmatter-idx-alpha_subscript _idGenCharOverride-1">0</span> phase, 174, 176</p>
			<p class="em-only_endmatter-idx1">G<span class="endmatter-idx1_subscript _idGenCharOverride-1">1</span> phase, 175</p>
			<p class="em-only_endmatter-idx1">G<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span> phase, 175–176</p>
			<p class="em-only_endmatter-idx1">Gadolinium-&#173;based contrast agents, 458</p>
			<p class="em-only_endmatter-idx1">Galactokinase, 289</p>
			<p class="em-only_endmatter-idx1">Galactokinase deficiency, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Galactosemia</p>
			<p class="em-only_endmatter-idx2">description of, 203, 204<span class="endmatter-idx2_italic">t,</span> 289</p>
			<p class="em-only_endmatter-idx2">galactose-&#173;free diet for, 235</p>
			<p class="em-only_endmatter-idx1">Gallamine, 382</p>
			<p class="em-only_endmatter-idx1">Gametes, 215</p>
			<p class="em-only_endmatter-idx1">Ganciclovir, 360<span class="endmatter-idx1_italic">t,</span> 432<span class="endmatter-idx1_italic">t,</span> 434–435</p>
			<p class="em-only_endmatter-idx1">Ganciclovir sodium, 432<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ganfort. <span class="endmatter-idx1_italic">See</span> Bimatoprost/timolol maleate</p>
			<p class="em-only_endmatter-idx1">Ganglion-&#173;blocking drugs, 383<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ganglion cell layer, 92</p>
			<p class="em-only_endmatter-idx1">Ganglion cells</p>
			<p class="em-only_endmatter-idx2">axons of, 87</p>
			<p class="em-only_endmatter-idx2">description of, 317</p>
			<p class="em-only_endmatter-idx1">Gasserian ganglion, 131</p>
			<p class="em-only_endmatter-idx1">Gastrulation, 143–144</p>
			<p class="em-only_endmatter-idx1">Gatifloxacin, 421<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">GCL.&#160;<span class="endmatter-idx1_italic">See</span> Ganglion cell layer</p>
			<p class="em-only_endmatter-idx1">Gel-&#173;forming drops, for drug delivery, 366</p>
			<p class="em-only_endmatter-idx1">Gelatinase, 294</p>
			<p class="em-only_endmatter-idx1">Gene(s)</p>
			<p class="em-only_endmatter-idx2">cancer, 183–184</p>
			<p class="em-only_endmatter-idx2">definition of, 176, 213</p>
			<p class="em-only_endmatter-idx2">disease association for, 187–188</p>
			<p class="em-only_endmatter-idx2">in&#173;de&#173;pen&#173;dent assortment of, 216–217</p>
			<p class="em-only_endmatter-idx2">linkage studies of, 187</p>
			<p class="em-only_endmatter-idx2">recessive, 202</p>
			<p class="em-only_endmatter-idx2">segregation of, 215–216</p>
			<p class="em-only_endmatter-idx2">size variations among, 213</p>
			<p class="em-only_endmatter-idx2">structure of, 176–177</p>
			<p class="em-only_endmatter-idx2">word origin of, 213</p>
			<p class="em-only_endmatter-idx1">Gene assignments, 187–188</p>
			<p class="em-only_endmatter-idx1">Gene dosage, 187</p>
			<p class="em-only_endmatter-idx1">Gene mapping, 188</p>
			<p class="em-only_endmatter-idx1">Gene therapy</p>
			<p class="em-only_endmatter-idx2">adeno-&#173;associated virus vectors, 194, 196</p>
			<p class="em-only_endmatter-idx2">dominant diseases treated with, 197–198</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic diseases treated with, 236</p>
			<p class="em-only_endmatter-idx2">replacement of absent gene product in X-&#173;linked and recessive diseases, 194, 196</p>
			<p class="em-only_endmatter-idx1">Gene transcription and translation</p>
			<p class="em-only_endmatter-idx2">definition of, 179</p>
			<p class="em-only_endmatter-idx2">overview of, 178–179</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic, 210–211</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic counseling</p>
			<p class="em-only_endmatter-idx2">description of, 205, 236–237</p>
			<p class="em-only_endmatter-idx2">&#173;family history in, 237</p>
			<p class="em-only_endmatter-idx2">issues in, 237–238</p>
			<p class="em-only_endmatter-idx2">preimplantation ge&#173;ne&#173;tic diagnosis, 221, <br />239–240</p>
			<p class="em-only_endmatter-idx2">prenatal diagnosis, 239</p>
			<p class="em-only_endmatter-idx2">referrals for providers of support for persons with disabilities, 240</p>
			<p class="em-only_endmatter-idx2">reproductive issues, 238–240</p>
			<p class="em-only_endmatter-idx2">requirements of, 237</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic diseases and disorders. <span class="endmatter-idx1_italic">See also specific disease or disorder</span></p>
			<p class="em-only_endmatter-idx2">chelation of excessive metabolites, 235</p>
			<p class="em-only_endmatter-idx2">clinical management of, 234–236</p>
			<p class="em-only_endmatter-idx2">complications of, 236</p>
			<p class="em-only_endmatter-idx2">dietary control of, 235</p>
			<p class="em-only_endmatter-idx2">drug therapy for, 236</p>
			<p class="em-only_endmatter-idx2">enzyme replacement therapy for, 235</p>
			<p class="em-only_endmatter-idx2">ethnic concentration of, 229</p>
			<p class="em-only_endmatter-idx2">explanation of, 234</p>
			<p class="em-only_endmatter-idx2">gene therapy for, 236</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic testing for, 238</p>
			<p class="em-only_endmatter-idx2">multifactorial inheritance of, 232–233</p>
			<p class="em-only_endmatter-idx2">polygenic inheritance of, 232–233</p>
			<p class="em-only_endmatter-idx2">prevalence of, 171</p>
			<p class="em-only_endmatter-idx2">racial concentration of, 229</p>
			<p class="em-only_endmatter-idx2">sequelae of, 236</p>
			<p class="em-only_endmatter-idx2">single-&#173;gene, 218</p>
			<p class="em-only_endmatter-idx2">treatment of, 235–236</p>
			<p class="em-only_endmatter-idx2">variability of, 218–219</p>
			<p class="em-only_endmatter-idx2">vitamin therapy for, 236</p>
			<p class="em-only_endmatter-idx2">vitreous affected by, 302, 304</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic heterogeneity, 212, 213<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic linkage, 175</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic map, 213</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic markers, 187</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tic testing</p>
			<p class="em-only_endmatter-idx2">AAO Task Force on Ge&#173;ne&#173;tic Testing recommendations for, 240–241</p>
			<p class="em-only_endmatter-idx2">description of, 238</p>
			<p class="em-only_endmatter-idx2">direct-&#173;to-&#173;consumer, 241</p>
			<p class="em-only_endmatter-idx2">of minors, 241</p>
			<p class="em-only_endmatter-idx1">Ge&#173;ne&#173;tics</p>
			<p class="em-only_endmatter-idx2">clinical</p>
			<p class="em-only_endmatter-idx3">chromosome analy&#173;sis. <span class="endmatter-idx3_italic">See</span> Chromosome analy&#173;sis</p>
			<p class="em-only_endmatter-idx3">chromosomes, 213–217</p>
			<p class="em-only_endmatter-idx3">expressivity, 220</p>
			<p class="em-only_endmatter-idx3">genes, 213–217</p>
			<p class="em-only_endmatter-idx3">inheritance patterns. <span class="endmatter-idx3_italic">See</span> Inheritance</p>
			<p class="em-only_endmatter-idx3">lyonization, 230–231, 231<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">meiosis, 215, 216<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">mitosis, 215</p>
			<p class="em-only_endmatter-idx3">mutations, 217–220. <span class="endmatter-idx3_italic">See also</span> Mutations</p>
			<p class="em-only_endmatter-idx3">overview of, 199–200</p>
			<p class="em-only_endmatter-idx3">pedigree analy&#173;sis in, 200–201, 201<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">penetrance, 219</p>
			<p class="em-only_endmatter-idx3">pleiotropism, 220</p>
			<p class="em-only_endmatter-idx3">terminology associated with, 210–212</p>
			<p class="em-only_endmatter-idx2">definition of, 171</p>
			<p class="em-only_endmatter-idx2">molecular</p>
			<p class="em-only_endmatter-idx3">cell cycle, 173–176, 174<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">DNA damage and repair, 181–182</p>
			<p class="em-only_endmatter-idx3">gene structure, 176–177</p>
			<p class="em-only_endmatter-idx3">gene therapy. <span class="endmatter-idx3_italic">See</span> Gene therapy</p>
			<p class="em-only_endmatter-idx3">gene transcription and translation. <span class="endmatter-idx3_italic">See</span> Gene transcription and translation</p>
			<p class="em-only_endmatter-idx3">mitochondrial diseases. <span class="endmatter-idx3_italic">See</span> Mitochondrial <br />diseases</p>
			<p class="em-only_endmatter-idx3">mutations</p>
			<p class="em-only_endmatter-idx4">disease and, 182–183</p>
			<p class="em-only_endmatter-idx4">screening for, 189–194, 190–193<span class="endmatter-idx4_italic">f</span></p>
			<p class="em-only_endmatter-idx3">noncoding DNA, 177–178</p>
			<p class="em-only_endmatter-idx2">pharmacoge&#173;ne&#173;tics, 233–234</p>
			<p class="em-only_endmatter-idx1">Geniculocalcarine radiation, 116<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Genome, 210, 218</p>
			<p class="em-only_endmatter-idx1">Genome editing, 198</p>
			<p class="em-only_endmatter-idx1">Genome-&#173;wide association studies, 182, 189–191, 193–194, 218</p>
			<p class="em-only_endmatter-idx1">Genotype, 218</p>
			<p class="em-only_endmatter-idx1">Gentamicin sulfate, 418<span class="endmatter-idx1_italic">t,</span> 425</p>
			<p class="em-only_endmatter-idx1">GFR.&#160;<span class="endmatter-idx1_italic">See</span> Glomerular filtration rate</p>
			<p class="em-only_endmatter-idx1">Gillespie syndrome, 225</p>
			<p class="em-only_endmatter-idx1">Gland of Krause, 28<span class="endmatter-idx1_italic">f,</span> 30<span class="endmatter-idx1_italic">t,</span> 41, 251, 253</p>
			<p class="em-only_endmatter-idx1">Gland of Moll, 29, 30<span class="endmatter-idx1_italic">t,</span> 30<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Gland of Wolfring, 30<span class="endmatter-idx1_italic">t,</span> 41, 251, 253</p>
			<p class="em-only_endmatter-idx1">Gland of Zeis, 28, 30<span class="endmatter-idx1_italic">t,</span> 30<span class="endmatter-idx1_italic">f,</span> 250</p>
			<p class="em-only_endmatter-idx1">Glaucoma</p>
			<p class="em-only_endmatter-idx2">angle-&#173;closure, 387</p>
			<p class="em-only_endmatter-idx2">oxidative stress in, 345</p>
			<p class="em-only_endmatter-idx2">primary open-&#173;angle, 233, 345, 377–378, 381, <br />387</p>
			<p class="em-only_endmatter-idx2">reactive oxygen species in, 345</p>
			<p class="em-only_endmatter-idx1">Glial cells, 317</p>
			<p class="em-only_endmatter-idx1">Globe</p>
			<p class="em-only_endmatter-idx2">layers of, 48–49</p>
			<p class="em-only_endmatter-idx2">posterior view of, 24<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">topographic features of, 48–49</p>
			<p class="em-only_endmatter-idx1">Glomerular filtration rate (GFR), 351–352</p>
			<p class="em-only_endmatter-idx1">Glucocorticoids</p>
			<p class="em-only_endmatter-idx2">administration of, 403, 407<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">adverse effects of, 401–403</p>
			<p class="em-only_endmatter-idx2">cell-&#173;specific effects of, 399</p>
			<p class="em-only_endmatter-idx2">in el&#173;derly patients, 401</p>
			<p class="em-only_endmatter-idx2">immune-&#173;mediated inflammation effects of, 399</p>
			<p class="em-only_endmatter-idx2">indications for, 399</p>
			<p class="em-only_endmatter-idx2">intraocular pressure elevation by, 401–402, 402<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">regimens for, 403–407</p>
			<p class="em-only_endmatter-idx2">types of, 403–407</p>
			<p class="em-only_endmatter-idx1">Glucose</p>
			<p class="em-only_endmatter-idx2">aqueous humor concentration of, 274–275</p>
			<p class="em-only_endmatter-idx2">lens metabolism of, 290</p>
			<p class="em-only_endmatter-idx2">in ret&#173;i&#173;nal pigment epithelium, 323</p>
			<p class="em-only_endmatter-idx2">in tear film, 252</p>
			<p class="em-only_endmatter-idx1">Glutathione (GSH)</p>
			<p class="em-only_endmatter-idx2">in aqueous humor, 275</p>
			<p class="em-only_endmatter-idx2">description of, 341</p>
			<p class="em-only_endmatter-idx2">oxidation-&#173;reduction cycle, 340</p>
			<p class="em-only_endmatter-idx2">reactive oxygen species and, 339</p>
			<p class="em-only_endmatter-idx1">Glutathione peroxidase, 341</p>
			<p class="em-only_endmatter-idx1">Glycerin, 397, 398<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Glycocalyx, 260, 261<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Glycosaminoglycans, 53, 263, 297</p>
			<p class="em-only_endmatter-idx1">GM<span class="endmatter-idx1_subscript _idGenCharOverride-1">1</span> gangliosidosis, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">GM<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span> gangliosidosis</p>
			<p class="em-only_endmatter-idx2">type I, 204<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">type II, 204<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Goblet cells</p>
			<p class="em-only_endmatter-idx2">description of, 30<span class="endmatter-idx2_italic">t,</span> 43, 44</p>
			<p class="em-only_endmatter-idx2">mucin production by, 253</p>
			<p class="em-only_endmatter-idx1">Goldenhar syndrome, 144</p>
			<p class="em-only_endmatter-idx1">Goldmann equation, 271, 273</p>
			<p class="em-only_endmatter-idx1">Graves orbitopathy, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Gray line, 28</p>
			<p class="em-only_endmatter-idx1">Gray &#173;matter, 458, 459<span class="endmatter-idx1_italic">t,</span> 460<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Gray zone, 55</p>
			<p class="em-only_endmatter-idx1">Greater superficial petrosal nerve, 135</p>
			<p class="em-only_endmatter-idx1">Greater wing of sphenoid bone, 6–7<span class="endmatter-idx1_italic">f,</span> 9–10<span class="endmatter-idx1_italic">f,</span> 11</p>
			<p class="em-only_endmatter-idx1">Ground substance, of cornea, 53</p>
			<p class="em-only_endmatter-idx1">Growth &#173;factors</p>
			<p class="em-only_endmatter-idx2">in aqueous humor, 277</p>
			<p class="em-only_endmatter-idx2">bioavailability of, 277</p>
			<p class="em-only_endmatter-idx2">definition of, 448</p>
			<p class="em-only_endmatter-idx2">in ocular development, 165–166</p>
			<p class="em-only_endmatter-idx2">in tear film, 252</p>
			<p class="em-only_endmatter-idx2">types of, 448–449</p>
			<p class="em-only_endmatter-idx1">GSH.&#160;<span class="endmatter-idx1_italic">See</span> Glutathione</p>
			<p class="em-only_endmatter-idx1">Guanine, 176</p>
			<p class="em-only_endmatter-idx1">Guanine nucleotide-&#173;binding proteins, 395</p>
			<p class="em-only_endmatter-idx1">Guanylate cyclase, 308, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">GWAS. <span class="endmatter-idx1_italic">See</span> Genome-&#173;wide association studies</p>
			<p class="em-only_endmatter-idx1">Gyrus rectus, 105, 108<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx-alpha_italic">Haemophilus influenzae,</span> 419</p>
			<p class="em-only_endmatter-idx1">Haller layer, 76, 77<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Haploid, 215</p>
			<p class="em-only_endmatter-idx1">Haploid insufficiency, 197</p>
			<p class="em-only_endmatter-idx1">Haploinsufficiency, 226</p>
			<p class="em-only_endmatter-idx1">HapMap, 189–190, 190<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hassall-&#173;Henle warts, 53</p>
			<p class="em-only_endmatter-idx1">Healon, 445</p>
			<p class="em-only_endmatter-idx1">Healon-5, 445</p>
			<p class="em-only_endmatter-idx1">Healon&#160;GV, 445</p>
			<p class="em-only_endmatter-idx1">Helicases, 181</p>
			<p class="em-only_endmatter-idx1">Hemidesmosomes, 51, 52<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hemifacial spasm, 359, 475<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hemorrhage, vitreous injury caused by, 302</p>
			<p class="em-only_endmatter-idx1">Hemorrhagic occlusive ret&#173;i&#173;nal vasculitis (HORV), <br />361</p>
			<p class="em-only_endmatter-idx1">Henle fiber layer, 84, 92, 94<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hereditary, 210–211</p>
			<p class="em-only_endmatter-idx1">Hereditary retinoblastomas, 226–227</p>
			<p class="em-only_endmatter-idx1">Hering’s law of equal innervation, 124</p>
			<p class="em-only_endmatter-idx1">Heritability, 210</p>
			<p class="em-only_endmatter-idx1">Hermansky-&#173;Pudlak syndrome, 229</p>
			<p class="em-only_endmatter-idx1">Herpes simplex keratitis, 447</p>
			<p class="em-only_endmatter-idx1">Herpes simplex virus (HSV), 434</p>
			<p class="em-only_endmatter-idx1">Herpes zoster virus (HZV), 434</p>
			<p class="em-only_endmatter-idx1">Herpetic keratitis, 394</p>
			<p class="em-only_endmatter-idx1">hESC. <span class="endmatter-idx1_italic">See</span> &#173;Human embryonic stem cells</p>
			<p class="em-only_endmatter-idx1">Heteroplasmy, 176</p>
			<p class="em-only_endmatter-idx1">Heterozygous, 214</p>
			<p class="em-only_endmatter-idx1">Hexose monophosphate pathway, 260</p>
			<p class="em-only_endmatter-idx1">Hexose monophosphate shunt, 289</p>
			<p class="em-only_endmatter-idx1">High-&#173;frequency ultrasound, 462</p>
			<p class="em-only_endmatter-idx1">Homatropaire. <span class="endmatter-idx1_italic">See</span> Homatropine hydrobromide</p>
			<p class="em-only_endmatter-idx1">Homatropine hydrobromide, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Homeobox genes</p>
			<p class="em-only_endmatter-idx2">description of, 164–165</p>
			<p class="em-only_endmatter-idx2">functions of, 171</p>
			<p class="em-only_endmatter-idx1">Homeotic selector genes, 171</p>
			<p class="em-only_endmatter-idx1">Homocystinuria, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Homologous chromosomes, 175, 215–216</p>
			<p class="em-only_endmatter-idx1">Homonymous hemianopia, 474<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Homozygous, 214</p>
			<p class="em-only_endmatter-idx1">Horizontal cells, 315<span class="endmatter-idx1_italic">f,</span> 316</p>
			<p class="em-only_endmatter-idx1">Horner muscle, 29, 32<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Horner syndrome</p>
			<p class="em-only_endmatter-idx2">apraclonidine for diagnosis of, 386</p>
			<p class="em-only_endmatter-idx2">imaging studies for, 475<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">HORV. <span class="endmatter-idx1_italic">See</span> Hemorrhagic occlusive ret&#173;i&#173;nal vasculitis</p>
			<p class="em-only_endmatter-idx1">HSV.&#160;<span class="endmatter-idx1_italic">See</span> Herpes simplex virus</p>
			<p class="em-only_endmatter-idx1">&#173;Human embryonic stem cells, 166</p>
			<p class="em-only_endmatter-idx1">&#173;Human Genome Proj&#173;ect, 187</p>
			<p class="em-only_endmatter-idx1">Hunter syndrome, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hurler syndrome, 204<span class="endmatter-idx1_italic">t,</span> 214</p>
			<p class="em-only_endmatter-idx1">Hyalocytes, 101, 294, 299<span class="endmatter-idx1_italic">f,</span> 299–300</p>
			<p class="em-only_endmatter-idx1">Hyaloid artery, 158<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Hyaloideocapsular ligament, 157</p>
			<p class="em-only_endmatter-idx1">Hyaluronan</p>
			<p class="em-only_endmatter-idx2">description of, 293</p>
			<p class="em-only_endmatter-idx2">in vitreous, 297</p>
			<p class="em-only_endmatter-idx1">Hyaluronic acid, 293, 371<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hyaluronidase, 440</p>
			<p class="em-only_endmatter-idx1">Hydrocortisone, 402<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hydrocortisone/neomycin sulfate/polymyxin B sulfate, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hydrocortisone/neomycin sulfate/polymyxin B sulfate/bacitracin zinc, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hydrogen peroxide (H2O2), 336, 337<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hydroxyamphetamine hydrobromide, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hydroxyamphetamine hydrobromide/tropicamide, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hydroxyl radical, 337<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hyperglycinemia, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Hyperosmolar drugs, 443</p>
			<p class="em-only_endmatter-idx1">Hypotension, phenylephrine hydrochloride for, 384</p>
			<p class="em-only_endmatter-idx1">Hypoxia inducible &#173;factor, 228</p>
			<p class="em-only_endmatter-idx1">HZV. <span class="endmatter-idx1_italic">See</span> Herpes zoster virus</p>
			<p class="em-only_endmatter-idx1">Ibuprofen, 409<span class="endmatter-idx-alpha_italic">t</span></p>
			<p class="em-only_endmatter-idx1">ICAM-1. <span class="endmatter-idx1_italic">See</span> Intercellular adhesion molecule 1</p>
			<p class="em-only_endmatter-idx1">ICG.&#160;<span class="endmatter-idx1_italic">See</span> Indocyanine green</p>
			<p class="em-only_endmatter-idx1">ICSI. <span class="endmatter-idx1_italic">See</span> Intracytoplasmic sperm injection</p>
			<p class="em-only_endmatter-idx1">Idiopathic intracranial hypertension, 391</p>
			<p class="em-only_endmatter-idx1">Idoxuridine, 432<span class="endmatter-idx1_italic">t,</span> 433</p>
			<p class="em-only_endmatter-idx1">IFIS. <span class="endmatter-idx1_italic">See</span> Intraoperative floppy iris syndrome</p>
			<p class="em-only_endmatter-idx1">IgA. <span class="endmatter-idx1_italic">See</span> Immunoglobulin&#160;A</p>
			<p class="em-only_endmatter-idx1">IgE. <span class="endmatter-idx1_italic">See</span> Immunoglobulin&#160;E</p>
			<p class="em-only_endmatter-idx1">IgE-&#173;mediated hypersensitivity reaction. <span class="endmatter-idx1_italic">See</span> Immunoglobulin E (IgE)–&#173;mediated hypersensitivity reaction</p>
			<p class="em-only_endmatter-idx1">IgG. <span class="endmatter-idx1_italic">See</span> Immunoglobulin&#160;G</p>
			<p class="em-only_endmatter-idx1">Ihh, 166</p>
			<p class="em-only_endmatter-idx1">Ilevro. <span class="endmatter-idx1_italic">See</span> Nepafenac</p>
			<p class="em-only_endmatter-idx1">ILM.&#160;<span class="endmatter-idx1_italic">See</span> Internal limiting membrane</p>
			<p class="em-only_endmatter-idx1">Imaging studies</p>
			<p class="em-only_endmatter-idx2">computed tomography. <span class="endmatter-idx2_italic">See</span> Computed tomography</p>
			<p class="em-only_endmatter-idx2">indications for, 454, 457, 473–476<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging. <span class="endmatter-idx2_italic">See</span> Magnetic resonance imaging</p>
			<p class="em-only_endmatter-idx2">ordering of, 472, 473–476<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ultrasound/ultrasonography. <span class="endmatter-idx2_italic">See</span> Ultrasound/ultrasonography</p>
			<p class="em-only_endmatter-idx1">Imidazoles, 429–431, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Imipenem/cilastatin sodium, 418<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Immunoglobulin A (IgA), 252</p>
			<p class="em-only_endmatter-idx1">Immunoglobulin E (IgE), 399</p>
			<p class="em-only_endmatter-idx1">Immunoglobulin E (IgE)–&#173;mediated hypersensitivity reaction, 351</p>
			<p class="em-only_endmatter-idx1">Immunoglobulin G (IgG), 399</p>
			<p class="em-only_endmatter-idx1">Immunomodulatory therapy (IMT), 403, 404–406<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Implants, for drug delivery, 364</p>
			<p class="em-only_endmatter-idx1">Imprinting</p>
			<p class="em-only_endmatter-idx2">definition of, 180</p>
			<p class="em-only_endmatter-idx2">diseases caused by abnormalities in, 180–181</p>
			<p class="em-only_endmatter-idx1">IMT.&#160;<span class="endmatter-idx1_italic">See</span> Immunomodulatory therapy</p>
			<p class="em-only_endmatter-idx1">In vitro fertilization, 238</p>
			<p class="em-only_endmatter-idx1">Inborn errors of metabolism, 203, 205</p>
			<p class="em-only_endmatter-idx1">Incomplete penetrance, 207</p>
			<p class="em-only_endmatter-idx1">Incontinentia pigmenti, 209–210</p>
			<p class="em-only_endmatter-idx1">In&#173;de&#173;pen&#173;dent assortment, 175, 216–217</p>
			<p class="em-only_endmatter-idx1">Indirect-&#173;acting adrenergic agonists, 387</p>
			<p class="em-only_endmatter-idx1">Indirect-&#173;acting agonists</p>
			<p class="em-only_endmatter-idx2">cholinergic, 379</p>
			<p class="em-only_endmatter-idx2">nicotinic, 381</p>
			<p class="em-only_endmatter-idx1">Indirect traumatic optic neuropathy, 115</p>
			<p class="em-only_endmatter-idx1">Indocyanine green (ICG), 362, 444</p>
			<p class="em-only_endmatter-idx1">Indomethacin, 409<span class="endmatter-idx1_italic">t,</span> 410</p>
			<p class="em-only_endmatter-idx1">INDs. <span class="endmatter-idx1_italic">See</span> Investigational new drugs</p>
			<p class="em-only_endmatter-idx1">Induced pluripotent stem cells</p>
			<p class="em-only_endmatter-idx2">CRISPR–&#173;Cas9 and, 198</p>
			<p class="em-only_endmatter-idx2">description of, 166</p>
			<p class="em-only_endmatter-idx1">Inducible nitric oxide synthase (iNOS), 394</p>
			<p class="em-only_endmatter-idx1">Infectious keratitis, 426</p>
			<p class="em-only_endmatter-idx1">Inferior canaliculus, 32<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inferior oblique muscle</p>
			<p class="em-only_endmatter-idx2">anatomy of, 17<span class="endmatter-idx2_italic">f,</span> 28<span class="endmatter-idx2_italic">f,</span> 107<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 19<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">origins of, 18</p>
			<p class="em-only_endmatter-idx1">Inferior ophthalmic vein, 12, 12<span class="endmatter-idx1_italic">f,</span> 26<span class="endmatter-idx1_italic">f,</span> 34<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inferior orbital fissure, 6<span class="endmatter-idx1_italic">f,</span> 10<span class="endmatter-idx1_italic">f,</span> 12</p>
			<p class="em-only_endmatter-idx1">Inferior punctum, 27</p>
			<p class="em-only_endmatter-idx1">Inferior rectus muscle</p>
			<p class="em-only_endmatter-idx2">anatomy of, 17<span class="endmatter-idx2_italic">f,</span> 20<span class="endmatter-idx2_italic">f,</span> 28<span class="endmatter-idx2_italic">f,</span> 107<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 19<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">computed tomography of, 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inferior tarsal muscle, 35</p>
			<p class="em-only_endmatter-idx1">Inferior turbinate, 14<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inferomedial orbital strut, 14</p>
			<p class="em-only_endmatter-idx1">Inferotemporal fossa, 12</p>
			<p class="em-only_endmatter-idx1">Inflamase Forte. <span class="endmatter-idx1_italic">See</span> Prednisolone sodium phosphate</p>
			<p class="em-only_endmatter-idx1">Inflammation, orbital</p>
			<p class="em-only_endmatter-idx2">imaging studies for, 476<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">nonsteroidal anti-&#173;inflammatory drugs for, 410</p>
			<p class="em-only_endmatter-idx1">Infliximab, 405<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Infraorbital artery, 23<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Infraorbital canal, 11</p>
			<p class="em-only_endmatter-idx1">Infraorbital foramen, 9<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Infraorbital groove, 6<span class="endmatter-idx1_italic">f,</span> 8, 9<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Infraorbital vein, 26<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Infundibulum, 108<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inheritance</p>
			<p class="em-only_endmatter-idx2">codominant patterns of, 203</p>
			<p class="em-only_endmatter-idx2">dominant</p>
			<p class="em-only_endmatter-idx3">autosomal, 206–208, 207<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">description of, 202–203</p>
			<p class="em-only_endmatter-idx3">X-&#173;linked, 209, 210<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx2">maternal, 210, 218</p>
			<p class="em-only_endmatter-idx2">multifactorial, 232–233</p>
			<p class="em-only_endmatter-idx2">polygenic, 232–233</p>
			<p class="em-only_endmatter-idx2">recessive</p>
			<p class="em-only_endmatter-idx3">autosomal, 203–206</p>
			<p class="em-only_endmatter-idx3">description of, 202–203</p>
			<p class="em-only_endmatter-idx3">X-&#173;linked, 208–209, 209<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx2">X-&#173;linked</p>
			<p class="em-only_endmatter-idx3">description of, 208</p>
			<p class="em-only_endmatter-idx3">disorders associated with, 210</p>
			<p class="em-only_endmatter-idx3">dominant, 209, 210<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">recessive, 208–209, 209<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Inner neuroblastic layer, 155<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Inner nuclear layer, 92</p>
			<p class="em-only_endmatter-idx1">Inner plexiform layer, 92</p>
			<p class="em-only_endmatter-idx1">iNOS. <span class="endmatter-idx1_italic">See</span> Inducible nitric oxide synthase</p>
			<p class="em-only_endmatter-idx1">Inositol, 275</p>
			<p class="em-only_endmatter-idx1">Insulin-&#173;like growth &#173;factor, 448</p>
			<p class="em-only_endmatter-idx1">Insulin-&#173;like growth &#173;factor binding proteins, 277</p>
			<p class="em-only_endmatter-idx1">Intercellular adhesion molecule 1 (ICAM-1), 252, 415</p>
			<p class="em-only_endmatter-idx1">Interdigitations, 286, 287<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Interferon, 447–448</p>
			<p class="em-only_endmatter-idx1">Interferon alfa-2b, 448</p>
			<p class="em-only_endmatter-idx1">Intermarginal sulcus, 28</p>
			<p class="em-only_endmatter-idx1">Intermittent ataxia, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Intermuscular septum, 44</p>
			<p class="em-only_endmatter-idx1">Internal carotid artery</p>
			<p class="em-only_endmatter-idx2">anatomy of, 106<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 138</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Internal limiting membrane (ILM)</p>
			<p class="em-only_endmatter-idx2">anatomy of, 73<span class="endmatter-idx2_italic">f </span></p>
			<p class="em-only_endmatter-idx2">development of, 155</p>
			<p class="em-only_endmatter-idx2">vitreoret&#173;i&#173;nal interface, 296</p>
			<p class="em-only_endmatter-idx1">Internal reflectivity, 463</p>
			<p class="em-only_endmatter-idx1">International HapMap Proj&#173;ect, 189–190</p>
			<p class="em-only_endmatter-idx1">Internuclear ophthalmoplegia, 475<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Interphotoreceptor retinoid-&#173;binding protein, 326</p>
			<p class="em-only_endmatter-idx1">Intersexes, 225</p>
			<p class="em-only_endmatter-idx1">Intracameral drug delivery, 359–360, 360<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Intracytoplasmic sperm injection, 239</p>
			<p class="em-only_endmatter-idx1">Intramuscular injections, 362</p>
			<p class="em-only_endmatter-idx1">Intraocular gases, 360<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Intraocular injections, 359–361</p>
			<p class="em-only_endmatter-idx1">Intraocular lenses, for drug delivery, 364–365</p>
			<p class="em-only_endmatter-idx1">Intraocular pressure</p>
			<p class="em-only_endmatter-idx2">apraclonidine hydrochloride effects on, 385</p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_accent">β</span>-&#173;agonist effects on, 390</p>
			<p class="em-only_endmatter-idx2">brimonidine effects on, 386</p>
			<p class="em-only_endmatter-idx2">carbachol effects on, 377</p>
			<p class="em-only_endmatter-idx2">carbonic anhydrase inhibitors’ effect on, 392</p>
			<p class="em-only_endmatter-idx2">glucocorticoid-&#173;induced elevation of, 401–402, 402<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">Goldmann equation and, 271, 273</p>
			<p class="em-only_endmatter-idx2">maintenance of, 271</p>
			<p class="em-only_endmatter-idx2">netarsudil effects on, 396</p>
			<p class="em-only_endmatter-idx2">rimexolone effects on, 403</p>
			<p class="em-only_endmatter-idx1">Intraoperative floppy iris syndrome (IFIS), 384</p>
			<p class="em-only_endmatter-idx1">Intravenous injections, 362</p>
			<p class="em-only_endmatter-idx1">Intravitreal drug delivery, 360<span class="endmatter-idx1_italic">t,</span> 361</p>
			<p class="em-only_endmatter-idx1">Introns</p>
			<p class="em-only_endmatter-idx2">description of, 176</p>
			<p class="em-only_endmatter-idx2">excision of, 179</p>
			<p class="em-only_endmatter-idx1">Investigational new drugs (INDs), 371</p>
			<p class="em-only_endmatter-idx1">Iodinated contrast agents, 457</p>
			<p class="em-only_endmatter-idx1">Ionization constant, 262</p>
			<p class="em-only_endmatter-idx1">Iontophoresis, 367</p>
			<p class="em-only_endmatter-idx1">Iopidine. <span class="endmatter-idx1_italic">See</span> Apraclonidine hydrochloride</p>
			<p class="em-only_endmatter-idx1">IPE.&#160;<span class="endmatter-idx1_italic">See</span> Iris pigment epithelium</p>
			<p class="em-only_endmatter-idx1">IRBP. <span class="endmatter-idx1_italic">See</span> Interphotoreceptor retinoid-&#173;binding protein</p>
			<p class="em-only_endmatter-idx1">Iridocyclitis, 380–381, 434</p>
			<p class="em-only_endmatter-idx1">Iris</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48<span class="endmatter-idx2_italic">f,</span> 69–70<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">anterior pigmented epithelium of, 70–71, 71<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">blood vessels of, 69</p>
			<p class="em-only_endmatter-idx2">collarette of, 69</p>
			<p class="em-only_endmatter-idx2">development of, 157, 159–160<span class="endmatter-idx2_italic">f,</span> 160</p>
			<p class="em-only_endmatter-idx2">dilator muscles of</p>
			<p class="em-only_endmatter-idx3">description of, 70–71, 160<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">phenylephrine hydrochloride effects on, 384</p>
			<p class="em-only_endmatter-idx2">functions of, 269</p>
			<p class="em-only_endmatter-idx2">intramuscular circle of, 22</p>
			<p class="em-only_endmatter-idx2">layers of, 71<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">nerves of, 69</p>
			<p class="em-only_endmatter-idx2">parasympathetic innervation of, 71</p>
			<p class="em-only_endmatter-idx2">physiology of, 269–270</p>
			<p class="em-only_endmatter-idx2">posterior pigmented epithelium of, 71–72</p>
			<p class="em-only_endmatter-idx2">prostaglandin analogues effect on, 393–394</p>
			<p class="em-only_endmatter-idx2">sphincter muscles of</p>
			<p class="em-only_endmatter-idx3">anatomy of, 71<span class="endmatter-idx3_italic">f,</span> 160<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">direct-&#173;acting cholinergic agonists’ effect on, 375</p>
			<p class="em-only_endmatter-idx2">stroma of, 68–69</p>
			<p class="em-only_endmatter-idx2">structures of, 68</p>
			<p class="em-only_endmatter-idx2">surfaces of, 71<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">sympathetic innervation of, 71</p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 471–472<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Iris pigment epithelium, 71–72</p>
			<p class="em-only_endmatter-idx1">Iron, in aqueous humor, 274</p>
			<p class="em-only_endmatter-idx1">Irreversible cholinesterase inhibitors, 379</p>
			<p class="em-only_endmatter-idx1">Irrigating solutions, 443</p>
			<p class="em-only_endmatter-idx1">Isoforms, 179–180</p>
			<p class="em-only_endmatter-idx1">Isoniazid, 233</p>
			<p class="em-only_endmatter-idx1">Isopto Atropine. <span class="endmatter-idx1_italic">See</span> Atropine sulfate</p>
			<p class="em-only_endmatter-idx1">Isopto Homatropine. <span class="endmatter-idx1_italic">See</span> Homatropine hydrobromide</p>
			<p class="em-only_endmatter-idx1">Isopto Hyoscine. <span class="endmatter-idx1_italic">See</span> Scopolamine hydrobromide</p>
			<p class="em-only_endmatter-idx1">Istalol. <span class="endmatter-idx1_italic">See</span> Timolol maleate</p>
			<p class="em-only_endmatter-idx1">Itraconazole, 429, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Junctional scotoma, 474<span class="endmatter-idx-alpha_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Juxtacanalicular trabecular meshwork</p>
			<p class="em-only_endmatter-idx2">definition of, 64</p>
			<p class="em-only_endmatter-idx2">Schlemm canal and, 65<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Kanamycin sulfate, 418<span class="endmatter-idx-alpha_italic">t,</span> 425</p>
			<p class="em-only_endmatter-idx1">Karyotype, 221</p>
			<p class="em-only_endmatter-idx1">Karyotyping, 221</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">K</span><span class="endmatter-idx1_italic_subscript _idGenCharOverride-1">cat</span><span class="endmatter-idx1_italic">,</span> 391</p>
			<p class="em-only_endmatter-idx1">Kearns-&#173;Sayre syndrome, 185</p>
			<p class="em-only_endmatter-idx1">Keratocytes, 53, 259, 263</p>
			<p class="em-only_endmatter-idx1">Ketoconazole, 429, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ketoprofen, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ketorolac tromethamine, 400<span class="endmatter-idx1_italic">t,</span> 409<span class="endmatter-idx1_italic">t,</span> 410</p>
			<p class="em-only_endmatter-idx1">Ketotifen fumarate, 412<span class="endmatter-idx1_italic">t,</span> 413</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Klebsiella</span> spp, 419</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">K</span><span class="endmatter-idx1_italic_subscript _idGenCharOverride-1">m</span><span class="endmatter-idx1_italic">,</span> 391</p>
			<p class="em-only_endmatter-idx1">Knudson’s hypothesis, retinoblastoma and, 227</p>
			<p class="em-only_endmatter-idx1">Krabbe disease, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">L cones, 312, 315</p>
			<p class="em-only_endmatter-idx1">Lacrimal artery, 23<span class="endmatter-idx1_italic">f,</span> 25<span class="endmatter-idx1_italic">f,</span> 40</p>
			<p class="em-only_endmatter-idx1">Lacrimal bone, 9<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lacrimal canaliculi, 42</p>
			<p class="em-only_endmatter-idx1">Lacrimal crest, 9<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lacrimal drainage system, 32<span class="endmatter-idx1_italic">f,</span> 40<span class="endmatter-idx1_italic">f,</span> 42<span class="endmatter-idx1_italic">f,</span> 42–43</p>
			<p class="em-only_endmatter-idx1">Lacrimal glands</p>
			<p class="em-only_endmatter-idx2">accessory, 41, 253. <span class="endmatter-idx2_italic">See also specific gland</span></p>
			<p class="em-only_endmatter-idx2">anatomy of, 39–41</p>
			<p class="em-only_endmatter-idx2">cells of, 40</p>
			<p class="em-only_endmatter-idx2">characteristics of, 30<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">development of, 163</p>
			<p class="em-only_endmatter-idx2">dysfunction of, 255<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fossa of, 7<span class="endmatter-idx2_italic">f,</span> 8</p>
			<p class="em-only_endmatter-idx2">innervation of, 251</p>
			<p class="em-only_endmatter-idx2">lobule of, 41<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 459<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">neurotransmitters in, 251</p>
			<p class="em-only_endmatter-idx2">orbital lobe of, 251</p>
			<p class="em-only_endmatter-idx2">palpebral, 39</p>
			<p class="em-only_endmatter-idx2">palpebral lobe of, 251</p>
			<p class="em-only_endmatter-idx2">secretions produced by, 40</p>
			<p class="em-only_endmatter-idx2">tear production from, 163</p>
			<p class="em-only_endmatter-idx1">Lacrimal nerve, 12<span class="endmatter-idx1_italic">f,</span> 131</p>
			<p class="em-only_endmatter-idx1">Lacrimal puncta, 41, 43</p>
			<p class="em-only_endmatter-idx1">Lacrimal reflex arc, 136<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lacrimal sac, 42</p>
			<p class="em-only_endmatter-idx2">anatomy of, 32<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fossa of, 6<span class="endmatter-idx2_italic">f,</span> 8</p>
			<p class="em-only_endmatter-idx1">Lactate, in aqueous humor, 274</p>
			<p class="em-only_endmatter-idx1">Lamina cribosa, 111, 113</p>
			<p class="em-only_endmatter-idx1">Lamina fusca, 58</p>
			<p class="em-only_endmatter-idx1">Lamina papyracea, 8</p>
			<p class="em-only_endmatter-idx1">Laminin, 304</p>
			<p class="em-only_endmatter-idx1">Lantoprostene bunod (LBN), 394<span class="endmatter-idx1_italic">t,</span> 395</p>
			<p class="em-only_endmatter-idx1">&#173;Laser subepithelial keratomileusis, 263</p>
			<p class="em-only_endmatter-idx1">Lastacaft. <span class="endmatter-idx1_italic">See</span> Alcaftadine</p>
			<p class="em-only_endmatter-idx1">Latanoprost, 363, 368, 393, 394<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Latanoprost/timolol maleate, 394<span class="endmatter-idx1_italic">t,</span> 397<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Lateral canthus, 27<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lateral geniculate nucleus</p>
			<p class="em-only_endmatter-idx2">anatomic relationships with, 124<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">anatomy of, 116–117<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">blood supply of, 122<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Lateral orbital wall, 10, 10<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lateral palpebral artery, 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lateral rectus muscle</p>
			<p class="em-only_endmatter-idx2">anatomy of, 34<span class="endmatter-idx2_italic">f,</span> 107<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">blood supply to, 21</p>
			<p class="em-only_endmatter-idx2">characteristics of, 19<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">computed tomography of, 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">innervation of, 21</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lateral transverse B-&#173;scan, 466<span class="endmatter-idx1_italic">f,</span> 466–467</p>
			<p class="em-only_endmatter-idx1">LBN.&#160;<span class="endmatter-idx1_italic">See</span> Lantoprostene bunod</p>
			<p class="em-only_endmatter-idx1">Leber congenital amaurosis</p>
			<p class="em-only_endmatter-idx2">genes that cause, 213<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic heterogeneity of, 212, 213<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2"><span class="endmatter-idx2_italic">RPE65</span> mutations as cause of, 196, 333</p>
			<p class="em-only_endmatter-idx1">Leber hereditary optic neuropathy (LHON)</p>
			<p class="em-only_endmatter-idx2">description of, 185–186</p>
			<p class="em-only_endmatter-idx2">&#173;family history of, 200</p>
			<p class="em-only_endmatter-idx1">Lecithin retinol acyltransferase, 326, 327<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Legionella pneumophila,</span> 427</p>
			<p class="em-only_endmatter-idx1">Legionnaires’ disease, 427</p>
			<p class="em-only_endmatter-idx1">Leigh necrotizing encephalopathy, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Lens</p>
			<p class="em-only_endmatter-idx2">anatomy of, 79</p>
			<p class="em-only_endmatter-idx2">bow zone/bow region of, 283</p>
			<p class="em-only_endmatter-idx2">capsule of, 79–80, 80<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">chemical composition of, 284–286</p>
			<p class="em-only_endmatter-idx2">cortex of, 283</p>
			<p class="em-only_endmatter-idx2">crystallins in, 281, 284–285</p>
			<p class="em-only_endmatter-idx2">cytoskeletal proteins in, 285</p>
			<p class="em-only_endmatter-idx2">definition of, 79, 281</p>
			<p class="em-only_endmatter-idx2">embryologic development of, 153–155, 154<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">epithelium of, 80, 82</p>
			<p class="em-only_endmatter-idx3">development of, 154<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">structure of, 282–283</p>
			<p class="em-only_endmatter-idx2">fibers of, 82, 283</p>
			<p class="em-only_endmatter-idx2">formation of, 153–155, 154<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">germinative zone of, 82</p>
			<p class="em-only_endmatter-idx2">glucose metabolism in, 290</p>
			<p class="em-only_endmatter-idx2">interdigitations, 286, 287<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 459<span class="endmatter-idx2_italic">t,</span> 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">major intrinsic protein expression by, 283, 285</p>
			<p class="em-only_endmatter-idx2">metabolism in, 289–291</p>
			<p class="em-only_endmatter-idx2">microscopic appearance of, 80<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">nucleus of, 283</p>
			<p class="em-only_endmatter-idx2">organ&#173;ization of, 81<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">oxidative damage to, 339–340</p>
			<p class="em-only_endmatter-idx2">physiology of, 286</p>
			<p class="em-only_endmatter-idx2">plasma membranes of, 284</p>
			<p class="em-only_endmatter-idx2">potassium in, 287</p>
			<p class="em-only_endmatter-idx2">proteins of</p>
			<p class="em-only_endmatter-idx3">description of, 284–285</p>
			<p class="em-only_endmatter-idx3">posttranslational modifications to, 286</p>
			<p class="em-only_endmatter-idx2">pump–&#173;leak hypothesis of solute movement in, 288<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">refractive index of, 281</p>
			<p class="em-only_endmatter-idx2">sodium in, 287</p>
			<p class="em-only_endmatter-idx2">sorbitol accumulation in, 291</p>
			<p class="em-only_endmatter-idx2">structure of, 281–283, 282<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">sutures of, 82</p>
			<p class="em-only_endmatter-idx2">transparency of, 286</p>
			<p class="em-only_endmatter-idx2">zonular fibers of, 82–83, 83<span class="endmatter-idx2_italic">f,</span> 282</p>
			<p class="em-only_endmatter-idx1">Lens capsule</p>
			<p class="em-only_endmatter-idx2">anatomy of, 281–282, 282<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">formation of, 154, 154<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">structure of, 281–282, 282<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lens equator, 283</p>
			<p class="em-only_endmatter-idx1">Lens pit, 153</p>
			<p class="em-only_endmatter-idx1">Lens vesicle, 153–154, 154<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lesser wing of sphenoid bone, 6–7<span class="endmatter-idx1_italic">f,</span> 11</p>
			<p class="em-only_endmatter-idx1">Leukotrienes, 408<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Levator aponeurosis, 28<span class="endmatter-idx1_italic">f,</span> 34–35, 35<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Levator palpebrae superioris</p>
			<p class="em-only_endmatter-idx2">anatomy of, 17<span class="endmatter-idx2_italic">f,</span> 20<span class="endmatter-idx2_italic">f,</span> 28<span class="endmatter-idx2_italic">f,</span> 33–35, 34<span class="endmatter-idx2_italic">f,</span> 107<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 19<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">computed tomography of, 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">innervation of, 21, 124</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">origins of, 18</p>
			<p class="em-only_endmatter-idx1">Levobunolol hydrochloride, 389<span class="endmatter-idx1_italic">t,</span> 390</p>
			<p class="em-only_endmatter-idx1">Levocabastine hydrochloride, 412, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Levofloxacin, 421<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">LFA-1. <span class="endmatter-idx1_italic">See</span> Lymphocyte function–&#173;associated antigen-1</p>
			<p class="em-only_endmatter-idx1">LHON. <span class="endmatter-idx1_italic">See</span> Leber hereditary optic neuropathy</p>
			<p class="em-only_endmatter-idx1">Lidocaine, 360<span class="endmatter-idx1_italic">t,</span> 438<span class="endmatter-idx1_italic">t,</span> 440–441</p>
			<p class="em-only_endmatter-idx1">Lifitegrast, for dry eye syndrome, 258, 415</p>
			<p class="em-only_endmatter-idx1">Ligament of Weiger, 157</p>
			<p class="em-only_endmatter-idx1">Light reflex, 126</p>
			<p class="em-only_endmatter-idx1">Likelihood ratio, 188</p>
			<p class="em-only_endmatter-idx1">Limbal palisades of Vogt, 56<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Limbus</p>
			<p class="em-only_endmatter-idx2">anatomy of, 55–56, 56<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 49</p>
			<p class="em-only_endmatter-idx1">LINEs. <span class="endmatter-idx1_italic">See</span> Long interspersed ele&#173;ments</p>
			<p class="em-only_endmatter-idx1">Linkage disequilibrium, 175</p>
			<p class="em-only_endmatter-idx1">Lipid layer of tear film, 249–250, 250<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lipid peroxidation, 336–338</p>
			<p class="em-only_endmatter-idx1">Lipid solubility, 357</p>
			<p class="em-only_endmatter-idx1">Lipid strip, 249</p>
			<p class="em-only_endmatter-idx1">Lipids, in ret&#173;i&#173;nal pigment epithelium, 324</p>
			<p class="em-only_endmatter-idx1">Lipofuscin, 98, 328</p>
			<p class="em-only_endmatter-idx1">Liposomes, for drug delivery, 366</p>
			<p class="em-only_endmatter-idx1">Lisch nodules, 220</p>
			<p class="em-only_endmatter-idx1">Local administration, of drugs, 359–361</p>
			<p class="em-only_endmatter-idx1">Local anesthetics</p>
			<p class="em-only_endmatter-idx2">composition of, 438</p>
			<p class="em-only_endmatter-idx2">intraocular surgery use of, 441–442</p>
			<p class="em-only_endmatter-idx2">mechanism of action, 439</p>
			<p class="em-only_endmatter-idx2">overview of, 437–440</p>
			<p class="em-only_endmatter-idx2">peribulbar anesthesia, 442</p>
			<p class="em-only_endmatter-idx2">regional anesthetics, 438<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">retrobulbar anesthesia, 442</p>
			<p class="em-only_endmatter-idx2">topical, 439<span class="endmatter-idx2_italic">t,</span> 439–440, 441–442</p>
			<p class="em-only_endmatter-idx2">toxic manifestations of, 439</p>
			<p class="em-only_endmatter-idx2">types of, 440–441</p>
			<p class="em-only_endmatter-idx1">Lockwood ligament, 34<span class="endmatter-idx1_italic">f,</span> 35</p>
			<p class="em-only_endmatter-idx1">Lodoxamide tromethamine, 412<span class="endmatter-idx1_italic">t,</span> 412–413</p>
			<p class="em-only_endmatter-idx1">Logarithm of odds score, 188</p>
			<p class="em-only_endmatter-idx1">Long arm 13 deletion syndrome, 226–227</p>
			<p class="em-only_endmatter-idx1">Long interspersed ele&#173;ments, 177</p>
			<p class="em-only_endmatter-idx1">Long posterior ciliary artery, 24<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Longitudinal ciliary muscle, 25<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Longitudinal scans, 464, 466<span class="endmatter-idx1_italic">f,</span> 468–469<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Loss of heterozygosity, 184</p>
			<p class="em-only_endmatter-idx1">Lotemax. <span class="endmatter-idx1_italic">See</span> Loteprednol etabonate</p>
			<p class="em-only_endmatter-idx1">Loteprednol etabonate, 400<span class="endmatter-idx1_italic">t,</span> 403, 411</p>
			<p class="em-only_endmatter-idx1">Loteprednol etabonate/tobramycin, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Louis-&#173;Bar syndrome, 181</p>
			<p class="em-only_endmatter-idx1">Low-&#173;frequency ultrasound, 462</p>
			<p class="em-only_endmatter-idx1">Lowe syndrome, 232<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Lower eyelids</p>
			<p class="em-only_endmatter-idx2">anatomy of, 26</p>
			<p class="em-only_endmatter-idx2">development of, 163</p>
			<p class="em-only_endmatter-idx2">muscles of, 35</p>
			<p class="em-only_endmatter-idx2">punctum of, 42</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">LOXL1</span> gene, 183</p>
			<p class="em-only_endmatter-idx1">LRAT. <span class="endmatter-idx1_italic">See</span> Lecithin retinol acyltransferase</p>
			<p class="em-only_endmatter-idx1">Lumigan. <span class="endmatter-idx1_italic">See</span> Bimatoprost</p>
			<p class="em-only_endmatter-idx1">Lutein, 94</p>
			<p class="em-only_endmatter-idx1">Lymphatics, of eyelids, 38, 39<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Lymphocyte function–&#173;associated antigen-1 (LFA-1), 258, 415</p>
			<p class="em-only_endmatter-idx1">Lymphocyte inhibitors, 406<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Lyonization, 180, 230–231, 231<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">M cones, 312, 317</p>
			<p class="em-only_endmatter-idx1">Macroautophagy, 283</p>
			<p class="em-only_endmatter-idx1">Macroglia, 317</p>
			<p class="em-only_endmatter-idx1">Macrolide antibiotics, 427</p>
			<p class="em-only_endmatter-idx1">Macula</p>
			<p class="em-only_endmatter-idx2">anatomy of, 83, 93–94</p>
			<p class="em-only_endmatter-idx2">antioxidant localization in, 344<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">B-&#173;scan ultrasonography of, 469<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fibers of, 111</p>
			<p class="em-only_endmatter-idx2">fovea of. <span class="endmatter-idx2_italic">See</span> Fovea</p>
			<p class="em-only_endmatter-idx1">Macula lutea, 93</p>
			<p class="em-only_endmatter-idx1">Macular degeneration</p>
			<p class="em-only_endmatter-idx2">age-&#173;related</p>
			<p class="em-only_endmatter-idx3">genome-&#173;wide association studies for, 193</p>
			<p class="em-only_endmatter-idx3">indocyanine green applications in, 444</p>
			<p class="em-only_endmatter-idx3">Manhattan plot for, 193<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">neovascular, 449</p>
			<p class="em-only_endmatter-idx3">oxidative stress in, 345</p>
			<p class="em-only_endmatter-idx3">vascular endothelial growth &#173;factor inhibitors for, 449</p>
			<p class="em-only_endmatter-idx2">disciform, 471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ultrasonographic findings in, 470<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Macular hole, 300</p>
			<p class="em-only_endmatter-idx1">Macular pucker, 300</p>
			<p class="em-only_endmatter-idx1">Magnetic resonance angiography (MRA), 455<span class="endmatter-idx1_italic">t,</span> 458</p>
			<p class="em-only_endmatter-idx1">Magnetic resonance imaging (MRI)</p>
			<p class="em-only_endmatter-idx2">computed tomography versus, 455<span class="endmatter-idx2_italic">t,</span> 457</p>
			<p class="em-only_endmatter-idx2">concerns regarding, 458, 460</p>
			<p class="em-only_endmatter-idx2">description of, 453</p>
			<p class="em-only_endmatter-idx2">diffusion-&#173;weighted imaging, 458, 461<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">disadvantages of, 458</p>
			<p class="em-only_endmatter-idx2">echo time, 457</p>
			<p class="em-only_endmatter-idx2">gray &#173;matter on, 458, 459<span class="endmatter-idx2_italic">t,</span> 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">indications for, 457, 473–476<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">metallic foreign bodies and, 458</p>
			<p class="em-only_endmatter-idx2">ocular anatomy on, 459<span class="endmatter-idx2_italic">t,</span> 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">princi&#173;ples of, 457</p>
			<p class="em-only_endmatter-idx2">repetition time, 457</p>
			<p class="em-only_endmatter-idx2">T1-&#173;weighted images, 457, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">T2-&#173;weighted images, 457–458, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Magnetic resonance venography (MVA), 455<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Main sensory nucleus, 129–130</p>
			<p class="em-only_endmatter-idx1">Major arterial circle, 24<span class="endmatter-idx1_italic">f,</span> 72</p>
			<p class="em-only_endmatter-idx1">Major intrinsic protein, 283, 285</p>
			<p class="em-only_endmatter-idx1">MAK-&#173;associated retinitis pigmentosa, 229</p>
			<p class="em-only_endmatter-idx1">MALT. <span class="endmatter-idx1_italic">See</span> Mucosa-&#173;associated lymphoid tissue</p>
			<p class="em-only_endmatter-idx1">Mammillary body, 108<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Manganese superoxide dismutase (MnSOD), 342</p>
			<p class="em-only_endmatter-idx1">Manhattan plot, 190–191, 192–193<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Mannitol, 275, 397–398, 398<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Mannosidosis, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Maple syrup urine disease, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Marcaine. <span class="endmatter-idx1_italic">See</span> Bupivacaine</p>
			<p class="em-only_endmatter-idx1">Marfan syndrome, 212</p>
			<p class="em-only_endmatter-idx2">fibrillin defects in, 298</p>
			<p class="em-only_endmatter-idx2">lens zonular fibers in, 82</p>
			<p class="em-only_endmatter-idx2">pleiotropism in, 220</p>
			<p class="em-only_endmatter-idx1">Marginal arterial cascade, 34<span class="endmatter-idx1_italic">f,</span> 37</p>
			<p class="em-only_endmatter-idx1">Massively parallel sequencing, 189</p>
			<p class="em-only_endmatter-idx1">Mast cell(s), 411</p>
			<p class="em-only_endmatter-idx1">Mast-&#173;cell stabilizers, 411–413</p>
			<p class="em-only_endmatter-idx1">Maternal inheritance, 210, 218</p>
			<p class="em-only_endmatter-idx1">Maternally inherited diabetes and deafness (MIDD), 185</p>
			<p class="em-only_endmatter-idx1">Matrix metalloproteinases</p>
			<p class="em-only_endmatter-idx2">-9, 252</p>
			<p class="em-only_endmatter-idx2">in cornea, 264</p>
			<p class="em-only_endmatter-idx2">in tear film, 252</p>
			<p class="em-only_endmatter-idx2">in vitreous from myopia patients, 301</p>
			<p class="em-only_endmatter-idx1">Maxidex. <span class="endmatter-idx1_italic">See</span> Dexamethasone sodium phosphate</p>
			<p class="em-only_endmatter-idx1">Maxillary antrum, 8</p>
			<p class="em-only_endmatter-idx1">Maxillary artery, 23<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Maxillary bone, 6<span class="endmatter-idx1_italic">f,</span> 9–10<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Maxillary sinus, 10<span class="endmatter-idx1_italic">f,</span> 12, 14<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Maxilloethmoidal suture, 9<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Maxitrol. <span class="endmatter-idx1_italic">See</span> Dexamethasone/neomycin sulfate/polymyxin B sulfate</p>
			<p class="em-only_endmatter-idx1">Meckel cave, 131</p>
			<p class="em-only_endmatter-idx1">Medial canthus, 27<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Medial lemniscus, 107<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Medial longitudinal fasciculus, 133</p>
			<p class="em-only_endmatter-idx1">Medial margin, of orbit, 8</p>
			<p class="em-only_endmatter-idx1">Medial orbital wall, 8, 9<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Medial palpebral artery, 23<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Medial rectus muscle</p>
			<p class="em-only_endmatter-idx2">anatomy of, 17<span class="endmatter-idx2_italic">f,</span> 107<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 19<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">computed tomography of, 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Medical therapy, 370–371</p>
			<p class="em-only_endmatter-idx1">Medi&#173;cation adherence, 373</p>
			<p class="em-only_endmatter-idx1">Medi&#173;cation compliance, 373</p>
			<p class="em-only_endmatter-idx1">Medrysone, 400<span class="endmatter-idx1_italic">t,</span> 402<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Meibomian glands</p>
			<p class="em-only_endmatter-idx2">anatomy of, 28<span class="endmatter-idx2_italic">f,</span> 30<span class="endmatter-idx2_italic">t,</span> 37<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">dysfunction of, 250</p>
			<p class="em-only_endmatter-idx2">innervation of, 254</p>
			<p class="em-only_endmatter-idx2">phospholipid secretion by, 249</p>
			<p class="em-only_endmatter-idx1">Meibum, 35</p>
			<p class="em-only_endmatter-idx1">Meiosis, 174–175, 215, 216<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Melanin</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 457</p>
			<p class="em-only_endmatter-idx2">in ret&#173;i&#173;nal pigment epithelium, 331</p>
			<p class="em-only_endmatter-idx1">Melanocytes, 78, 161, 393</p>
			<p class="em-only_endmatter-idx1">Melanogenesis, 331</p>
			<p class="em-only_endmatter-idx1">Melanosomes, 98, 393</p>
			<p class="em-only_endmatter-idx1">MELAS. <span class="endmatter-idx1_italic">See</span> Mitochondrial encephalomyopathy, lactic acidosis, and stroke-&#173;like episodes</p>
			<p class="em-only_endmatter-idx1">Meloxicam, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Membrane proteins, in lens, 285</p>
			<p class="em-only_endmatter-idx1">Membrane-&#173;spanning mucins, 253</p>
			<p class="em-only_endmatter-idx1">MEMS. <span class="endmatter-idx1_italic">See</span> Microelectromechanical systems</p>
			<p class="em-only_endmatter-idx1">Mendel, Gregor, 202</p>
			<p class="em-only_endmatter-idx1">Mendelian diseases, 218</p>
			<p class="em-only_endmatter-idx1">Meningeal sheaths, 114<span class="endmatter-idx1_italic">f,</span> 114–115</p>
			<p class="em-only_endmatter-idx1">Meningiomas, 105</p>
			<p class="em-only_endmatter-idx1">Mepivacaine, 438<span class="endmatter-idx1_italic">t,</span> 440</p>
			<p class="em-only_endmatter-idx1">Merlin, 228</p>
			<p class="em-only_endmatter-idx1">Mesencephalic nucleus, 129</p>
			<p class="em-only_endmatter-idx1">Mesencephalon, 123, 145<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Mesoderm</p>
			<p class="em-only_endmatter-idx2">derivatives of, 149<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">description of, 143, 145<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in embryologic development, 150<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">hyaloid artery arising from, 158<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Messenger&#160;RNA</p>
			<p class="em-only_endmatter-idx2">description of, 176</p>
			<p class="em-only_endmatter-idx2">intron excision, 179</p>
			<p class="em-only_endmatter-idx2">proteins, 273</p>
			<p class="em-only_endmatter-idx1">Metabolic acidosis, 392</p>
			<p class="em-only_endmatter-idx1">Metachromatic leukodystrophy, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Metaphase, 174, 174<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Metarhodopsin&#160;II, 308</p>
			<p class="em-only_endmatter-idx1">Methazolamide, 391<span class="endmatter-idx1_italic">t,</span> 392</p>
			<p class="em-only_endmatter-idx1">Methicillin-&#173;resistant <span class="endmatter-idx1_italic">Staphylococcus aureus</span> (MRSA), 359, 426</p>
			<p class="em-only_endmatter-idx1">Methicillin sodium, 418<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Methotrexate, 404<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Methylation, 180</p>
			<p class="em-only_endmatter-idx1">Methylprednisolone, 399</p>
			<p class="em-only_endmatter-idx1">Metipranolol hydrochloride, 389<span class="endmatter-idx1_italic">t,</span> 390</p>
			<p class="em-only_endmatter-idx1">Meyer loop, 116, 116<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Mezlocillin sodium, 419</p>
			<p class="em-only_endmatter-idx1">mGy. <span class="endmatter-idx1_italic">See</span> Milligray</p>
			<p class="em-only_endmatter-idx1">Micafungin, 431, 431<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Miconazole nitrate, 429, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Microautophagy, 283</p>
			<p class="em-only_endmatter-idx1">Microelectromechanical systems (MEMS), 367</p>
			<p class="em-only_endmatter-idx1">Microglia, 317</p>
			<p class="em-only_endmatter-idx1">Microinvasive glaucoma surgery, Schlemm canal in, 64</p>
			<p class="em-only_endmatter-idx1">Micropinocytotic vesicles, 64</p>
			<p class="em-only_endmatter-idx1">Microsatellites, 177</p>
			<p class="em-only_endmatter-idx1">Microsomal triglyceride transfer protein, 314<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">MIDD. <span class="endmatter-idx1_italic">See</span> Maternally inherited diabetes and deafness</p>
			<p class="em-only_endmatter-idx1">&#173;Middle ce&#173;re&#173;bral artery, 106<span class="endmatter-idx1_italic">f,</span> 139<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">&#173;Middle cranial fossa, 106<span class="endmatter-idx1_italic">f,</span> 460<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">&#173;Middle limiting membrane (MLM), 92</p>
			<p class="em-only_endmatter-idx1">&#173;Middle turbinate, 14<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Milligray (mGy), 456</p>
			<p class="em-only_endmatter-idx1">Millisievert (mSv), 456</p>
			<p class="em-only_endmatter-idx1">Minocycline, 424</p>
			<p class="em-only_endmatter-idx1">Minors, ge&#173;ne&#173;tic testing of, 241</p>
			<p class="em-only_endmatter-idx1">Miotics, 378, 378<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Mismatch repair, 181</p>
			<p class="em-only_endmatter-idx1">Missense mutations, 183</p>
			<p class="em-only_endmatter-idx1">Mitochondria, 176</p>
			<p class="em-only_endmatter-idx1">Mitochondrial diseases</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 184–185</p>
			<p class="em-only_endmatter-idx2">chronic progressive external ophthalmoplegia, 185</p>
			<p class="em-only_endmatter-idx2">Leber hereditary optic neuropathy, 185–186</p>
			<p class="em-only_endmatter-idx2">maternally inherited diabetes and deafness, 185</p>
			<p class="em-only_endmatter-idx2">mitochondrial encephalomyopathy, lactic acidosis, and stroke-&#173;like episodes, 185</p>
			<p class="em-only_endmatter-idx2">neuropathy, ataxia, and retinitis pigmentosa, 186</p>
			<p class="em-only_endmatter-idx2">phenotype of, 184</p>
			<p class="em-only_endmatter-idx2">severity of, 184</p>
			<p class="em-only_endmatter-idx1">Mitochondrial&#160;DNA</p>
			<p class="em-only_endmatter-idx2">acquisition of, 176</p>
			<p class="em-only_endmatter-idx2">diseases associated with. <span class="endmatter-idx2_italic">See</span> Mitochondrial diseases</p>
			<p class="em-only_endmatter-idx2">replicative segregation of, 184</p>
			<p class="em-only_endmatter-idx2">ribosomal RNA encoded by, 184</p>
			<p class="em-only_endmatter-idx2">spontaneous deletions and mutations of, 184</p>
			<p class="em-only_endmatter-idx1">Mitochondrial encephalomyopathy, lactic acidosis, and stroke-&#173;like episodes (MELAS), 185</p>
			<p class="em-only_endmatter-idx1">Mitomycin&#160;C, 371<span class="endmatter-idx1_italic">t,</span> 413–414</p>
			<p class="em-only_endmatter-idx1">Mitophagy, 283</p>
			<p class="em-only_endmatter-idx1">Mitosis, 173, 215</p>
			<p class="em-only_endmatter-idx1">Mitotic nondisjunction, 224</p>
			<p class="em-only_endmatter-idx1">MLM.&#160;<span class="endmatter-idx1_italic">See</span> &#173;Middle limiting membrane</p>
			<p class="em-only_endmatter-idx1">MnSOD. <span class="endmatter-idx1_italic">See</span> Manganese superoxide dismutase</p>
			<p class="em-only_endmatter-idx1">Molecular ge&#173;ne&#173;tics</p>
			<p class="em-only_endmatter-idx2">cell cycle, 173–176, 174<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">DNA damage and repair, 181–182</p>
			<p class="em-only_endmatter-idx2">gene structure, 176–177</p>
			<p class="em-only_endmatter-idx2">gene therapy. <span class="endmatter-idx2_italic">See</span> Gene therapy</p>
			<p class="em-only_endmatter-idx2">gene transcription and translation. <span class="endmatter-idx2_italic">See</span> Gene transcription and translation</p>
			<p class="em-only_endmatter-idx2">mitochondrial diseases. <span class="endmatter-idx2_italic">See</span> Mitochondrial diseases</p>
			<p class="em-only_endmatter-idx2">mutations</p>
			<p class="em-only_endmatter-idx3">disease and, 182–183</p>
			<p class="em-only_endmatter-idx3">screening for, 189–194, 190–193<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">noncoding DNA, 177–178</p>
			<p class="em-only_endmatter-idx1">Monoamine oxidase inhibitors, <span class="endmatter-idx1_greek">α</span><span class="endmatter-idx2_subscript _idGenCharOverride-1">2</span>-&#173;adrenergic agonist interactions with, 386</p>
			<p class="em-only_endmatter-idx1">Monogenic diseases, 218</p>
			<p class="em-only_endmatter-idx1">Monosomy, 223</p>
			<p class="em-only_endmatter-idx1">Morphogenic gradients, 164–166</p>
			<p class="em-only_endmatter-idx1">Morphogens, 165</p>
			<p class="em-only_endmatter-idx1">Mosaicism, 224–225</p>
			<p class="em-only_endmatter-idx1">Mosaics, 224</p>
			<p class="em-only_endmatter-idx1">Moxeza. <span class="endmatter-idx1_italic">See</span> Moxifloxacin hydrochloride</p>
			<p class="em-only_endmatter-idx1">Moxifloxacin hydrochloride, 360<span class="endmatter-idx1_italic">t,</span> 421<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Moxisylyte, 387</p>
			<p class="em-only_endmatter-idx1">MRA.&#160;<span class="endmatter-idx1_italic">See</span> Magnetic resonance angiography</p>
			<p class="em-only_endmatter-idx1">MRI.&#160;<span class="endmatter-idx1_italic">See</span> Magnetic resonance imaging</p>
			<p class="em-only_endmatter-idx1">MRSA. <span class="endmatter-idx1_italic">See</span> Methicillin-&#173;resistant <span class="endmatter-idx1_italic">Staphylococcus aureus</span></p>
			<p class="em-only_endmatter-idx1">mSv. <span class="endmatter-idx1_italic">See</span> Millisievert</p>
			<p class="em-only_endmatter-idx1">Mucin glycoproteins, 260</p>
			<p class="em-only_endmatter-idx1">Mucins, 253</p>
			<p class="em-only_endmatter-idx1">Mucopolysaccharidoses, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Mucosa-&#173;associated lymphoid tissue, 43</p>
			<p class="em-only_endmatter-idx1">M<span class="endmatter-idx1_accent">ü</span>ller cells</p>
			<p class="em-only_endmatter-idx2">description of, 88–89, 92, 111, 112<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">development of, 155<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">M<span class="endmatter-idx1_accent">ü</span>ller muscle, 26, 33, 35</p>
			<p class="em-only_endmatter-idx1">Multifactorial inheritance, 232–233</p>
			<p class="em-only_endmatter-idx1">Muscarinic drugs</p>
			<p class="em-only_endmatter-idx2">adverse effects of, 378</p>
			<p class="em-only_endmatter-idx2">agonists</p>
			<p class="em-only_endmatter-idx3">adverse effects of, 378</p>
			<p class="em-only_endmatter-idx3">direct-&#173;acting, 375–379, 376–377<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">indirect-&#173;acting, 379</p>
			<p class="em-only_endmatter-idx2">antagonists, 380–381</p>
			<p class="em-only_endmatter-idx1">Muscarinic receptors, 374, 374<span class="endmatter-idx1_italic">f,</span> 375<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Muscle of Riolan, 29, 30<span class="endmatter-idx1_italic">f,</span> 32<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Mutagens, 217</p>
			<p class="em-only_endmatter-idx1">Mutations</p>
			<p class="em-only_endmatter-idx2">definition of, 182–183, 217</p>
			<p class="em-only_endmatter-idx2">gain of function caused by, 183</p>
			<p class="em-only_endmatter-idx2">missense, 183</p>
			<p class="em-only_endmatter-idx2">nonsense, 183</p>
			<p class="em-only_endmatter-idx2">null, 183</p>
			<p class="em-only_endmatter-idx2">point, 217</p>
			<p class="em-only_endmatter-idx2">polymorphisms versus, 182–183</p>
			<p class="em-only_endmatter-idx2">screening methods for, 189–194, 190–193<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">single base-&#173;pair, 183</p>
			<p class="em-only_endmatter-idx1">MVA.&#160;<span class="endmatter-idx1_italic">See</span> Magnetic resonance venography</p>
			<p class="em-only_endmatter-idx1">Myasthenia gravis</p>
			<p class="em-only_endmatter-idx2">neostigmine methylsulfate for, 381</p>
			<p class="em-only_endmatter-idx2">prostigmine for diagnosis of, 362</p>
			<p class="em-only_endmatter-idx1">Mycophenolate mofetil, 404<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Mycoplasma pneumoniae,</span> 427</p>
			<p class="em-only_endmatter-idx1">Mydfrin. <span class="endmatter-idx1_italic">See</span> Phenylephrine hydrochloride</p>
			<p class="em-only_endmatter-idx1">Mydral. <span class="endmatter-idx1_italic">See</span> Tropicamide</p>
			<p class="em-only_endmatter-idx1">Mydriacyl. <span class="endmatter-idx1_italic">See</span> Tropicamide</p>
			<p class="em-only_endmatter-idx1">Mydriasis, 380, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Myelinated nerve fibers, 62</p>
			<p class="em-only_endmatter-idx1">Myopia, vitreous affected by, 301</p>
			<p class="em-only_endmatter-idx1">Myosin VIIA, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Myositis, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Myotonic dystrophy, 218</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx-alpha_italic">N</span>-&#173;retinylidene-&#173;phosphatidylethanolamine, 328</p>
			<p class="em-only_endmatter-idx1">Nabumetone, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">NADH reductase. <span class="endmatter-idx1_italic">See</span> Nicotinamide adenine dinucleotide (NADH) reductase</p>
			<p class="em-only_endmatter-idx1">NADPH. <span class="endmatter-idx1_italic">See</span> Nicotinamide adenine dinucleotide phosphate</p>
			<p class="em-only_endmatter-idx1">Nafcillin, 418</p>
			<p class="em-only_endmatter-idx1">Na<span class="endmatter-idx1_symbol_superscript _idGenCharOverride-1">+</span>,K<span class="endmatter-idx1_symbol_superscript _idGenCharOverride-1">+</span>-&#173;ATPase</p>
			<p class="em-only_endmatter-idx2">description of, 266, 271, 287</p>
			<p class="em-only_endmatter-idx2">in ret&#173;i&#173;nal pigment epithelium, 324</p>
			<p class="em-only_endmatter-idx1">Nalidixic acid, 420</p>
			<p class="em-only_endmatter-idx1">Nanotechnology, for drug delivery, 366–367</p>
			<p class="em-only_endmatter-idx1">Naphazoline hydrochloride, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Naphazoline hydrochloride/antazoline phosphate, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Naphazoline hydrochloride/pheniramine maleate, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Naphcon-&#173;A.&#160;<span class="endmatter-idx1_italic">See</span> Naphazoline hydrochloride/pheniramine maleate</p>
			<p class="em-only_endmatter-idx1">Naproxen, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">NARP. <span class="endmatter-idx1_italic">See</span> Neuropathy, ataxia, and retinitis <br />pigmentosa</p>
			<p class="em-only_endmatter-idx1">Nasal vein, 26<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Nasociliary nerve, 12<span class="endmatter-idx1_italic">f,</span> 132, 132<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Nasofrontal vein, 26<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Nasolacrimal canal, 9</p>
			<p class="em-only_endmatter-idx1">Nasolacrimal duct, 42</p>
			<p class="em-only_endmatter-idx2">anatomy of, 9<span class="endmatter-idx2_italic">f,</span> 11</p>
			<p class="em-only_endmatter-idx2">description of, 8</p>
			<p class="em-only_endmatter-idx1">Natacyn. <span class="endmatter-idx1_italic">See</span> Natamycin</p>
			<p class="em-only_endmatter-idx1">Natamycin, 429, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">NDP,</span> 212</p>
			<p class="em-only_endmatter-idx1">Near reflex, 126</p>
			<p class="em-only_endmatter-idx1">Near synkinesis, 126</p>
			<p class="em-only_endmatter-idx1">Near triad, 126</p>
			<p class="em-only_endmatter-idx1">Nedocromil sodium, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Neisseria</span> spp, 419</p>
			<p class="em-only_endmatter-idx1">Neo-&#173;Synephrine. <span class="endmatter-idx1_italic">See</span> Phenylephrine hydrochloride</p>
			<p class="em-only_endmatter-idx1">Neofrin. <span class="endmatter-idx1_italic">See</span> Phenylephrine hydrochloride</p>
			<p class="em-only_endmatter-idx1">Neomycin sulfate, 418<span class="endmatter-idx1_italic">t,</span> 426</p>
			<p class="em-only_endmatter-idx1">Neomycin sulfate/polymyxin B sulfate/prednisolone acetate, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Neosporin. <span class="endmatter-idx1_italic">See</span> Polymyxin B sulfate/neomycin sulfate/gramicidin</p>
			<p class="em-only_endmatter-idx1">Neostigmine methylsulfate, 381</p>
			<p class="em-only_endmatter-idx1">Nepafenac, 400<span class="endmatter-idx1_italic">t,</span> 410</p>
			<p class="em-only_endmatter-idx1">Nephrogenic systemic fibrosis, 458</p>
			<p class="em-only_endmatter-idx1">Netarsudil, 396</p>
			<p class="em-only_endmatter-idx1">Nettleship-&#173;Falls ocular albinism, 230</p>
			<p class="em-only_endmatter-idx1">Neural crest cells</p>
			<p class="em-only_endmatter-idx2">definition of, 143</p>
			<p class="em-only_endmatter-idx2">ectomesenchymal cells derived from, 162<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">migration of, 146–147<span class="endmatter-idx2_italic">f,</span> 161<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">types of, 144</p>
			<p class="em-only_endmatter-idx1">Neural ret&#173;ina</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">development of, 155, 155<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">lamination of, 155</p>
			<p class="em-only_endmatter-idx1">Neuroectoderm, 149<span class="endmatter-idx1_italic">t</span>, 150<span class="endmatter-idx1_italic">f,</span> 160</p>
			<p class="em-only_endmatter-idx1">Neuroectodermal cells, 157</p>
			<p class="em-only_endmatter-idx1">Neuroendocrine proteins, in aqueous humor, 276</p>
			<p class="em-only_endmatter-idx1">Neurofibromatosis 1</p>
			<p class="em-only_endmatter-idx2">expressivity in, 220</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tics of, 227–228</p>
			<p class="em-only_endmatter-idx1">Neuromuscular blocking drugs, 383<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Neuronal nitric oxide synthase (nNOS), 394</p>
			<p class="em-only_endmatter-idx1">Neurons, ret&#173;i&#173;nal, 315–317, 328</p>
			<p class="em-only_endmatter-idx1">Neuropathy, ataxia, and retinitis pigmentosa, 186</p>
			<p class="em-only_endmatter-idx1">Neuropeptide Y (NPY), 249</p>
			<p class="em-only_endmatter-idx1">Neurosensory ret&#173;ina</p>
			<p class="em-only_endmatter-idx2">cells of, 305</p>
			<p class="em-only_endmatter-idx2">definition of, 84</p>
			<p class="em-only_endmatter-idx2">description of, 83</p>
			<p class="em-only_endmatter-idx2">external limiting membrane of, 91</p>
			<p class="em-only_endmatter-idx2">ganglion cell layer of, 92</p>
			<p class="em-only_endmatter-idx2">glial ele&#173;ments of, 88</p>
			<p class="em-only_endmatter-idx2">inner nuclear layer of, 92</p>
			<p class="em-only_endmatter-idx2">inner plexiform layer of, 92</p>
			<p class="em-only_endmatter-idx2">internal limiting membrane of, 92</p>
			<p class="em-only_endmatter-idx2">layers of, 84, 85<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">&#173;middle limiting membrane of, 92</p>
			<p class="em-only_endmatter-idx2">nerve fiber layer of, 92</p>
			<p class="em-only_endmatter-idx2">neuronal ele&#173;ments of, 84–88, 86<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">outer nuclear layer of, 91–92</p>
			<p class="em-only_endmatter-idx2">outer plexiform layer of, 91–92</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium and, 91</p>
			<p class="em-only_endmatter-idx2">stratification of, 91–93, 93<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">vascular ele&#173;ments of, 88–90, 90–91<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Neurotransmitters, 374, 374<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Neurotrophic proteins, in aqueous humor, 276</p>
			<p class="em-only_endmatter-idx1">Nevanac. <span class="endmatter-idx1_italic">See</span> Nepafenac</p>
			<p class="em-only_endmatter-idx1">Nicotinamide adenine dinucleotide (NADH) reductase, 343</p>
			<p class="em-only_endmatter-idx1">Nicotinamide adenine dinucleotide phosphate (NADPH), 311, 336</p>
			<p class="em-only_endmatter-idx1">Nicotinic drugs</p>
			<p class="em-only_endmatter-idx2">antagonists, 382, 383<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">indirect-&#173;acting agonists, 381</p>
			<p class="em-only_endmatter-idx1">Nicotinic receptors, 374, 374<span class="endmatter-idx1_italic">f,</span> 375<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Niemann-&#173;Pick disease, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Nitric oxide (NO), 394–395</p>
			<p class="em-only_endmatter-idx1">Nitric oxide donors, 394–395</p>
			<p class="em-only_endmatter-idx1">Nizoral. <span class="endmatter-idx1_italic">See</span> Ketoconazole</p>
			<p class="em-only_endmatter-idx1">nNOS. <span class="endmatter-idx1_italic">See</span> Neuronal nitric oxide synthase</p>
			<p class="em-only_endmatter-idx1">NO.&#160;<span class="endmatter-idx1_italic">See</span> Nitric oxide</p>
			<p class="em-only_endmatter-idx1">Noncoding&#160;DNA, 177–178</p>
			<p class="em-only_endmatter-idx1">Noncompliance, 373, 373<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Nondepolarizing agents, 382</p>
			<p class="em-only_endmatter-idx1">Nondisjunction</p>
			<p class="em-only_endmatter-idx2">meiotic, 223</p>
			<p class="em-only_endmatter-idx2">mitotic, 224</p>
			<p class="em-only_endmatter-idx1">Nonhomologous chromosomes, 216</p>
			<p class="em-only_endmatter-idx1">Noninvasive prenatal screening, 239</p>
			<p class="em-only_endmatter-idx1">Nonpenetrance, 219</p>
			<p class="em-only_endmatter-idx1">Nonpigmented epithelium</p>
			<p class="em-only_endmatter-idx2">definition of, 270</p>
			<p class="em-only_endmatter-idx2">tight junctions of, 270, 275</p>
			<p class="em-only_endmatter-idx1">Nonsense mutations, 183</p>
			<p class="em-only_endmatter-idx1">Nonsteroidal anti-&#173;inflammatory drugs (NSAIDs). <span class="endmatter-idx1_italic">See also specific drugs</span></p>
			<p class="em-only_endmatter-idx2">corneal complications of, 411</p>
			<p class="em-only_endmatter-idx2">cyclooxygenase inhibition by, 409</p>
			<p class="em-only_endmatter-idx2">cystoid macular edema treated with, 410</p>
			<p class="em-only_endmatter-idx2">derivatives of, 407–409</p>
			<p class="em-only_endmatter-idx2">types of, 400<span class="endmatter-idx2_italic">t,</span> 409<span class="endmatter-idx2_italic">t,</span> 409–411</p>
			<p class="em-only_endmatter-idx1">Norflox. <span class="endmatter-idx1_italic">See</span> Norfloxacin</p>
			<p class="em-only_endmatter-idx1">Norfloxacin, 421<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Norrie disease, 212</p>
			<p class="em-only_endmatter-idx1">Novocain. <span class="endmatter-idx1_italic">See</span> Procaine</p>
			<p class="em-only_endmatter-idx1">NPE.&#160;<span class="endmatter-idx1_italic">See</span> Nonpigmented epithelium</p>
			<p class="em-only_endmatter-idx1">NPY. <span class="endmatter-idx1_italic">See</span> Neuropeptide Y</p>
			<p class="em-only_endmatter-idx1">Nrf2. <span class="endmatter-idx1_italic">See</span> Nuclear &#173;factor erythroid 2–&#173;related &#173;factor</p>
			<p class="em-only_endmatter-idx1">Nrl, 155</p>
			<p class="em-only_endmatter-idx1">NSAIDs. <span class="endmatter-idx1_italic">See</span> Nonsteroidal anti-&#173;inflammatory drugs</p>
			<p class="em-only_endmatter-idx1">Nuclear &#173;factor erythroid 2–&#173;related &#173;factor (Nrf2), 338</p>
			<p class="em-only_endmatter-idx1">Nucleic acids, in ret&#173;i&#173;nal pigment epithelium, 324</p>
			<p class="em-only_endmatter-idx1">Nucleotides, 176</p>
			<p class="em-only_endmatter-idx1">Null allele, 194</p>
			<p class="em-only_endmatter-idx1">Null mutations, 183</p>
			<p class="em-only_endmatter-idx1">Nystagmus, 475<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ocriplasmin, 304</p>
			<p class="em-only_endmatter-idx1">Ocu-&#173;Dex. <span class="endmatter-idx1_italic">See</span> Dexamethasone sodium phosphate</p>
			<p class="em-only_endmatter-idx1">Ocufen. <span class="endmatter-idx1_italic">See</span> Flurbiprofen sodium</p>
			<p class="em-only_endmatter-idx1">Ocuflox. <span class="endmatter-idx1_italic">See</span> Ofloxacin</p>
			<p class="em-only_endmatter-idx1">Ocular adnexa</p>
			<p class="em-only_endmatter-idx2">anatomy of, 5–15, 6–15<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">development of, 163, 164<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">extraocular muscles. <span class="endmatter-idx2_italic">See</span> Extraocular muscles</p>
			<p class="em-only_endmatter-idx2">glands of, 30<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">orbit. <span class="endmatter-idx2_italic">See</span> Orbit</p>
			<p class="em-only_endmatter-idx1">Ocular albinism</p>
			<p class="em-only_endmatter-idx2">description of, 78</p>
			<p class="em-only_endmatter-idx2">X-&#173;linked, 230</p>
			<p class="em-only_endmatter-idx1">Ocular decongestants, 416–417</p>
			<p class="em-only_endmatter-idx1">Ocular development</p>
			<p class="em-only_endmatter-idx2">adnexa, 163, 164<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">anterior chamber, 161, 161<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroid, 160–161</p>
			<p class="em-only_endmatter-idx2">ciliary body, 157, 159<span class="endmatter-idx2_italic">f,</span> 160</p>
			<p class="em-only_endmatter-idx2">cornea, 161–162<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">diffusible ligands in, 165–166</p>
			<p class="em-only_endmatter-idx2">embryogenesis in, 143–144, 144–146<span class="endmatter-idx2_italic">f,</span> 148<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">extraocular muscles, 162–163</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic cascades, 164–166</p>
			<p class="em-only_endmatter-idx2">growth &#173;factors in, 165–166</p>
			<p class="em-only_endmatter-idx2">homeobox genes, 164–165</p>
			<p class="em-only_endmatter-idx2">iris, 157, 159–160<span class="endmatter-idx2_italic">f,</span> 160</p>
			<p class="em-only_endmatter-idx2">lacrimal gland, 163</p>
			<p class="em-only_endmatter-idx2">lens, 153–155, 154<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">morphogenic gradients, 164–166</p>
			<p class="em-only_endmatter-idx2">morphogens in, 165</p>
			<p class="em-only_endmatter-idx2">neural crest cell migration in, 146–147<span class="endmatter-idx2_italic">f,</span> 161<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">optic nerve, 156<span class="endmatter-idx2_italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx2">orbit, 164</p>
			<p class="em-only_endmatter-idx2">ret&#173;ina, 155, 155<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium, 157</p>
			<p class="em-only_endmatter-idx2">sclera, 162</p>
			<p class="em-only_endmatter-idx2">timeline of, 148, 150–151<span class="endmatter-idx2_italic">f,</span> 152<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">uvea, 157</p>
			<p class="em-only_endmatter-idx2">vitreous, 157, 158<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ocular drug design, 363–365</p>
			<p class="em-only_endmatter-idx1">Ocular emollients, 415</p>
			<p class="em-only_endmatter-idx1">Ocular foreign bodies, 458</p>
			<p class="em-only_endmatter-idx1">Ocular hypotony, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ocular inserts, 363–364</p>
			<p class="em-only_endmatter-idx1">Ocular pharmacotherapeutics. <span class="endmatter-idx1_italic">See</span> Pharmacotherapeutics</p>
			<p class="em-only_endmatter-idx1">Ocular surgery, anesthetics in, 441–442</p>
			<p class="em-only_endmatter-idx1">Oculocardiac reflex, 130</p>
			<p class="em-only_endmatter-idx1">Oculocutaneous albinism, 78, 215, 229</p>
			<p class="em-only_endmatter-idx1">Oculomotor foramen, 20<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Oculomotor nerve</p>
			<p class="em-only_endmatter-idx2">anatomy of, 108<span class="endmatter-idx2_italic">f,</span> 123–126</p>
			<p class="em-only_endmatter-idx2">extraocular muscles innervated by, 21</p>
			<p class="em-only_endmatter-idx2">fascicular portion of, 124</p>
			<p class="em-only_endmatter-idx2">inferior division of, 125</p>
			<p class="em-only_endmatter-idx2">muscles innervated by, 123</p>
			<p class="em-only_endmatter-idx2">nucleus complex of, 123, 123<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">palsy of, 475<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">subnuclei of, 123</p>
			<p class="em-only_endmatter-idx2">superior division of, 125</p>
			<p class="em-only_endmatter-idx1">Oculomotor nerve palsy, 126</p>
			<p class="em-only_endmatter-idx1">Ocumeter, 389<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ocupress. <span class="endmatter-idx1_italic">See</span> Carteolol hydrochloride</p>
			<p class="em-only_endmatter-idx1">Off-&#173;bipolar cells, 315</p>
			<p class="em-only_endmatter-idx1">Off-&#173;label drug use, 370–371, 371t</p>
			<p class="em-only_endmatter-idx1">Ofloxacin, 421<span class="endmatter-idx1_italic">t,</span> 422</p>
			<p class="em-only_endmatter-idx1">Oguchi disease, 229</p>
			<p class="em-only_endmatter-idx1">Ointments, 358–359</p>
			<p class="em-only_endmatter-idx1">Olfactory bulb, 108<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Olfactory fossa, 460<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Olfactory nerve, 105, 108<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Olfactory tract, 105</p>
			<p class="em-only_endmatter-idx1">Oligodendrocytes, 157</p>
			<p class="em-only_endmatter-idx1">Olopatadine hydrochloride, 413</p>
			<p class="em-only_endmatter-idx1">Omega-3 fatty acids, 250</p>
			<p class="em-only_endmatter-idx1">Omidria, 384</p>
			<p class="em-only_endmatter-idx1">OMIM. <span class="endmatter-idx1_italic">See</span> Online Mendelian Inheritance in Man</p>
			<p class="em-only_endmatter-idx1">Omnipred. <span class="endmatter-idx1_italic">See</span> Prednisolone acetate</p>
			<p class="em-only_endmatter-idx1">On-&#173;bipolar cells, 315–317</p>
			<p class="em-only_endmatter-idx1">“On-&#173;label” prescribing, 370</p>
			<p class="em-only_endmatter-idx1">Oncogenes, 183</p>
			<p class="em-only_endmatter-idx1">ONH.&#160;<span class="endmatter-idx1_italic">See</span> Optic nerve head</p>
			<p class="em-only_endmatter-idx1">ONL.&#160;<span class="endmatter-idx1_italic">See</span> Outer nuclear layer</p>
			<p class="em-only_endmatter-idx1">Online Mendelian Inheritance in Man, 187–188</p>
			<p class="em-only_endmatter-idx1">Opcon-&#173;A.&#160;<span class="endmatter-idx1_italic">See</span> Naphazoline hydrochloride/pheniramine maleate</p>
			<p class="em-only_endmatter-idx1">Open reading frame, 176</p>
			<p class="em-only_endmatter-idx1">Ophthalmic artery</p>
			<p class="em-only_endmatter-idx2">anatomy of, 21, 23<span class="endmatter-idx2_italic">f,</span> 25<span class="endmatter-idx2_italic">f,</span> 106<span class="endmatter-idx2_italic">f,</span> 119</p>
			<p class="em-only_endmatter-idx2">branches of, 21</p>
			<p class="em-only_endmatter-idx1">Ophthalmic viscosurgical devices (OVDs), 360<span class="endmatter-idx1_italic">t,</span> 445</p>
			<p class="em-only_endmatter-idx1">Ophthetic. <span class="endmatter-idx1_italic">See</span> Proparacaine</p>
			<p class="em-only_endmatter-idx1">OPL.&#160;<span class="endmatter-idx1_italic">See</span> Outer plexiform layer</p>
			<p class="em-only_endmatter-idx1">Optic atrophy, in DIDMOAD syndrome, 220</p>
			<p class="em-only_endmatter-idx1">Optic canal</p>
			<p class="em-only_endmatter-idx2">anatomy of, 6<span class="endmatter-idx2_italic">f,</span> 10</p>
			<p class="em-only_endmatter-idx2">computed tomography of, 11<span class="endmatter-idx2_italic">f,</span> 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic chiasm</p>
			<p class="em-only_endmatter-idx2">anatomy of, 108<span class="endmatter-idx2_italic">f,</span> 115–116</p>
			<p class="em-only_endmatter-idx2">blood supply of, 122<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Optic cup, 111</p>
			<p class="em-only_endmatter-idx2">anatomy of, 159<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">formation of, 305</p>
			<p class="em-only_endmatter-idx2">invagination of, 153</p>
			<p class="em-only_endmatter-idx1">Optic cup margin, 159<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic disc, 83</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 110</p>
			<p class="em-only_endmatter-idx2">edema of, 470<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic foramen, 10</p>
			<p class="em-only_endmatter-idx1">Optic nerve</p>
			<p class="em-only_endmatter-idx2">anatomy of, 8, 20<span class="endmatter-idx2_italic">f,</span> 48<span class="endmatter-idx2_italic">f,</span> 109, 109<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">blood supply of, 119–122, 120–122<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">computed tomography of, 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">development of, 156<span class="endmatter-idx2_italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx2">embryologic development of, 156<span class="endmatter-idx2_italic">f,</span> 157</p>
			<p class="em-only_endmatter-idx2">external (dural) sheath of, 114, 114<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">intracanalicular region of, 115</p>
			<p class="em-only_endmatter-idx2">intracranial region of, 115</p>
			<p class="em-only_endmatter-idx2">intraocular region of, 110–113, 111–113<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">intraorbital region of, 113–115, 121</p>
			<p class="em-only_endmatter-idx2">lateral geniculate nucleus of, 116–117<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 459<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">meningeal sheaths of, 114<span class="endmatter-idx2_italic">f,</span> 114–115</p>
			<p class="em-only_endmatter-idx2">meninges of, 115</p>
			<p class="em-only_endmatter-idx2">regional differences in, 110<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">topographic areas of, 109</p>
			<p class="em-only_endmatter-idx2">vascular supply of, 121<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic nerve drusen, 473<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Optic nerve head (ONH), 94</p>
			<p class="em-only_endmatter-idx2">description of, 109</p>
			<p class="em-only_endmatter-idx2">laminar area of, 113</p>
			<p class="em-only_endmatter-idx2">prelaminar area of, 111</p>
			<p class="em-only_endmatter-idx2">retrolaminar area of, 113</p>
			<p class="em-only_endmatter-idx2">schematic repre&#173;sen&#173;ta&#173;tion of, 112<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">size of, 110</p>
			<p class="em-only_endmatter-idx2">spontaneous venous pulsation of, 114</p>
			<p class="em-only_endmatter-idx2">superficial nerve fiber layer of, 111, 113<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic nerve sheath, 459<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Optic neuritis, 474<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Optic neuropathy, 474<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Optic pits, 148</p>
			<p class="em-only_endmatter-idx1">Optic radiations, 116, 118<span class="endmatter-idx1_italic">f,</span> 122<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Optic stalk, 150<span class="endmatter-idx1_italic">f,</span> 157, 165<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Optic tract</p>
			<p class="em-only_endmatter-idx2">anatomy of, 116</p>
			<p class="em-only_endmatter-idx2">blood supply of, 122<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">visual pathways in, 115</p>
			<p class="em-only_endmatter-idx1">Optic vesicles, 148, 165<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Opticin, 298</p>
			<p class="em-only_endmatter-idx1">OptiPranolol. <span class="endmatter-idx1_italic">See</span> Metipranolol hydrochloride</p>
			<p class="em-only_endmatter-idx1">Optivar. <span class="endmatter-idx1_italic">See</span> Azelastine hydrochloride</p>
			<p class="em-only_endmatter-idx1">Ora serrata</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48<span class="endmatter-idx2_italic">f,</span> 99, 100<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 83</p>
			<p class="em-only_endmatter-idx1">Orbicularis oculi muscle</p>
			<p class="em-only_endmatter-idx2">anatomy of, 28<span class="endmatter-idx2_italic">f,</span> 29, 31<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">innervation of, 29</p>
			<p class="em-only_endmatter-idx2">palpebral, 29</p>
			<p class="em-only_endmatter-idx2">pretarsal, 34<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">tarsal, 42</p>
			<p class="em-only_endmatter-idx1">Orbit</p>
			<p class="em-only_endmatter-idx2">anatomy of, 5–15, 6–15<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">arteries of, 23<span class="endmatter-idx2_italic">f,</span> 25<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">bony, 6<span class="endmatter-idx2_italic">f,</span> 6–7</p>
			<p class="em-only_endmatter-idx2">canals of, 6<span class="endmatter-idx2_italic">f,</span> 11</p>
			<p class="em-only_endmatter-idx2">computed tomography of, 11<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">connective tissues of, 45<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">depth of, 5</p>
			<p class="em-only_endmatter-idx2">development of, 164</p>
			<p class="em-only_endmatter-idx2">dimensions of, 5</p>
			<p class="em-only_endmatter-idx2">entrance to, 5</p>
			<p class="em-only_endmatter-idx2">extraocular muscle distribution in, 20</p>
			<p class="em-only_endmatter-idx2">fissures of, 11–12, 11–12<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">foramina of, 10–11</p>
			<p class="em-only_endmatter-idx2">inflammation of</p>
			<p class="em-only_endmatter-idx3">imaging studies for, 476<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">nonsteroidal anti-&#173;inflammatory drugs for, 410</p>
			<p class="em-only_endmatter-idx2">margin of, 7<span class="endmatter-idx2_italic">f,</span> 8</p>
			<p class="em-only_endmatter-idx2">neoplasms of, 470<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">periorbital sinuses and, 12–15</p>
			<p class="em-only_endmatter-idx2">rim of, 8</p>
			<p class="em-only_endmatter-idx2">roof of, 7<span class="endmatter-idx2_italic">f,</span> 8</p>
			<p class="em-only_endmatter-idx2">trauma of, 476<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">tumors of, 476<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">vascular supply and drainage of, 22–26, 23–26<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">veins of, 26<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">vortex veins of, 22, 24<span class="endmatter-idx2_italic">f,</span> 26</p>
			<p class="em-only_endmatter-idx1">Orbital apex, 5, 12<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Orbital cellulitis, 476<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Orbital diseases, 476<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Orbital fat, 28<span class="endmatter-idx1_italic">f,</span> 32, 33<span class="endmatter-idx1_italic">f,</span> 459<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Orbital floor</p>
			<p class="em-only_endmatter-idx2">anatomy of, 8–9, 9<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">fractures of, 9</p>
			<p class="em-only_endmatter-idx2">right, 9–10<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Orbital pseudotumor, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Orbital septum, 28<span class="endmatter-idx1_italic">f,</span> 29, 31</p>
			<p class="em-only_endmatter-idx1">Orbital wall</p>
			<p class="em-only_endmatter-idx2">lateral, 10, 10<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">medial, 8, 9<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">ORF.&#160;<span class="endmatter-idx1_italic">See</span> Open reading frame</p>
			<p class="em-only_endmatter-idx1">Organic anions, in aqueous humor, 274</p>
			<p class="em-only_endmatter-idx1">Ornithine aminotransferase, 314<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Osmitrol. <span class="endmatter-idx1_italic">See</span> Mannitol</p>
			<p class="em-only_endmatter-idx1">Osmotic drugs, 397–398, 398<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ouabain, 287, 330</p>
			<p class="em-only_endmatter-idx1">Outer neuroblastic layer, 155<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Outer nuclear layer, 91–92</p>
			<p class="em-only_endmatter-idx1">Outer plexiform layer (OPL), 91–92</p>
			<p class="em-only_endmatter-idx1">OVDs. <span class="endmatter-idx1_italic">See</span> Ophthalmic viscosurgical devices</p>
			<p class="em-only_endmatter-idx1">Oxaprozin, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Oxidative stress</p>
			<p class="em-only_endmatter-idx2">in age-&#173;related macular degeneration, 345</p>
			<p class="em-only_endmatter-idx2">&#173;causes of, 335</p>
			<p class="em-only_endmatter-idx2">ciliary body and, 269</p>
			<p class="em-only_endmatter-idx2">in diabetic retinopathy, 345</p>
			<p class="em-only_endmatter-idx2">in glaucoma, 345</p>
			<p class="em-only_endmatter-idx2">in vision-&#173;threatening ophthalmic diseases, 343–346</p>
			<p class="em-only_endmatter-idx2">&#173;after vitrectomy, 302</p>
			<p class="em-only_endmatter-idx1">Oxybuprocaine. <span class="endmatter-idx1_italic">See</span> Benoxinate</p>
			<p class="em-only_endmatter-idx1">Oxygen</p>
			<p class="em-only_endmatter-idx2">in aqueous humor, 278</p>
			<p class="em-only_endmatter-idx2">in vitreous, 302, 303<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">p53, 181</p>
			<p class="em-only_endmatter-idx1">Palatine bone, 6<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Palisades of Vogt, 261</p>
			<p class="em-only_endmatter-idx1">Palpebral conjunctiva, 28<span class="endmatter-idx1_italic">f,</span> 36, 37<span class="endmatter-idx1_italic">f,</span> 43</p>
			<p class="em-only_endmatter-idx1">Palpebral fissure, 26, 27<span class="endmatter-idx1_italic">f,</span> 36<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Palpebral lacrimal gland, 39</p>
			<p class="em-only_endmatter-idx1">Pancuronium, 382</p>
			<p class="em-only_endmatter-idx1">Papilledema, 473<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Papillomacular fibers, 87</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">para</span>-&#173;Aminobenzenesulfonamide, 423</p>
			<p class="em-only_endmatter-idx1">Parafovea, 85</p>
			<p class="em-only_endmatter-idx1">Parcaine. <span class="endmatter-idx1_italic">See</span> Proparacaine</p>
			<p class="em-only_endmatter-idx1">Paremyd. <span class="endmatter-idx1_italic">See</span> Hydroxyamphetamine hydrobromide/tropicamide</p>
			<p class="em-only_endmatter-idx1">Parinaud oculoglandular syndrome, 38</p>
			<p class="em-only_endmatter-idx1">Pars plana of ciliary body, 72, 100<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pars plicata of ciliary body, 72, 73<span class="endmatter-idx1_italic">f,</span> 100<span class="endmatter-idx1_italic">f,</span> 472<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">PAX2,</span> mutations of, 179</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">PAX6,</span> 164</p>
			<p class="em-only_endmatter-idx2">in aniridia, 225–226</p>
			<p class="em-only_endmatter-idx2">description of, 179</p>
			<p class="em-only_endmatter-idx2">mutations of, 226</p>
			<p class="em-only_endmatter-idx1">PCAB. <span class="endmatter-idx1_italic">See</span> Pharmacy Compounding Accreditation Board</p>
			<p class="em-only_endmatter-idx1">PCR.&#160;<span class="endmatter-idx1_italic">See</span> Polymerase chain reaction</p>
			<p class="em-only_endmatter-idx1">PE.&#160;<span class="endmatter-idx1_italic">See</span> Pigmented epithelium</p>
			<p class="em-only_endmatter-idx1">Pearson marrow-&#173;pancreas syndrome, 185</p>
			<p class="em-only_endmatter-idx1">Pedigree analy&#173;sis, 200–201, 201<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pegaptanib, 449</p>
			<p class="em-only_endmatter-idx1">Pemirolast potassium, 412<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Penetrance, 219</p>
			<p class="em-only_endmatter-idx1">Penicillin(s), 417–419</p>
			<p class="em-only_endmatter-idx1">Penicillinase-&#173;resistant penicillins, 418</p>
			<p class="em-only_endmatter-idx1">Pentose phosphate pathway, 289</p>
			<p class="em-only_endmatter-idx1">Perfluorocarbon, 360<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Peribulbar anesthesia, 442</p>
			<p class="em-only_endmatter-idx1">Pericytes, 89, 317–318</p>
			<p class="em-only_endmatter-idx1">Perifovea, 97</p>
			<p class="em-only_endmatter-idx1">Periocular injections, 359</p>
			<p class="em-only_endmatter-idx1">Periorbital lacerations, 32</p>
			<p class="em-only_endmatter-idx1">Periorbital sinuses</p>
			<p class="em-only_endmatter-idx2">anatomy of, 12–15</p>
			<p class="em-only_endmatter-idx2">computed tomography of, 14<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">orbit and, 12–15</p>
			<p class="em-only_endmatter-idx1">Periorbital space–occupying lesions, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Peripapillary microangiopathy, 186</p>
			<p class="em-only_endmatter-idx1">Peripheral arterial cascade, 28<span class="endmatter-idx1_italic">f,</span> 34<span class="endmatter-idx1_italic">f,</span> 38</p>
			<p class="em-only_endmatter-idx1">Peripheral cornea, 51</p>
			<p class="em-only_endmatter-idx1">Peripheral vitreous, 296</p>
			<p class="em-only_endmatter-idx1">Peripherin, 308, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Permeability coefficient, 357</p>
			<p class="em-only_endmatter-idx1">Peroxin, 314<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Per&#173;sis&#173;tent fetal vasculature, 293, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Per&#173;sis&#173;tent hyperplastic primary vitreous, 293</p>
			<p class="em-only_endmatter-idx1">Persons with disabilities, referrals for providers of support for, 240</p>
			<p class="em-only_endmatter-idx1">PET-&#173;CT.&#160;<span class="endmatter-idx1_italic">See</span> Positron emission tomography (PET)-&#173;computed tomography</p>
			<p class="em-only_endmatter-idx1">Petroclinoid ligament, 133</p>
			<p class="em-only_endmatter-idx1">PGD.&#160;<span class="endmatter-idx1_italic">See</span> Preimplantation ge&#173;ne&#173;tic diagnosis</p>
			<p class="em-only_endmatter-idx1">PGF<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span><span class="endmatter-idx1_greek_subscript _idGenCharOverride-1">α</span>. <span class="endmatter-idx1_italic">See</span> Prostaglandin&#160;F<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span><span class="endmatter-idx1_greek_subscript _idGenCharOverride-1">α</span></p>
			<p class="em-only_endmatter-idx1">Phagosomes, 99, 323</p>
			<p class="em-only_endmatter-idx1">Phakinin, 285</p>
			<p class="em-only_endmatter-idx1">Phakomatoses, 227–229</p>
			<p class="em-only_endmatter-idx1">Pharmacodynamics, 349–350, 367</p>
			<p class="em-only_endmatter-idx1">Pharmacoge&#173;ne&#173;tics, 233–234, 368</p>
			<p class="em-only_endmatter-idx1">Pharmacogenomics, 368</p>
			<p class="em-only_endmatter-idx1">Pharmacokinetics</p>
			<p class="em-only_endmatter-idx2">definition of, 349–350</p>
			<p class="em-only_endmatter-idx2">topical eyedrops, 355<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pharmacologic princi&#173;ples</p>
			<p class="em-only_endmatter-idx2">in el&#173;derly patients, 351–352</p>
			<p class="em-only_endmatter-idx2">pharmacodynamics, 349–350, 367</p>
			<p class="em-only_endmatter-idx2">pharmacokinetics. <span class="endmatter-idx2_italic">See</span> Pharmacokinetics</p>
			<p class="em-only_endmatter-idx2">pharmacotherapeutics, 349–350</p>
			<p class="em-only_endmatter-idx2">terminology associated with, 349</p>
			<p class="em-only_endmatter-idx2">toxicity, 350–351</p>
			<p class="em-only_endmatter-idx1">Pharmacology, 349</p>
			<p class="em-only_endmatter-idx1">Pharmacotherapeutics. <span class="endmatter-idx1_italic">See also specific drug</span></p>
			<p class="em-only_endmatter-idx2">compliance with, 373</p>
			<p class="em-only_endmatter-idx2">compounded phar&#173;ma&#173;ceu&#173;ti&#173;cals, 372–373</p>
			<p class="em-only_endmatter-idx2">definition of, 349–350</p>
			<p class="em-only_endmatter-idx2">&#173;legal aspects of, 370–371</p>
			<p class="em-only_endmatter-idx2">noncompliance with, 373</p>
			<p class="em-only_endmatter-idx1">Pharmacy Compounding Accreditation Board (PCAB), 372</p>
			<p class="em-only_endmatter-idx1">Phenethicillin, 417</p>
			<p class="em-only_endmatter-idx1">Phenocopy, 218</p>
			<p class="em-only_endmatter-idx1">Phenotype, 218</p>
			<p class="em-only_endmatter-idx1">Phenylephrine hydrochloride</p>
			<p class="em-only_endmatter-idx2">blood pressure affected by, 384</p>
			<p class="em-only_endmatter-idx2">description of, 379, 380<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">intracameral use of, 360<span class="endmatter-idx2_italic">t,</span> 384</p>
			<p class="em-only_endmatter-idx1">Phosphate, in aqueous humor, 274</p>
			<p class="em-only_endmatter-idx1">Phosphatidylcholine, in ret&#173;i&#173;nal pigment epithelium, 324</p>
			<p class="em-only_endmatter-idx1">Phosphatidylethanolamine, in ret&#173;i&#173;nal pigment epithelium, 324</p>
			<p class="em-only_endmatter-idx1">Phosphodiesterase, 308, 310<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Phospholine iodide, 379</p>
			<p class="em-only_endmatter-idx1">Phospholipase&#160;A<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span>, 407, 424</p>
			<p class="em-only_endmatter-idx1">Photo-&#173;oxidation, 337</p>
			<p class="em-only_endmatter-idx1">Photoreceptor(s)</p>
			<p class="em-only_endmatter-idx2">cones. <span class="endmatter-idx2_italic">See</span> Cones</p>
			<p class="em-only_endmatter-idx2">depolarized state of, 308, 309<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">inner segments of, 317, 321</p>
			<p class="em-only_endmatter-idx2">outer segments of, 306, 307<span class="endmatter-idx2_italic">f,</span> 310<span class="endmatter-idx2_italic">f,</span> 321</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal degeneration caused by gene defects in, 312</p>
			<p class="em-only_endmatter-idx2">rods. <span class="endmatter-idx2_italic">See</span> Rod(s)</p>
			<p class="em-only_endmatter-idx1">Photoreceptor cells</p>
			<p class="em-only_endmatter-idx2">anatomy of, 86<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 84</p>
			<p class="em-only_endmatter-idx2">synaptic bodies of, 87<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Phototransduction</p>
			<p class="em-only_endmatter-idx2">cone, 311</p>
			<p class="em-only_endmatter-idx2">definition of, 306</p>
			<p class="em-only_endmatter-idx2">rod, 306–308</p>
			<p class="em-only_endmatter-idx1">Physostigmine, 378<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Phytanoyl-&#173;CoA hydroxylase, 314<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Pigment epithelium–&#173;derived &#173;factor, 332</p>
			<p class="em-only_endmatter-idx1">Pigmented epithelium, 270</p>
			<p class="em-only_endmatter-idx1">Pilocarpine hydrochloride</p>
			<p class="em-only_endmatter-idx2">Adie tonic pupil diagnosed using, 377</p>
			<p class="em-only_endmatter-idx2">characteristics of, 378<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ocular inserts for delivery of, 363</p>
			<p class="em-only_endmatter-idx2">ointment, 378<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">primary open-&#173;angle glaucoma treated with, 377–378</p>
			<p class="em-only_endmatter-idx1">Pineal gland, 116<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Piperacillin sodium, 419</p>
			<p class="em-only_endmatter-idx1">Piroxicam, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Placental growth &#173;factor, 277</p>
			<p class="em-only_endmatter-idx1">Plasma, 273<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Plasma proteins, in aqueous humor, 275–276</p>
			<p class="em-only_endmatter-idx1">Pleiotropism, 220</p>
			<p class="em-only_endmatter-idx1">PLGA. <span class="endmatter-idx1_italic">See</span> Poly(lactic-&#173;<span class="endmatter-idx1_italic">co</span>-&#173;glycolic acid)</p>
			<p class="em-only_endmatter-idx1">Plica semilunaris, 27<span class="endmatter-idx1_italic">f,</span> 44</p>
			<p class="em-only_endmatter-idx1">POAG. <span class="endmatter-idx1_italic">See</span> Primary open-&#173;angle glaucoma</p>
			<p class="em-only_endmatter-idx1">Point mutations, 217</p>
			<p class="em-only_endmatter-idx1">Polar amphiphilic phospholipids, 249</p>
			<p class="em-only_endmatter-idx1">Poly-&#173;Dex. <span class="endmatter-idx1_italic">See</span> Dexamethasone/neomycin sulfate/polymyxin B sulfate</p>
			<p class="em-only_endmatter-idx1">Poly-&#173;Pred. <span class="endmatter-idx1_italic">See</span> Neomycin sulfate/polymyxin B sulfate/prednisolone acetate</p>
			<p class="em-only_endmatter-idx1">Polyallelism, 214</p>
			<p class="em-only_endmatter-idx1">Polyenes, 429, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Polyhexamethylene biguanide, 437</p>
			<p class="em-only_endmatter-idx1">Polyinosinic acid–&#173;polycytidylic acid, 447</p>
			<p class="em-only_endmatter-idx1">Poly(lactic-&#173;<span class="endmatter-idx1_italic">co</span>-&#173;glycolic acid) (PLGA), 360<span class="endmatter-idx1_italic">t,</span> 364</p>
			<p class="em-only_endmatter-idx1">Polymerase chain reaction (PCR)</p>
			<p class="em-only_endmatter-idx2">fluo&#173;rescent, 239</p>
			<p class="em-only_endmatter-idx2">princi&#173;ples of, 186–187</p>
			<p class="em-only_endmatter-idx2">thermal cycling in, 186</p>
			<p class="em-only_endmatter-idx1">Polymorphisms</p>
			<p class="em-only_endmatter-idx2">definition of, 183, 218</p>
			<p class="em-only_endmatter-idx2">mutations versus, 182–183</p>
			<p class="em-only_endmatter-idx2">single-&#173;nucleotide, 182, 193–194, 195<span class="endmatter-idx2_italic">f,</span> 218, 368</p>
			<p class="em-only_endmatter-idx1">Polymyxin B sulfate, 418<span class="endmatter-idx1_italic">t,</span> 427–428</p>
			<p class="em-only_endmatter-idx1">Polymyxin B sulfate/bacitracin zinc, 421<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Polymyxin B sulfate/neomycin sulfate/bacitracin zinc, 421<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Polymyxin B sulfate/neomycin sulfate/gramicidin, 421<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Polymyxin B sulfate/trimethoprim sulfate, 421<span class="endmatter-idx1_italic">t,</span> 427–428</p>
			<p class="em-only_endmatter-idx1">Polyol pathway, 289, 291</p>
			<p class="em-only_endmatter-idx1">PolyPhen, 194</p>
			<p class="em-only_endmatter-idx1">Polytrim. <span class="endmatter-idx1_italic">See</span> Polymyxin B sulfate/trimethoprim sulfate</p>
			<p class="em-only_endmatter-idx1">Polyunsaturated fatty acids (PUFAs), 324, 336–337, 340</p>
			<p class="em-only_endmatter-idx1">Polyvinyl alcohol (PVA), 357</p>
			<p class="em-only_endmatter-idx1">Positional candidate gene screening, 189</p>
			<p class="em-only_endmatter-idx1">Positron emission tomography (PET)-&#173;computed tomography, 454</p>
			<p class="em-only_endmatter-idx1">Posterior ce&#173;re&#173;bral artery, 106<span class="endmatter-idx1_italic">f,</span> 108<span class="endmatter-idx1_italic">f,</span> 139<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior chamber</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48</p>
			<p class="em-only_endmatter-idx2">dimensions of, 49<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior ciliary arteries, 23–24<span class="endmatter-idx1_italic">f,</span> 120</p>
			<p class="em-only_endmatter-idx1">Posterior clinoid, 106<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior colobomas, 153</p>
			<p class="em-only_endmatter-idx1">Posterior communicating artery</p>
			<p class="em-only_endmatter-idx2">anatomy of, 106–107<span class="endmatter-idx2_italic">f,</span> 124, 139<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">aneurysms of, 125</p>
			<p class="em-only_endmatter-idx1">Posterior cornea, 54<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior ethmoidal artery, 23<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior ethmoidal foramen, 6<span class="endmatter-idx1_italic">f,</span> 11</p>
			<p class="em-only_endmatter-idx1">Posterior hyaloid, 296, 296<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior lacrimal crest, 6<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior nonpigmented epithelium of the iris, 159<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Posterior pigmented epithelium, 71–72</p>
			<p class="em-only_endmatter-idx1">Posterior pole, 296–297</p>
			<p class="em-only_endmatter-idx1">Posterior scleritis, 465</p>
			<p class="em-only_endmatter-idx1">Posterior subcapsular cataract, 283</p>
			<p class="em-only_endmatter-idx1">Posterior synechiae, 380</p>
			<p class="em-only_endmatter-idx1">Posterior vitreous detachment (PVD)</p>
			<p class="em-only_endmatter-idx2">description of, 300, 301<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">enzymes that induce, 304</p>
			<p class="em-only_endmatter-idx2">ultrasonographic findings in, 471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Postganglionic fibers, 15</p>
			<p class="em-only_endmatter-idx1">Potassium, in lens, 287</p>
			<p class="em-only_endmatter-idx1">Povidone-&#173;iodine solution, 428</p>
			<p class="em-only_endmatter-idx1">Prader-&#173;Willi syndrome, imprinting abnormalities as cause of, 180–181</p>
			<p class="em-only_endmatter-idx1">Pralidoxime, 379</p>
			<p class="em-only_endmatter-idx1">Precorneal tear film. <span class="endmatter-idx1_italic">See also</span> Tear film</p>
			<p class="em-only_endmatter-idx2">components of, 247</p>
			<p class="em-only_endmatter-idx2">description of, 49–50, 259</p>
			<p class="em-only_endmatter-idx2">functions of, 247</p>
			<p class="em-only_endmatter-idx2">layers of, 247, 248<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Precursor&#160;RNA, 176</p>
			<p class="em-only_endmatter-idx1">Pred-&#173;G.&#160;<span class="endmatter-idx1_italic">See</span> Prednisolone acetate/gentamicin sulfate</p>
			<p class="em-only_endmatter-idx1">Pred Mild. <span class="endmatter-idx1_italic">See</span> Prednisolone acetate</p>
			<p class="em-only_endmatter-idx1">Prednisol. <span class="endmatter-idx1_italic">See</span> Prednisolone sodium phosphate</p>
			<p class="em-only_endmatter-idx1">Prednisolone acetate, 356, 400<span class="endmatter-idx1_italic">t,</span> 402<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Prednisolone acetate/gentamicin sulfate, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Prednisolone acetate/sulfacetamide sodium, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Prednisolone sodium phosphate, 400<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Prednisolone sodium phosphate/sulfacetamide sodium, 422<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Preimplantation ge&#173;ne&#173;tic diagnosis (PGD), 221, 239–240</p>
			<p class="em-only_endmatter-idx1">Prenatal diagnosis, 239</p>
			<p class="em-only_endmatter-idx1">Presbyopia, 75</p>
			<p class="em-only_endmatter-idx1">Preservatives, 351</p>
			<p class="em-only_endmatter-idx1">Primary open-&#173;angle glaucoma (POAG), 233, 345, 377–378, 381, 387</p>
			<p class="em-only_endmatter-idx1">Primary visual cortex, 119, 119<span class="endmatter-idx1_italic">f,</span> 122<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Primary vitreous, 157, 159<span class="endmatter-idx1_italic">f,</span> 297</p>
			<p class="em-only_endmatter-idx1">Primers, 186</p>
			<p class="em-only_endmatter-idx1">Probenecid, 236</p>
			<p class="em-only_endmatter-idx1">Procaine, 438<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Procerus muscle, 31<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Prodrugs, 363</p>
			<p class="em-only_endmatter-idx1">Prolate corner, 48</p>
			<p class="em-only_endmatter-idx1">Prolensa. <span class="endmatter-idx1_italic">See</span> Bromfenac sodium</p>
			<p class="em-only_endmatter-idx1">Proliferative diabetic retinopathy, 301</p>
			<p class="em-only_endmatter-idx1">Proliferative retinopathy</p>
			<p class="em-only_endmatter-idx2">treatment of, 414</p>
			<p class="em-only_endmatter-idx2">ultrasonographic findings in, 471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Proliferative vitreoretinopathy, 332–333</p>
			<p class="em-only_endmatter-idx1">Proparacaine, 439<span class="endmatter-idx1_italic">t,</span> 441</p>
			<p class="em-only_endmatter-idx1">Prophase, 174, 174<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Propine. <span class="endmatter-idx1_italic">See</span> Dipivefrin hydrochloride</p>
			<p class="em-only_endmatter-idx1">Prostaglandin analogues, 269, 393–394, 394<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Prostaglandin-&#173;endoperoxide synthase, 408</p>
			<p class="em-only_endmatter-idx1">Prostaglandin&#160;F<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span><span class="endmatter-idx1_greek_subscript _idGenCharOverride-1">α</span> (PGF<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span><span class="endmatter-idx1_greek_subscript _idGenCharOverride-1">α</span>), 393</p>
			<p class="em-only_endmatter-idx1">Prostaglandin&#160;F<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span><span class="endmatter-idx1_greek_subscript _idGenCharOverride-1">α</span> receptor gene <span class="endmatter-idx1_italic">(PTGFR),</span> 368</p>
			<p class="em-only_endmatter-idx1">Prostaglandin&#160;G<span class="endmatter-idx1_subscript _idGenCharOverride-1">2</span><span class="endmatter-idx1_greek_subscript _idGenCharOverride-1">α</span>, 410</p>
			<p class="em-only_endmatter-idx1">Prostigmine, 362</p>
			<p class="em-only_endmatter-idx1">Protein(s)</p>
			<p class="em-only_endmatter-idx2">in aqueous humor, 275–276</p>
			<p class="em-only_endmatter-idx2">cytoskeletal, 285</p>
			<p class="em-only_endmatter-idx2">in lens, 284–286</p>
			<p class="em-only_endmatter-idx2">membrane, 285</p>
			<p class="em-only_endmatter-idx2">in ret&#173;i&#173;nal pigment epithelium, 323–324</p>
			<p class="em-only_endmatter-idx2">in tear film, 252</p>
			<p class="em-only_endmatter-idx2">in vitreous, 298</p>
			<p class="em-only_endmatter-idx1">Proteinase inhibitors, in aqueous humor, 276</p>
			<p class="em-only_endmatter-idx1">Proteinases, in aqueous humor, 276</p>
			<p class="em-only_endmatter-idx1">Proteoglycans, in cornea, 53</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Proteus</span> spp, 419</p>
			<p class="em-only_endmatter-idx1">Proto-&#173;oncogenes, 183</p>
			<p class="em-only_endmatter-idx1">Pseudocholinesterase, 234, 379</p>
			<p class="em-only_endmatter-idx1">Pseudodominance, 206</p>
			<p class="em-only_endmatter-idx1">Pseudoexfoliation syndrome, single-&#173;nucleotide polymorphisms in, 195<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pseudohermaphrodites, 225</p>
			<p class="em-only_endmatter-idx1">Pseudomembranous colitis, 426</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Pseudomonas aeruginosa,</span> 420, 422</p>
			<p class="em-only_endmatter-idx1">Pseudotumor cerebri, 391</p>
			<p class="em-only_endmatter-idx1">Pterygoid venous plexus, 26<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pterygopalatine fossa, 12, 132</p>
			<p class="em-only_endmatter-idx1">Pterygopalatine ganglion, 12</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">PTGFR. See</span> Prostaglandin F2<span class="endmatter-idx1_greek">α</span> receptor gene</p>
			<p class="em-only_endmatter-idx1">PUFAs. <span class="endmatter-idx1_italic">See</span> Polyunsaturated fatty acids</p>
			<p class="em-only_endmatter-idx1">Punctal plug–&#173;mediated drug delivery, 366</p>
			<p class="em-only_endmatter-idx1">Punctum of canaliculus, 27</p>
			<p class="em-only_endmatter-idx1">Pupil reflexes</p>
			<p class="em-only_endmatter-idx2">light reflex, 126, 127<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">near reflex, 126</p>
			<p class="em-only_endmatter-idx2">pathways for, 126, 127<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Pupillary light reflex, 126, 127<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Purified neurotoxin complex, 443</p>
			<p class="em-only_endmatter-idx1">PVA.&#160;<span class="endmatter-idx1_italic">See</span> Polyvinyl alcohol</p>
			<p class="em-only_endmatter-idx1">PVD.&#160;<span class="endmatter-idx1_italic">See</span> Posterior vitreous detachment</p>
			<p class="em-only_endmatter-idx1">PVR.&#160;<span class="endmatter-idx1_italic">See</span> Proliferative vitreoretinopathy</p>
			<p class="em-only_endmatter-idx1">Quixin. <span class="endmatter-idx-alpha_italic">See</span> Levofloxacin</p>
			<p class="em-only_endmatter-idx1">Rab escort protein 1, 314<span class="endmatter-idx-alpha_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Radial ciliary muscle, 25<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Radial ultrasound biomicroscopy scans, 468–469, 472<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Radiation retinopathy, 346</p>
			<p class="em-only_endmatter-idx1">Ranibizumab, 449</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">ras,</span> 183</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">RB1</span> gene mutations, 227</p>
			<p class="em-only_endmatter-idx1">RBP.&#160;<span class="endmatter-idx1_italic">See</span> Retinol-&#173;binding protein</p>
			<p class="em-only_endmatter-idx1">RCFM. <span class="endmatter-idx1_italic">See</span> Retrocorneal fibrous membrane</p>
			<p class="em-only_endmatter-idx1">RDH.&#160;<span class="endmatter-idx1_italic">See</span> Retinol dehydrogenase</p>
			<p class="em-only_endmatter-idx1">Reactive oxygen species (ROS)</p>
			<p class="em-only_endmatter-idx2">cell protection from, 339</p>
			<p class="em-only_endmatter-idx2">defense mechanisms and, 338–339</p>
			<p class="em-only_endmatter-idx2">description of, 335</p>
			<p class="em-only_endmatter-idx2">detoxification of, 336<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">generation of, 336<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">in glaucoma, 345</p>
			<p class="em-only_endmatter-idx2">oxidative stress caused by, 335</p>
			<p class="em-only_endmatter-idx2">pathways of, 337<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">radiation retinopathy caused by, 346</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal vulnerability to, 340–341</p>
			<p class="em-only_endmatter-idx2">sources of, 336</p>
			<p class="em-only_endmatter-idx2">UV light as source of, 339</p>
			<p class="em-only_endmatter-idx1">Rebamipide, 416</p>
			<p class="em-only_endmatter-idx1">Recessive diseases, 194</p>
			<p class="em-only_endmatter-idx1">Recessive inheritance</p>
			<p class="em-only_endmatter-idx2">autosomal, 203–206</p>
			<p class="em-only_endmatter-idx2">description of, 202–203</p>
			<p class="em-only_endmatter-idx2">X-&#173;linked, 208–209, 209<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Recombination frequency, 188</p>
			<p class="em-only_endmatter-idx1">Red-&#173;green color vision defects, 312</p>
			<p class="em-only_endmatter-idx1">Red-&#173;green color vision deficiency, 232<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">“Red man syndrome,” 427</p>
			<p class="em-only_endmatter-idx1">Red nucleus, 107<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Reflex tearing, 358</p>
			<p class="em-only_endmatter-idx1">Refsum disease, 204<span class="endmatter-idx1_italic">t,</span> 314<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Regional anesthetics, 438<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Repetition time (TR), 457</p>
			<p class="em-only_endmatter-idx1">Replicative segregation, 184</p>
			<p class="em-only_endmatter-idx1">Rescula. <span class="endmatter-idx1_italic">See</span> Unoprostone isopropyl</p>
			<p class="em-only_endmatter-idx1">Residence time, 354</p>
			<p class="em-only_endmatter-idx1">Respiratory burst, 336</p>
			<p class="em-only_endmatter-idx1">Ret&#173;ina</p>
			<p class="em-only_endmatter-idx2">adhesion of, 331–332</p>
			<p class="em-only_endmatter-idx2">anatomy of, 49, 83, 84<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">anomalies of, ultrasonographic findings in, <br />470<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">antioxidant localization in, 344<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">arterioles of, 90</p>
			<p class="em-only_endmatter-idx2">blood vessels of, 90</p>
			<p class="em-only_endmatter-idx2">blood–&#173;retina barrier, 88, 90<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">cells of, 305</p>
			<p class="em-only_endmatter-idx3">amacrine cells, 316</p>
			<p class="em-only_endmatter-idx3">bipolar cells, 315–318, 316<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">classes of, 315–318, 316<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">ganglion cells, 317</p>
			<p class="em-only_endmatter-idx3">glial cells, 317</p>
			<p class="em-only_endmatter-idx3">horizontal cells, 315<span class="endmatter-idx3_italic">f,</span> 316</p>
			<p class="em-only_endmatter-idx3">neurons, 315–317, 328</p>
			<p class="em-only_endmatter-idx3">vascular cells, 317–318</p>
			<p class="em-only_endmatter-idx2">circulation of, 90</p>
			<p class="em-only_endmatter-idx2">development of, 155, 155<span class="endmatter-idx2_italic">f,</span> 306<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">electrophysiology of, 318–319</p>
			<p class="em-only_endmatter-idx2">embryologic development of, 155, 155<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">embryology of, 83</p>
			<p class="em-only_endmatter-idx2">gyrate atrophy of, 204<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">layers of, 89<span class="endmatter-idx2_italic">f,</span> 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 459<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">neural</p>
			<p class="em-only_endmatter-idx3">anatomy of, 48<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">development of, 155, 155<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">lamination of, 155</p>
			<p class="em-only_endmatter-idx2">neurosensory</p>
			<p class="em-only_endmatter-idx3">cells of, 305</p>
			<p class="em-only_endmatter-idx3">definition of, 84</p>
			<p class="em-only_endmatter-idx3">description of, 83</p>
			<p class="em-only_endmatter-idx3">external limiting membrane of, 91</p>
			<p class="em-only_endmatter-idx3">ganglion cell layer of, 92</p>
			<p class="em-only_endmatter-idx3">glial ele&#173;ments of, 88</p>
			<p class="em-only_endmatter-idx3">inner nuclear layer of, 92</p>
			<p class="em-only_endmatter-idx3">inner plexiform layer of, 92</p>
			<p class="em-only_endmatter-idx3">internal limiting membrane of, 92</p>
			<p class="em-only_endmatter-idx3">layers of, 84, 85<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">&#173;middle limiting membrane of, 92</p>
			<p class="em-only_endmatter-idx3">nerve fiber layer of, 92</p>
			<p class="em-only_endmatter-idx3">neuronal ele&#173;ments of, 84–88, 86<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">outer nuclear layer of, 91–92</p>
			<p class="em-only_endmatter-idx3">outer plexiform layer of, 91–92</p>
			<p class="em-only_endmatter-idx3">ret&#173;i&#173;nal pigment epithelium and, 91</p>
			<p class="em-only_endmatter-idx3">stratification of, 91–93, 93<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">vascular ele&#173;ments of, 88–90, 90–91<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">reactive oxygen species vulnerability of, 340–341</p>
			<p class="em-only_endmatter-idx2">“Rim” proteins, 308</p>
			<p class="em-only_endmatter-idx2">thickness of, 93</p>
			<p class="em-only_endmatter-idx2">topography of, 93–97, 96<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">vascular supply of, 155</p>
			<p class="em-only_endmatter-idx2">veins of, 90</p>
			<p class="em-only_endmatter-idx2">visual pathways of, 115</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal break, 471<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal degeneration, gene defects that cause, 312, <br />314<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal detachment</p>
			<p class="em-only_endmatter-idx2">definition of, 98</p>
			<p class="em-only_endmatter-idx2">description of, 93, 331</p>
			<p class="em-only_endmatter-idx2">rhegmatogenous, 332</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal ganglion cells (RGCs), 335</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal organoids, 166–167</p>
			<p class="em-only_endmatter-idx1">Ret&#173;i&#173;nal pigment epithelium (RPE)</p>
			<p class="em-only_endmatter-idx2">anatomy of, 77<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">antioxidants in, 341–343</p>
			<p class="em-only_endmatter-idx2">apical membrane of, 330</p>
			<p class="em-only_endmatter-idx2">autophagy in, 332</p>
			<p class="em-only_endmatter-idx2">basal surface of, 321</p>
			<p class="em-only_endmatter-idx2">biochemical composition of, 323–324</p>
			<p class="em-only_endmatter-idx2">cells of</p>
			<p class="em-only_endmatter-idx3">11-&#173;<span class="endmatter-idx3_italic">cis</span>-&#173;retinal generation by, 326</p>
			<p class="em-only_endmatter-idx3">cytoplasm of, 99</p>
			<p class="em-only_endmatter-idx3">description of, 97</p>
			<p class="em-only_endmatter-idx3">functions of, 98–99</p>
			<p class="em-only_endmatter-idx3">illustration of, 322<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">melanin granules in, 321, 323</p>
			<p class="em-only_endmatter-idx3">Na<span class="endmatter-idx3_symbol_superscript _idGenCharOverride-1">+</span>,K<span class="endmatter-idx3_symbol_superscript _idGenCharOverride-1">+</span>-&#173;ATPase in, 324</p>
			<p class="em-only_endmatter-idx3">number of, 321</p>
			<p class="em-only_endmatter-idx2">choriocapillaris and, 322<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">congenital hypertrophy of, in familial adenomatous polyposis, 201, 202<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">development of, 157, 306<span class="endmatter-idx2_italic">f,</span> 321</p>
			<p class="em-only_endmatter-idx2">in disease, 332–333, 333<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">embryology of, 97</p>
			<p class="em-only_endmatter-idx2">functions of, 97</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic defects in, 332</p>
			<p class="em-only_endmatter-idx2">glucose in, 323</p>
			<p class="em-only_endmatter-idx2">histology of, 329<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">lipids in, 324</p>
			<p class="em-only_endmatter-idx2">melanin pigment in, 331</p>
			<p class="em-only_endmatter-idx2">net ionic fluxes in, 330</p>
			<p class="em-only_endmatter-idx2">neurosensory ret&#173;ina and, 91</p>
			<p class="em-only_endmatter-idx2">nucleic acids in, 324</p>
			<p class="em-only_endmatter-idx2">phagocytosis of shed photoreceptor outer-&#173;segment discs by, 328</p>
			<p class="em-only_endmatter-idx2">phosphatidylcholine in, 324</p>
			<p class="em-only_endmatter-idx2">phosphatidylethanolamine in, 324</p>
			<p class="em-only_endmatter-idx2">physiologic roles of, 324–332, 325<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">pigmentation in, 331</p>
			<p class="em-only_endmatter-idx2">proteins in, 323–324</p>
			<p class="em-only_endmatter-idx2">in ret&#173;i&#173;nal adhesion, 331–332</p>
			<p class="em-only_endmatter-idx2">RPE65 expression in, 324</p>
			<p class="em-only_endmatter-idx2">secretions by, 332</p>
			<p class="em-only_endmatter-idx2">structure of, 321–323</p>
			<p class="em-only_endmatter-idx2">tight junctions in, 85</p>
			<p class="em-only_endmatter-idx2">transport proteins in, 330</p>
			<p class="em-only_endmatter-idx2">vitamin A regeneration in, 326–328, 327<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retinitis pigmentosa</p>
			<p class="em-only_endmatter-idx2">autosomal dominant, 207, 312</p>
			<p class="em-only_endmatter-idx2">autosomal recessive, 312</p>
			<p class="em-only_endmatter-idx2">description of, 180</p>
			<p class="em-only_endmatter-idx2">inheritance patterns for, 207, 211</p>
			<p class="em-only_endmatter-idx2">MAK-&#173;associated, 229</p>
			<p class="em-only_endmatter-idx2">X-&#173;linked, 231<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retinoblastoma</p>
			<p class="em-only_endmatter-idx2">aniridia versus, 226</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tics of, 226–227</p>
			<p class="em-only_endmatter-idx2">hereditary, 226–227</p>
			<p class="em-only_endmatter-idx2">Knudson’s hypothesis and, 227</p>
			<p class="em-only_endmatter-idx2">sporadic, 228</p>
			<p class="em-only_endmatter-idx2">tumorigenesis in, 226</p>
			<p class="em-only_endmatter-idx2">ultrasonographic findings in, 470<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retinoic acid, 166</p>
			<p class="em-only_endmatter-idx1">Retinoid cycle, 326, 327<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retinol, 311</p>
			<p class="em-only_endmatter-idx1">Retinol-&#173;binding protein, 326</p>
			<p class="em-only_endmatter-idx1">Retinol dehydrogenase, 327</p>
			<p class="em-only_endmatter-idx1">Retinopathy of prematurity, 470<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Retrobulbar anesthesia, 442</p>
			<p class="em-only_endmatter-idx1">Retrobulbar meningitis, 114</p>
			<p class="em-only_endmatter-idx1">Retrocorneal fibrous membrane, 267</p>
			<p class="em-only_endmatter-idx1">Retrolaminar area, 113</p>
			<p class="em-only_endmatter-idx1">Retrovir. <span class="endmatter-idx1_italic">See</span> Zidovudine</p>
			<p class="em-only_endmatter-idx1">Reversible cholinesterase inhibitors, 379</p>
			<p class="em-only_endmatter-idx1">Reye syndrome, 410</p>
			<p class="em-only_endmatter-idx1">RGCs. <span class="endmatter-idx1_italic">See</span> Ret&#173;i&#173;nal ganglion cells</p>
			<p class="em-only_endmatter-idx1">Rhegmatogenous ret&#173;i&#173;nal detachment, 332</p>
			<p class="em-only_endmatter-idx1">Rho guanosine triphosphate hydrolase (Rho GTPase), 395</p>
			<p class="em-only_endmatter-idx1">Rho kinase inhibitors, 395–396</p>
			<p class="em-only_endmatter-idx1">Rho kinase (ROCK), 395–396</p>
			<p class="em-only_endmatter-idx1">Rhodopsin, 306–308, 307<span class="endmatter-idx1_italic">f,</span> 326</p>
			<p class="em-only_endmatter-idx1">Rhodopsin kinase, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Rhodopsin <span class="endmatter-idx1_italic">(RHO)</span> gene mutation, 312</p>
			<p class="em-only_endmatter-idx1">Ribosomal&#160;RNA, mitochondrial DNA–&#173;encoded, 184</p>
			<p class="em-only_endmatter-idx1">Ribozymes, 197–198</p>
			<p class="em-only_endmatter-idx1">Riley-&#173;Day syndrome, 204<span class="endmatter-idx1_italic">t,</span> 229</p>
			<p class="em-only_endmatter-idx1">“Rim” proteins, 308</p>
			<p class="em-only_endmatter-idx1">Rimexolone, 400<span class="endmatter-idx1_italic">t,</span> 403</p>
			<p class="em-only_endmatter-idx1">Ripasudil, 396</p>
			<p class="em-only_endmatter-idx1">Rituximab, 406<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">RNA</p>
			<p class="em-only_endmatter-idx2">messenger</p>
			<p class="em-only_endmatter-idx3">description of, 176</p>
			<p class="em-only_endmatter-idx3">intron excision, 179</p>
			<p class="em-only_endmatter-idx3">proteins, 273</p>
			<p class="em-only_endmatter-idx2">precursor, 176</p>
			<p class="em-only_endmatter-idx2">ret&#173;i&#173;nal pigment epithelium synthesis of, 324</p>
			<p class="em-only_endmatter-idx2">ribosomal, mitochondrial DNA-&#173;encoded, 184</p>
			<p class="em-only_endmatter-idx2">short interfering, 198</p>
			<p class="em-only_endmatter-idx2">transfer, mitochondrial DNA-&#173;encoded, 184</p>
			<p class="em-only_endmatter-idx1">ROCK. <span class="endmatter-idx1_italic">See</span> Rho kinase</p>
			<p class="em-only_endmatter-idx1">Rocuronium, 382</p>
			<p class="em-only_endmatter-idx1">Rod(s)</p>
			<p class="em-only_endmatter-idx2">anatomy of, 85, 86<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">cones versus, 306</p>
			<p class="em-only_endmatter-idx2">inner segment of, 85</p>
			<p class="em-only_endmatter-idx2">light effects on, 318, 318<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">neuronal ele&#173;ments of, 88</p>
			<p class="em-only_endmatter-idx2">number of, 84</p>
			<p class="em-only_endmatter-idx2">outer segments of, 98<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">phototransduction of, 306–308</p>
			<p class="em-only_endmatter-idx1">Rod ABC transporter, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Rod cGMP-&#173;gated channel, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Rod cGMP phosphodiesterase, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Rod outer segment protein 1, 308, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Rod transducin, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Romycin. <span class="endmatter-idx1_italic">See</span> Erythromycin</p>
			<p class="em-only_endmatter-idx1">ROS.&#160;<span class="endmatter-idx1_italic">See</span> Reactive oxygen species</p>
			<p class="em-only_endmatter-idx1">Rose bengal, 444</p>
			<p class="em-only_endmatter-idx1">RPE.&#160;<span class="endmatter-idx1_italic">See</span> Ret&#173;i&#173;nal pigment epithelium</p>
			<p class="em-only_endmatter-idx1">RPE65</p>
			<p class="em-only_endmatter-idx2">description of, 324, 333<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">gene therapy &#173;trials with, 196</p>
			<p class="em-only_endmatter-idx2">Leber congenital amaurosis caused by, 196, 333</p>
			<p class="em-only_endmatter-idx1">Rubeosis iridis, 22, 72</p>
			<p class="em-only_endmatter-idx1">S-&#173;cone monochromatism, 232<span class="endmatter-idx-alpha_italic">t</span></p>
			<p class="em-only_endmatter-idx1">S cones, 312</p>
			<p class="em-only_endmatter-idx1">Sandhoff disease, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Sanfilippo syndrome, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Sanger sequencing, 189</p>
			<p class="em-only_endmatter-idx1">Satellites, 177</p>
			<p class="em-only_endmatter-idx1">Sattler layer, 76, 77<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Scheie syndrome, 204<span class="endmatter-idx1_italic">t,</span> 214</p>
			<p class="em-only_endmatter-idx1">Schlemm canal, 161</p>
			<p class="em-only_endmatter-idx2">anatomy of, 61, 64</p>
			<p class="em-only_endmatter-idx2">collector channels from, 64, 67<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">endothelial lining of, 66<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">juxtacanalicular trabecular meshwork and, 65<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">schematic repre&#173;sen&#173;ta&#173;tion of, 67<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Schmidt sign, 232<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Schwalbe line, 55, 59<span class="endmatter-idx1_italic">f,</span> 61, 63, 99</p>
			<p class="em-only_endmatter-idx1">Schwann cells, 157</p>
			<p class="em-only_endmatter-idx1">Schwannomin, 228</p>
			<p class="em-only_endmatter-idx1">Sclera</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48, 48<span class="endmatter-idx2_italic">f,</span> 56–59, 265<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">avascular nature of, 57, 57<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">collagen fibers of, 58–59</p>
			<p class="em-only_endmatter-idx2">composition of, 265<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">development of, 162</p>
			<p class="em-only_endmatter-idx2">emissaria of, 58</p>
			<p class="em-only_endmatter-idx2">episcleral vessels of, 57, 57<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 459<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">rupture of, 57</p>
			<p class="em-only_endmatter-idx2">stroma of, 58</p>
			<p class="em-only_endmatter-idx2">uveal attachment to, 66</p>
			<p class="em-only_endmatter-idx1">Scleral spur, 159<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx2">anatomy of, 59<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">cells of, 62</p>
			<p class="em-only_endmatter-idx2">formation of, 161</p>
			<p class="em-only_endmatter-idx1">Scleral sulcus, internal, 61</p>
			<p class="em-only_endmatter-idx1">Scopolamine hydrobromide, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Seafood allergy, 428</p>
			<p class="em-only_endmatter-idx1">Second-&#173;generation cephalosporins, 419</p>
			<p class="em-only_endmatter-idx1">Secondary vitreous, 157, 158<span class="endmatter-idx1_italic">f,</span> 293</p>
			<p class="em-only_endmatter-idx1">Secretory IgA (sIgA), 252</p>
			<p class="em-only_endmatter-idx1">Segregation, ge&#173;ne&#173;tic, 215–216</p>
			<p class="em-only_endmatter-idx1">Selenium, 341</p>
			<p class="em-only_endmatter-idx1">Selenoprotein&#160;P, 276</p>
			<p class="em-only_endmatter-idx1">Sella turcica, 106<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Semilunar ganglion, 131</p>
			<p class="em-only_endmatter-idx1">Sensorcaine. <span class="endmatter-idx1_italic">See</span> Bupivacaine</p>
			<p class="em-only_endmatter-idx1">Sex chromosomes</p>
			<p class="em-only_endmatter-idx2">aneuploidy of, 223</p>
			<p class="em-only_endmatter-idx2">mosaicism, 225</p>
			<p class="em-only_endmatter-idx1">Sex-&#173;determining region, 208</p>
			<p class="em-only_endmatter-idx1">sflt-1, 259</p>
			<p class="em-only_endmatter-idx1">Shh, 166</p>
			<p class="em-only_endmatter-idx1">Short arm 11 deletion syndrome, 225–226</p>
			<p class="em-only_endmatter-idx1">Short ciliary arteries, 22, 23<span class="endmatter-idx1_italic">f,</span> 120<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Short ciliary nerves, 16, 76</p>
			<p class="em-only_endmatter-idx1">Short interfering RNA, 198</p>
			<p class="em-only_endmatter-idx1">Short interspersed ele&#173;ments, 177</p>
			<p class="em-only_endmatter-idx1">Short posterior ciliary artery, 24<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Sickle cell disease, 214</p>
			<p class="em-only_endmatter-idx1">Sickle cell hemoglobinopathies, 229</p>
			<p class="em-only_endmatter-idx1">sIgA. <span class="endmatter-idx1_italic">See</span> Secretory IgA</p>
			<p class="em-only_endmatter-idx1">Silicone oil, 360<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Simbrinza. <span class="endmatter-idx1_italic">See</span> Brinzolamide/brimonidine tartrate suspension</p>
			<p class="em-only_endmatter-idx1">SINEs. <span class="endmatter-idx1_italic">See</span> Short interspersed ele&#173;ments</p>
			<p class="em-only_endmatter-idx1">Single base-&#173;pair mutations, 183</p>
			<p class="em-only_endmatter-idx1">Single-&#173;gene disorders, 218</p>
			<p class="em-only_endmatter-idx1">Single &#173;nucleotide polymorphisms, 182, 193–194, 195<span class="endmatter-idx1_italic">f,</span> 218, 368</p>
			<p class="em-only_endmatter-idx1">Single-&#173;photon emission computed tomography (SPECT), 454</p>
			<p class="em-only_endmatter-idx1">Singlet oxygen, 337<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">siRNA. <span class="endmatter-idx1_italic">See</span> Short interfering RNA</p>
			<p class="em-only_endmatter-idx1">Sirolimus, 405<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Skipped generation, 207, 219</p>
			<p class="em-only_endmatter-idx1">Skull, 106<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Slow inactivators, 233</p>
			<p class="em-only_endmatter-idx1">SMAS. <span class="endmatter-idx1_italic">See</span> Superficial musculoaponeurotic system</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">SNRPN</span> gene, 180–181</p>
			<p class="em-only_endmatter-idx1">Sodium, in lens, 287</p>
			<p class="em-only_endmatter-idx1">Sodium chloride, 443</p>
			<p class="em-only_endmatter-idx1">Sodium fluorescein, 362, 444</p>
			<p class="em-only_endmatter-idx1">Sodium-&#173;potassium pump, 287, 307, 324</p>
			<p class="em-only_endmatter-idx1">Soluble proteins, in vitreous, 298</p>
			<p class="em-only_endmatter-idx1">Soluble vascular endothelial growth &#173;factor receptor 1, 180</p>
			<p class="em-only_endmatter-idx1">Solutes</p>
			<p class="em-only_endmatter-idx2">low-&#173;molecular-&#173;weight, in vitreous, 298–299</p>
			<p class="em-only_endmatter-idx2">pump–&#173;leak hypothesis of, in lens, 288<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Somatic development, 153<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Sorbitol, 291</p>
			<p class="em-only_endmatter-idx1">Sorbitol pathway, 289</p>
			<p class="em-only_endmatter-idx1">SPECT. <span class="endmatter-idx1_italic">See</span> Single-&#173;photon emission computed tomography</p>
			<p class="em-only_endmatter-idx1">Sphenoid bone</p>
			<p class="em-only_endmatter-idx2">greater wing of, 6–7<span class="endmatter-idx2_italic">f,</span> 9–10<span class="endmatter-idx2_italic">f,</span> 11</p>
			<p class="em-only_endmatter-idx2">lesser wing of, 6–7<span class="endmatter-idx2_italic">f,</span> 11</p>
			<p class="em-only_endmatter-idx1">Sphenoid sinus, 460<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Spherule, 85</p>
			<p class="em-only_endmatter-idx1">Sphingomyelin, 284</p>
			<p class="em-only_endmatter-idx1">Spiral of Tillaux, 99</p>
			<p class="em-only_endmatter-idx1">Spliceosomes, 179</p>
			<p class="em-only_endmatter-idx1">Splicing</p>
			<p class="em-only_endmatter-idx2">alternative, 179</p>
			<p class="em-only_endmatter-idx2">definition of, 179</p>
			<p class="em-only_endmatter-idx1">Sporanox. <span class="endmatter-idx1_italic">See</span> Itraconazole</p>
			<p class="em-only_endmatter-idx1">SRY.&#160;<span class="endmatter-idx1_italic">See</span> Sex-&#173;determining region</p>
			<p class="em-only_endmatter-idx1">Standardization of Uveitis Nomenclature, 66</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Staphylococcus aureus,</span> 420, 422</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Staphylococcus epidermidis,</span> 422</p>
			<p class="em-only_endmatter-idx1">Stargardt disease, 328</p>
			<p class="em-only_endmatter-idx1">Steinert disease, 218</p>
			<p class="em-only_endmatter-idx1">Stem cells</p>
			<p class="em-only_endmatter-idx2">definition of, 166</p>
			<p class="em-only_endmatter-idx2">&#173;human embryonic, 166</p>
			<p class="em-only_endmatter-idx2">induced pluripotent, 166</p>
			<p class="em-only_endmatter-idx1">Stickler syndrome, 302</p>
			<p class="em-only_endmatter-idx1">Strabismus, 44</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Streptococcus epidermidis,</span> 422</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Streptococcus pneumoniae,</span> 422</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Streptococcus viridans,</span> 426</p>
			<p class="em-only_endmatter-idx1">Streptokinase, 445</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">Streptomyces caespitosus,</span> 414</p>
			<p class="em-only_endmatter-idx1">Streptomycin, 426</p>
			<p class="em-only_endmatter-idx1">Striate cortex, 115, 116<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Stroma</p>
			<p class="em-only_endmatter-idx2">choroidal, 77</p>
			<p class="em-only_endmatter-idx2">ciliary body, 73</p>
			<p class="em-only_endmatter-idx2">corneal</p>
			<p class="em-only_endmatter-idx3">anatomy of, 53</p>
			<p class="em-only_endmatter-idx3">composition of, 53, 58</p>
			<p class="em-only_endmatter-idx2">glucose delivery to, 259</p>
			<p class="em-only_endmatter-idx2">iris, 68–69</p>
			<p class="em-only_endmatter-idx2">keratocytes of, 259</p>
			<p class="em-only_endmatter-idx1">Subarachnoid space, 114</p>
			<p class="em-only_endmatter-idx1">Suborbicularis oculi fat, 28<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Subret&#173;i&#173;nal space, 330–331</p>
			<p class="em-only_endmatter-idx1">Substantia nigra, 107<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Succinylcholine, 234, 379, 382</p>
			<p class="em-only_endmatter-idx1">Sugar cataracts, 289–291</p>
			<p class="em-only_endmatter-idx1">Sulfacetamide ophthalmic solutions, 423</p>
			<p class="em-only_endmatter-idx1">Sulfacetamide sodium, 421<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Sulfite oxidase deficiency, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Sulfonamides, 361, 423–424</p>
			<p class="em-only_endmatter-idx1">Sulindac, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Superficial musculoaponeurotic system, <br />134</p>
			<p class="em-only_endmatter-idx1">Superficial nerve fiber layer, 111, 113<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Superficial plexus, 57</p>
			<p class="em-only_endmatter-idx1">Superficial temporal artery, 38</p>
			<p class="em-only_endmatter-idx1">Superior cerebellar artery, 107<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Superior eyelid crease, 27</p>
			<p class="em-only_endmatter-idx1">Superior oblique muscle</p>
			<p class="em-only_endmatter-idx2">anatomy of, 8, 17<span class="endmatter-idx2_italic">f,</span> 20<span class="endmatter-idx2_italic">f,</span> 28<span class="endmatter-idx2_italic">f,</span> 107<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 19<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">innervation of, 21</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">origins of, 18</p>
			<p class="em-only_endmatter-idx1">Superior oblique tendon, 17<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Superior ophthalmic vein, 26<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Superior orbital fissure</p>
			<p class="em-only_endmatter-idx2">anatomy of, 6<span class="endmatter-idx2_italic">f,</span> 11, 106<span class="endmatter-idx2_italic">f,</span> 132</p>
			<p class="em-only_endmatter-idx2">computed tomography of, 11<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Superior punctum, 27</p>
			<p class="em-only_endmatter-idx1">Superior rectus muscle</p>
			<p class="em-only_endmatter-idx2">anatomy of, 17<span class="endmatter-idx2_italic">f,</span> 20<span class="endmatter-idx2_italic">f,</span> 28<span class="endmatter-idx2_italic">f,</span> 107<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 19<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">computed tomography of, 456<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Superior rectus tendon, 17<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Superior turbinate, 14<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Superoxide anion, 337<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Superoxide dismutase, 342</p>
			<p class="em-only_endmatter-idx1">Supraciliary space, 76</p>
			<p class="em-only_endmatter-idx1">Supraorbital artery, 23<span class="endmatter-idx1_italic">f,</span> 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Supraorbital foramen, 7<span class="endmatter-idx1_italic">f,</span> 10–11</p>
			<p class="em-only_endmatter-idx1">Supraorbital notch, 7<span class="endmatter-idx1_italic">f,</span> 8</p>
			<p class="em-only_endmatter-idx1">Supraorbital vein, 26<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Supratrochlear artery, 23<span class="endmatter-idx1_italic">f,</span> 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Supratrochlear nerve, 131</p>
			<p class="em-only_endmatter-idx1">Surface-&#173;active agents, 358</p>
			<p class="em-only_endmatter-idx1">Surface ectoderm, 144, 144<span class="endmatter-idx1_italic">f</span>, 149<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Surfactants, 358</p>
			<p class="em-only_endmatter-idx1">Surgery, anesthetics in, 441–442</p>
			<p class="em-only_endmatter-idx1">Suspension, 349, 356</p>
			<p class="em-only_endmatter-idx1">Sustained-&#173;release drug delivery, 363–365</p>
			<p class="em-only_endmatter-idx1">Sustained-&#173;release oral preparations, 362</p>
			<p class="em-only_endmatter-idx1">Symporters, 271</p>
			<p class="em-only_endmatter-idx1">Synaptic body, 85</p>
			<p class="em-only_endmatter-idx1">Syntenic traits, 217</p>
			<p class="em-only_endmatter-idx1">T-&#173;cell inhibitors, 404<span class="endmatter-idx-alpha_italic">t</span></p>
			<p class="em-only_endmatter-idx1">T1-&#173;weighted images, 457, 460<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">T2-&#173;weighted images, 457–458, 460<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Tachyphylaxis, 389</p>
			<p class="em-only_endmatter-idx1">Tacrolimus, 405<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tafluprost, 363, 393, 394<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Taq polymerase, 186</p>
			<p class="em-only_endmatter-idx1">Tarsal glands, 249</p>
			<p class="em-only_endmatter-idx1">Tarsal plates, 34<span class="endmatter-idx1_italic">f,</span> 35</p>
			<p class="em-only_endmatter-idx1">Tarsus, 28<span class="endmatter-idx1_italic">f,</span> 36</p>
			<p class="em-only_endmatter-idx1">TASS. <span class="endmatter-idx1_italic">See</span> Toxic anterior segment syndrome</p>
			<p class="em-only_endmatter-idx1">Taxon-&#173;specific crystallins, 285</p>
			<p class="em-only_endmatter-idx1">Tay-&#173;Sachs disease</p>
			<p class="em-only_endmatter-idx2">description of, 204<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">ethnic characteristics of, 229</p>
			<p class="em-only_endmatter-idx1">TDF.&#160;<span class="endmatter-idx1_italic">See</span> Testis-&#173;determining &#173;factor</p>
			<p class="em-only_endmatter-idx1">TE.&#160;<span class="endmatter-idx1_italic">See</span> Echo time</p>
			<p class="em-only_endmatter-idx1">Tear(s), artificial, 415</p>
			<p class="em-only_endmatter-idx1">Tear film. <span class="endmatter-idx1_italic">See also</span> Precorneal tear film</p>
			<p class="em-only_endmatter-idx2">antimicrobial components of, 252</p>
			<p class="em-only_endmatter-idx2">aqueous component of, 251–252</p>
			<p class="em-only_endmatter-idx2">components of, 247</p>
			<p class="em-only_endmatter-idx2">cytokines in, 252</p>
			<p class="em-only_endmatter-idx2">description of, 49–50, 247, 259</p>
			<p class="em-only_endmatter-idx2">dysfunction of, 252, 256–258. <span class="endmatter-idx2_italic">See also</span> Dry eye syndrome</p>
			<p class="em-only_endmatter-idx2">electrolytes in, 251</p>
			<p class="em-only_endmatter-idx2">functions of, 247</p>
			<p class="em-only_endmatter-idx2">glucose levels in, 252</p>
			<p class="em-only_endmatter-idx2">growth &#173;factors in, 252</p>
			<p class="em-only_endmatter-idx2">layers of, 247, 248<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">lipid layer of, 249–250, 250<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">matrix metalloproteinase 9 levels in, 252</p>
			<p class="em-only_endmatter-idx2">mucoaqueous layer of, 251–253</p>
			<p class="em-only_endmatter-idx2">nonpolar lipids in, 250<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">osmolarity of, 257</p>
			<p class="em-only_endmatter-idx2">peptide hormones in, 254</p>
			<p class="em-only_endmatter-idx2">polar lipids in, 250<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">properties of, 249<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">proteins in, 252</p>
			<p class="em-only_endmatter-idx2">secretion of, 252–255</p>
			<p class="em-only_endmatter-idx2">solutes of, 252</p>
			<p class="em-only_endmatter-idx2">ste&#173;roid hormones in, 255</p>
			<p class="em-only_endmatter-idx2">thickness of, 248, 249<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tear lake, 248<span class="endmatter-idx1_italic">f,</span> 352</p>
			<p class="em-only_endmatter-idx1">Tear meniscus, 247</p>
			<p class="em-only_endmatter-idx1">Tear reflex pathway, 135</p>
			<p class="em-only_endmatter-idx1">Tear substitutes, for dry eye syndrome, 258</p>
			<p class="em-only_endmatter-idx1">Telomeric&#160;DNA, 178</p>
			<p class="em-only_endmatter-idx1">Telophase, 174, 174<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Temporal lobe, 460<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Tenon capsule</p>
			<p class="em-only_endmatter-idx2">anatomy of, 44, 45<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">functions of, 57</p>
			<p class="em-only_endmatter-idx1">Terson syndrome, 471<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Tertiary vitreous, 157, 158<span class="endmatter-idx1_italic">f,</span> 293</p>
			<p class="em-only_endmatter-idx1">Testis-&#173;determining &#173;factor, 208</p>
			<p class="em-only_endmatter-idx1">Tetracaine, 439<span class="endmatter-idx1_italic">t,</span> 441</p>
			<p class="em-only_endmatter-idx1">Tetracyclines, 424–425</p>
			<p class="em-only_endmatter-idx1">Tetrahydrotriamcinolone, 402<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">TetraVisc. <span class="endmatter-idx1_italic">See</span> Tetracaine</p>
			<p class="em-only_endmatter-idx1">Thalamus, 116<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Thermal cycling, 186</p>
			<p class="em-only_endmatter-idx1">Third-&#173;generation cephalosporins, 420</p>
			<p class="em-only_endmatter-idx1">3<span class="symbol">′</span> untranslated region, 176</p>
			<p class="em-only_endmatter-idx1">Thrombin, 446</p>
			<p class="em-only_endmatter-idx1">Thrombospondin 1, 301</p>
			<p class="em-only_endmatter-idx1">Thymidine kinase, 434</p>
			<p class="em-only_endmatter-idx1">Thymine, 176</p>
			<p class="em-only_endmatter-idx1">Thymoxamine hydrochloride, 387</p>
			<p class="em-only_endmatter-idx1">Thyroid eye disease, 476<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Ticarcillin sodium, 418<span class="endmatter-idx1_italic">t,</span> 419</p>
			<p class="em-only_endmatter-idx1">Tight junctions, 51, 52<span class="endmatter-idx1_italic">f,</span> 270</p>
			<p class="em-only_endmatter-idx1">Timolol hemihydrate, 389<span class="endmatter-idx1_italic">t,</span> 390</p>
			<p class="em-only_endmatter-idx1">Timolol maleate, 389<span class="endmatter-idx1_italic">t,</span> 390</p>
			<p class="em-only_endmatter-idx1">Timoptic, 389<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Timoptic-&#173;XE, 389<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">TIMP3, 333<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tissue inhibitor of metalloproteinase, 332</p>
			<p class="em-only_endmatter-idx1">Tissue plasminogen activator (tPA), 360<span class="endmatter-idx1_italic">t,</span> 371<span class="endmatter-idx1_italic">t,</span> 445</p>
			<p class="em-only_endmatter-idx1">Tobradex. <span class="endmatter-idx1_italic">See</span> Dexamethasone/tobramycin</p>
			<p class="em-only_endmatter-idx1">Tobramycin sulfate, 418<span class="endmatter-idx1_italic">t,</span> 421<span class="endmatter-idx1_italic">t,</span> 425</p>
			<p class="em-only_endmatter-idx1">Tobrasol. <span class="endmatter-idx1_italic">See</span> Tobramycin sulfate</p>
			<p class="em-only_endmatter-idx1">Tobrex. <span class="endmatter-idx1_italic">See</span> Tobramycin sulfate</p>
			<p class="em-only_endmatter-idx1">Tocilizumab, 406<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tolmetin, 409<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tonic cells, 317</p>
			<p class="em-only_endmatter-idx1">Topical anesthetics, 441–442</p>
			<p class="em-only_endmatter-idx1">Topical drugs</p>
			<p class="em-only_endmatter-idx2">absorption of, 355–356</p>
			<p class="em-only_endmatter-idx2">binding of, 358</p>
			<p class="em-only_endmatter-idx2">concentration of, 356–357</p>
			<p class="em-only_endmatter-idx2">eyedrops, 352–358</p>
			<p class="em-only_endmatter-idx2">ionic charge of, 358</p>
			<p class="em-only_endmatter-idx2">lipid solubility of, 357</p>
			<p class="em-only_endmatter-idx2">ointments, 358–359</p>
			<p class="em-only_endmatter-idx2">pH, 358</p>
			<p class="em-only_endmatter-idx2">pharmacokinetics of, 355<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">reflex tearing, 358</p>
			<p class="em-only_endmatter-idx2">retention of, 352–355</p>
			<p class="em-only_endmatter-idx2">solubility of, 356–357</p>
			<p class="em-only_endmatter-idx2">surfactants, 358</p>
			<p class="em-only_endmatter-idx2">viscosity of, 357</p>
			<p class="em-only_endmatter-idx1">Toxic anterior segment syndrome (TASS), 360</p>
			<p class="em-only_endmatter-idx1">Toxicity, 350–351</p>
			<p class="em-only_endmatter-idx1">tPA. <span class="endmatter-idx1_italic">See</span> Tissue plasminogen activator</p>
			<p class="em-only_endmatter-idx1">TR.&#160;<span class="endmatter-idx1_italic">See</span> Repetition time</p>
			<p class="em-only_endmatter-idx1">Trabecular meshwork</p>
			<p class="em-only_endmatter-idx2">aging changes to, 63</p>
			<p class="em-only_endmatter-idx2">anatomy of, 61<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">composition of, 63</p>
			<p class="em-only_endmatter-idx2">corneoscleral, 63–64</p>
			<p class="em-only_endmatter-idx2">juxtacanalicular, 64</p>
			<p class="em-only_endmatter-idx2">layers of, 63</p>
			<p class="em-only_endmatter-idx2">nitric oxide production in, 395</p>
			<p class="em-only_endmatter-idx2">uveal, 63</p>
			<p class="em-only_endmatter-idx1">Trabeculectomy, limbus-&#173;based, 56<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Trabeculocytes, 63</p>
			<p class="em-only_endmatter-idx1">Trait</p>
			<p class="em-only_endmatter-idx2">definition of, 202</p>
			<p class="em-only_endmatter-idx2">dominant, 202–203</p>
			<p class="em-only_endmatter-idx2">recessive, 202</p>
			<p class="em-only_endmatter-idx2">syntenic, 217</p>
			<p class="em-only_endmatter-idx1">Tranexamic acid, 446–447</p>
			<p class="em-only_endmatter-idx1">Transcription &#173;factors, 179</p>
			<p class="em-only_endmatter-idx1">Transducin, 308</p>
			<p class="em-only_endmatter-idx1">Transfer&#160;RNA, mitochondrial DNA-&#173;encoded, 184</p>
			<p class="em-only_endmatter-idx1">Transferrin, in vitreous, 298</p>
			<p class="em-only_endmatter-idx1">Transforming growth &#173;factor <span class="endmatter-idx2_accent">β</span>, 448</p>
			<p class="em-only_endmatter-idx1">Transketolase, 260</p>
			<p class="em-only_endmatter-idx1">Translation, 179</p>
			<p class="em-only_endmatter-idx1">Transthyretin, 326</p>
			<p class="em-only_endmatter-idx1">Transverse facial artery, 38<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Transverse scans, 464–467, 466–467<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">“Trapdoor”-&#173;type fractures, 9</p>
			<p class="em-only_endmatter-idx1">Travatan. <span class="endmatter-idx1_italic">See</span> Travoprost</p>
			<p class="em-only_endmatter-idx1">Travatan&#160;Z.&#160;<span class="endmatter-idx1_italic">See</span> Travoprost</p>
			<p class="em-only_endmatter-idx1">Travoprost, 363, 394<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Travoprost/timolol maleate, 394<span class="endmatter-idx1_italic">t,</span> 397<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Triamcinolone acetonide, 360<span class="endmatter-idx1_italic">t,</span> 371<span class="endmatter-idx1_italic">t,</span> 407, 444</p>
			<p class="em-only_endmatter-idx1">Triazoles, 429–431, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Trifluridine, 432<span class="endmatter-idx1_italic">t,</span> 433</p>
			<p class="em-only_endmatter-idx1">Trigeminal ganglion, 131</p>
			<p class="em-only_endmatter-idx1">Trigeminal nerve</p>
			<p class="em-only_endmatter-idx2">anatomy of, 107–108<span class="endmatter-idx2_italic">f,</span> 128–129</p>
			<p class="em-only_endmatter-idx2">branches of, 107<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">divisions of, 131–133</p>
			<p class="em-only_endmatter-idx2">innervations by, 128, 129<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">intracranial pathway of, 131</p>
			<p class="em-only_endmatter-idx2">main sensory nucleus of, 129–130</p>
			<p class="em-only_endmatter-idx2">mandibular division of, 133</p>
			<p class="em-only_endmatter-idx2">maxillary division of, 132</p>
			<p class="em-only_endmatter-idx2">mesencephalic nucleus of, 129</p>
			<p class="em-only_endmatter-idx2">motor nucleus of, 131</p>
			<p class="em-only_endmatter-idx2">nuclear complex of, 129</p>
			<p class="em-only_endmatter-idx2">ophthalmic division of, 130, 131–132, 132<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">pathways of, 129<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">sensory nucleus of, 129–130</p>
			<p class="em-only_endmatter-idx2">spinal nucleus and tract of, 130–131</p>
			<p class="em-only_endmatter-idx1">Trinucleotides, 176, 178</p>
			<p class="em-only_endmatter-idx1">Trisomy, 222</p>
			<p class="em-only_endmatter-idx1">Trisomy 21</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic errors in, 223</p>
			<p class="em-only_endmatter-idx2">mosaicism, 225</p>
			<p class="em-only_endmatter-idx2">pharmacoge&#173;ne&#173;tics and, 233–234</p>
			<p class="em-only_endmatter-idx1">Trivariant color vision, 312</p>
			<p class="em-only_endmatter-idx1">Trochlea, 17<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Trochlear fossa, 7<span class="endmatter-idx1_italic">f,</span> 8</p>
			<p class="em-only_endmatter-idx1">Trochlear nerve</p>
			<p class="em-only_endmatter-idx2">anatomy of, 12<span class="endmatter-idx2_italic">f,</span> 127–128</p>
			<p class="em-only_endmatter-idx2">extraocular muscles innervated by, 21</p>
			<p class="em-only_endmatter-idx2">fascicles of, 128</p>
			<p class="em-only_endmatter-idx2">palsy of, 475<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tropicacyl. <span class="endmatter-idx1_italic">See</span> Tropicamide</p>
			<p class="em-only_endmatter-idx1">Tropicamide, 380<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tropocollagen, 294</p>
			<p class="em-only_endmatter-idx1">Trusopt Ocumeter Plus. <span class="endmatter-idx1_italic">See</span> Dorzolamide hydrochloride</p>
			<p class="em-only_endmatter-idx1">Trypan blue, 360<span class="endmatter-idx1_italic">t,</span> 444</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">TSC1,</span> 228</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">TSC2,</span> 228</p>
			<p class="em-only_endmatter-idx1">Tuberous sclerosis, 228–229</p>
			<p class="em-only_endmatter-idx1">Tubulin, 285</p>
			<p class="em-only_endmatter-idx1">Tumor necrosis &#173;factor inhibitors, 405<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Tumor suppressor genes</p>
			<p class="em-only_endmatter-idx2">definition of, 183</p>
			<p class="em-only_endmatter-idx2">examples of, 183–184</p>
			<p class="em-only_endmatter-idx1">Tunica vasculosa lentis, 154, 158<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Turner syndrome, 225</p>
			<p class="em-only_endmatter-idx1">2-&#173;hit hypothesis, 184</p>
			<p class="em-only_endmatter-idx1">Tyrosinemia, 204<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">UBM.&#160;<span class="endmatter-idx-alpha_italic">See</span> Ultrasound biomicroscopy</p>
			<p class="em-only_endmatter-idx1">Ultrafiltration, 271</p>
			<p class="em-only_endmatter-idx1">Ultrasound biomicroscopy (UBM)</p>
			<p class="em-only_endmatter-idx2">of anterior chamber, 60<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">axial scans, 468, 471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">characteristics of, 468</p>
			<p class="em-only_endmatter-idx2">ocular anatomy on, 471–472<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">radial scans, 468–469, 472<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Ultrasound/ultrasonography</p>
			<p class="em-only_endmatter-idx2">A-&#173;scan probe, 463<span class="endmatter-idx2_italic">t,</span> 463<span class="endmatter-idx2_italic">f,</span> 463–464</p>
			<p class="em-only_endmatter-idx2">B-&#173;scan</p>
			<p class="em-only_endmatter-idx3">axial scans, 464–465, 464–465<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">dynamic, 467–468, 469<span class="endmatter-idx3_italic">t,</span> 470–471<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">longitudinal scans, 464, 466<span class="endmatter-idx3_italic">f,</span> 468–469<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">probe for, 463<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">tissue-&#173;specific gain setting for, 469<span class="endmatter-idx3_italic">t</span></p>
			<p class="em-only_endmatter-idx3">transverse scans, 464–467, 466–467<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">types of, 464, 465<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx2">definition of, 462</p>
			<p class="em-only_endmatter-idx2">devices for, 462, 463<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">disease-&#173;/disorder-&#173;specific findings, 470–471<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">high-&#173;frequency, 462</p>
			<p class="em-only_endmatter-idx2">indications for, 462</p>
			<p class="em-only_endmatter-idx2">low-&#173;frequency, 462</p>
			<p class="em-only_endmatter-idx2">macula imaging on, 469<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Unoprostone isopropyl, 393, 394<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Upper eyelids</p>
			<p class="em-only_endmatter-idx2">anatomy of, 26</p>
			<p class="em-only_endmatter-idx2">development of, 163, 164<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">muscles of, 33–35</p>
			<p class="em-only_endmatter-idx1">Urea</p>
			<p class="em-only_endmatter-idx2">in aqueous humor, 275</p>
			<p class="em-only_endmatter-idx2">therapeutic uses of, 397–398, 398<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Uric acid, 236</p>
			<p class="em-only_endmatter-idx1">Urinary stones, 392</p>
			<p class="em-only_endmatter-idx1">Urine alkalinization, 392</p>
			<p class="em-only_endmatter-idx1">Urokinase, 445</p>
			<p class="em-only_endmatter-idx1">US Pharmacopeia (USP), 372</p>
			<p class="em-only_endmatter-idx1">Usher syndrome, 234, 313<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">USP. <span class="endmatter-idx2_italic">See</span> US Pharmacopeia</p>
			<p class="em-only_endmatter-idx1">UV light</p>
			<p class="em-only_endmatter-idx2">blockage of, 288<span class="endmatter-idx2_italic">f,</span> 338</p>
			<p class="em-only_endmatter-idx2">definition of, 286</p>
			<p class="em-only_endmatter-idx2">reactive oxygen species from, 339</p>
			<p class="em-only_endmatter-idx1">Uvea</p>
			<p class="em-only_endmatter-idx2">anatomy of, 49, 68<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">choroid. <span class="endmatter-idx2_italic">See</span> Choroid</p>
			<p class="em-only_endmatter-idx2">ciliary body. <span class="endmatter-idx2_italic">See</span> Ciliary body</p>
			<p class="em-only_endmatter-idx2">development of, 157</p>
			<p class="em-only_endmatter-idx2">iris. <span class="endmatter-idx2_italic">See</span> Iris</p>
			<p class="em-only_endmatter-idx2">parts of, 64, 68<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">scleral attachment of, 66</p>
			<p class="em-only_endmatter-idx1">Uveal trabecular meshwork, 63</p>
			<p class="em-only_endmatter-idx1">Uveal tract, 157, 269</p>
			<p class="em-only_endmatter-idx1">Uveitis</p>
			<p class="em-only_endmatter-idx2">anterior, muscarinic antagonists for, 380–381</p>
			<p class="em-only_endmatter-idx2">classification of, 66</p>
			<p class="em-only_endmatter-idx2">immunomodulatory medi&#173;cations for, 404–406<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Uveoscleral pathway, 60</p>
			<p class="em-only_endmatter-idx1">Valacyclovir hydrochloride, 432<span class="endmatter-idx-alpha_italic">t,</span> 435</p>
			<p class="em-only_endmatter-idx1">Valcyte. <span class="endmatter-idx1_italic">See</span> Valganciclovir</p>
			<p class="em-only_endmatter-idx1">Valganciclovir, 432<span class="endmatter-idx1_italic">t,</span> 435</p>
			<p class="em-only_endmatter-idx1">Valtrex&#160;HZV.&#160;<span class="endmatter-idx1_italic">See</span> Valacyclovir hydrochloride</p>
			<p class="em-only_endmatter-idx1">van der Waals forces, 331, 367</p>
			<p class="em-only_endmatter-idx1">Vancomycin, 359, 360<span class="endmatter-idx1_italic">t,</span> 418<span class="endmatter-idx1_italic">t,</span> 426–427</p>
			<p class="em-only_endmatter-idx1">Vascular cells, 317–318</p>
			<p class="em-only_endmatter-idx1">Vascular endothelial growth &#173;factor(s) (VEGF)</p>
			<p class="em-only_endmatter-idx2">in aqueous humor, 277–278</p>
			<p class="em-only_endmatter-idx2">description of, 448–449</p>
			<p class="em-only_endmatter-idx2">VEGF-&#173;A, 259, 278</p>
			<p class="em-only_endmatter-idx2">in vitreous, 301</p>
			<p class="em-only_endmatter-idx1">Vascular endothelial growth &#173;factor receptors</p>
			<p class="em-only_endmatter-idx2">description of, 277</p>
			<p class="em-only_endmatter-idx2">VEGFR-1, 180, 278</p>
			<p class="em-only_endmatter-idx2">VEGFR-2, 278</p>
			<p class="em-only_endmatter-idx2">VEGFR-3, 278</p>
			<p class="em-only_endmatter-idx1">Vasculotropin, 49</p>
			<p class="em-only_endmatter-idx1">Vasoactive intestinal polypeptide (VIP), 249</p>
			<p class="em-only_endmatter-idx1">Vasocidin. <span class="endmatter-idx1_italic">See</span> Prednisolone sodium phosphate/sulfacetamide sodium</p>
			<p class="em-only_endmatter-idx1">Vasocon-&#173;A.&#160;<span class="endmatter-idx1_italic">See</span> Naphazoline hydrochloride/antazoline phosphate</p>
			<p class="em-only_endmatter-idx1">Vasogenic edema, 461<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">VCAID. <span class="endmatter-idx1_italic">See</span> Vitreous cavity–&#173;associated immune deviation</p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">VCAN</span> gene, 297</p>
			<p class="em-only_endmatter-idx1">Vecuronium, 382</p>
			<p class="em-only_endmatter-idx1">VEGF. <span class="endmatter-idx1_italic">See</span> Vascular endothelial growth &#173;factor(s)</p>
			<p class="em-only_endmatter-idx1">Venous sinuses, 136, 138, 138<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vernal conjunctivitis, 252</p>
			<p class="em-only_endmatter-idx1">Versican, 297</p>
			<p class="em-only_endmatter-idx1">Vertebral artery, 108<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vexol. <span class="endmatter-idx1_italic">See</span> Rimexolone</p>
			<p class="em-only_endmatter-idx1">Vfend. <span class="endmatter-idx1_italic">See</span> Voriconazole</p>
			<p class="em-only_endmatter-idx1">Vicious circle theory of dry eye syndrome, 254, 256<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vidarabine monohydrate, 432<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vigamox. <span class="endmatter-idx1_italic">See</span> Moxifloxacin hydrochloride</p>
			<p class="em-only_endmatter-idx1">Vimentin, 285</p>
			<p class="em-only_endmatter-idx1">VIP.&#160;<span class="endmatter-idx1_italic">See</span> Vasoactive intestinal polypeptide</p>
			<p class="em-only_endmatter-idx1">Vira-&#173;A.&#160;<span class="endmatter-idx1_italic">See</span> Vidarabine monohydrate</p>
			<p class="em-only_endmatter-idx1">Viroptic. <span class="endmatter-idx1_italic">See</span> Trifluridine</p>
			<p class="em-only_endmatter-idx1">Viscosity, 357</p>
			<p class="em-only_endmatter-idx1">Visine-&#173;A.&#160;<span class="endmatter-idx1_italic">See</span> Naphazoline hydrochloride/pheniramine maleate</p>
			<p class="em-only_endmatter-idx1">Vision loss, transient, 474<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vistide. <span class="endmatter-idx1_italic">See</span> Cidofovir</p>
			<p class="em-only_endmatter-idx1">Visual cycle, 326, 327<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Visual pathways</p>
			<p class="em-only_endmatter-idx2">anatomy of, 115, 116<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">blood supply of, 119–122, 120–122<span class="endmatter-idx2_italic">f,</span> 121<span class="endmatter-idx2_italic">f,</span> 122<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">vascular supply of, 121<span class="endmatter-idx2_italic">f,</span> 122<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1"><span class="endmatter-idx1_italic">VIT1,</span> 298</p>
			<p class="em-only_endmatter-idx1">Vitamin&#160;A, in ret&#173;i&#173;nal pigment epithelium, 326–328, 327<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vitamin&#160;C.&#160;<span class="endmatter-idx1_italic">See</span> Ascorbate</p>
			<p class="em-only_endmatter-idx1">Vitamin&#160;E, 340, 342, 344<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vitamin supplements, 447</p>
			<p class="em-only_endmatter-idx1">Vitamin therapy, 236</p>
			<p class="em-only_endmatter-idx1">Vitrasert. <span class="endmatter-idx1_italic">See</span> Ganciclovir</p>
			<p class="em-only_endmatter-idx1">Vitrectomy, 302</p>
			<p class="em-only_endmatter-idx1">Vitreolysis, enzymatic, 304</p>
			<p class="em-only_endmatter-idx1">Vitreoret&#173;i&#173;nal interface, 296, 300</p>
			<p class="em-only_endmatter-idx1">Vitreous</p>
			<p class="em-only_endmatter-idx2">age-&#173;related changes in, 278, 300–304</p>
			<p class="em-only_endmatter-idx2">anatomy of, 102<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">as angiogenesis inhibitor, 301</p>
			<p class="em-only_endmatter-idx2">chondroitin sulfate in, 297</p>
			<p class="em-only_endmatter-idx2">collagen fibers in</p>
			<p class="em-only_endmatter-idx3">age-&#173;related breakdown of, 300</p>
			<p class="em-only_endmatter-idx3">description of, 101, 294–297, 295–296<span class="endmatter-idx3_italic">f</span></p>
			<p class="em-only_endmatter-idx3">proteins associated with, 298</p>
			<p class="em-only_endmatter-idx2">composition of, 273<span class="endmatter-idx2_italic">t,</span> 294–300</p>
			<p class="em-only_endmatter-idx2">cortical, 296</p>
			<p class="em-only_endmatter-idx2">development of, 157, 158<span class="endmatter-idx2_italic">f,</span> 293</p>
			<p class="em-only_endmatter-idx2">functions of, 101</p>
			<p class="em-only_endmatter-idx2">ge&#173;ne&#173;tic diseases involving, 302, 304</p>
			<p class="em-only_endmatter-idx2">hemorrhage-&#173;related injury of, 302</p>
			<p class="em-only_endmatter-idx2">hyalocytes in, 299<span class="endmatter-idx2_italic">f,</span> 299–300</p>
			<p class="em-only_endmatter-idx2">hyaluronan in, 297</p>
			<p class="em-only_endmatter-idx2">illustration of, 102<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">inflammation of, 302</p>
			<p class="em-only_endmatter-idx2">liquefaction of, 300–301</p>
			<p class="em-only_endmatter-idx2">low-&#173;molecular-&#173;weight solutes in, 298–299</p>
			<p class="em-only_endmatter-idx2">magnetic resonance imaging of, 459<span class="endmatter-idx2_italic">t,</span> 460<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">myopia effects on, 301</p>
			<p class="em-only_endmatter-idx2">oxygen movement in, 302, 303<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">peripheral, 296</p>
			<p class="em-only_endmatter-idx2">posterior attachments of, 103<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">posterior vitreous detachment, 300, 301<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">primary, 157, 159<span class="endmatter-idx2_italic">f,</span> 293</p>
			<p class="em-only_endmatter-idx2">proteins in, 298</p>
			<p class="em-only_endmatter-idx2">secondary, 157, 158<span class="endmatter-idx2_italic">f,</span> 293</p>
			<p class="em-only_endmatter-idx2">soluble proteins in, 298</p>
			<p class="em-only_endmatter-idx2">tertiary, 157, 158<span class="endmatter-idx2_italic">f,</span> 293</p>
			<p class="em-only_endmatter-idx2">vitrectomy effects on, 302</p>
			<p class="em-only_endmatter-idx2">zonular fibers of, 298</p>
			<p class="em-only_endmatter-idx1">Vitreous base, 101, 102<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Vitreous body, 48, 49<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vitreous cavity</p>
			<p class="em-only_endmatter-idx2">anatomy of, 48</p>
			<p class="em-only_endmatter-idx2">ascorbate in, 302, 303<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">description of, 101</p>
			<p class="em-only_endmatter-idx1">Vitreous cavity–&#173;associated immune deviation, 299</p>
			<p class="em-only_endmatter-idx1">Vitreous humor, 48, 101</p>
			<p class="em-only_endmatter-idx1">Voltaren. <span class="endmatter-idx1_italic">See</span> Diclofenac sodium</p>
			<p class="em-only_endmatter-idx1">von Hippel–Lindau syndrome, 228</p>
			<p class="em-only_endmatter-idx1">von Recklinghausen disease. <span class="endmatter-idx1_italic">See</span> Neurofibromatosis 1</p>
			<p class="em-only_endmatter-idx1">Voretigene neparvovec, 196</p>
			<p class="em-only_endmatter-idx1">Voriconazole, 430<span class="endmatter-idx1_italic">t</span></p>
			<p class="em-only_endmatter-idx1">Vortex veins, 22, 24<span class="endmatter-idx1_italic">f,</span> 26</p>
			<p class="em-only_endmatter-idx1">Vyzulta. <span class="endmatter-idx1_italic">See</span> Lantoprostene bunod</p>
			<p class="em-only_endmatter-idx1">Waardenburg syndrome, 206</p>
			<p class="em-only_endmatter-idx1">Wagner syndrome, 302, 304</p>
			<p class="em-only_endmatter-idx1">WAGR syndrome, 225</p>
			<p class="em-only_endmatter-idx1">Watershed zone, 120</p>
			<p class="em-only_endmatter-idx1">Wear-&#173;and-&#173;tear pigment, 98–99</p>
			<p class="em-only_endmatter-idx1">Whitnall ligament, 28<span class="endmatter-idx1_italic">f,</span> 34–35<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Whitnall tubercle, 10</p>
			<p class="em-only_endmatter-idx1">Whole-&#173;exome sequencing, 189</p>
			<p class="em-only_endmatter-idx1">Whole-&#173;genome shotgun sequencing, 191<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Wilms tumor, aniridia versus, 226</p>
			<p class="em-only_endmatter-idx1">Wilson disease, 235</p>
			<p class="em-only_endmatter-idx1">Wnt, 166</p>
			<p class="em-only_endmatter-idx1">X-&#173;inactivation, 180</p>
			<p class="em-only_endmatter-idx1">X-&#173;linked diseases</p>
			<p class="em-only_endmatter-idx2">gene therapy for, 194</p>
			<p class="em-only_endmatter-idx2">ocular findings in, 232<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">X-&#173;linked inheritance</p>
			<p class="em-only_endmatter-idx2">description of, 208</p>
			<p class="em-only_endmatter-idx2">disorders associated with, 210</p>
			<p class="em-only_endmatter-idx2">dominant, 209, 210<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx2">recessive, 208–209, 209<span class="endmatter-idx2_italic">t</span></p>
			<p class="em-only_endmatter-idx1">X-&#173;linked ocular albinism, 230</p>
			<p class="em-only_endmatter-idx1">Xalacom. <span class="endmatter-idx1_italic">See</span> Latanoprost/timolol maleate</p>
			<p class="em-only_endmatter-idx1">Xalatan. <span class="endmatter-idx1_italic">See</span> Latanoprost</p>
			<p class="em-only_endmatter-idx1">Xeroderma pigmentosum, 181–182</p>
			<p class="em-only_endmatter-idx1">Xibrom. <span class="endmatter-idx1_italic">See</span> Bromfenac sodium</p>
			<p class="em-only_endmatter-idx1">Xylocaine. <span class="endmatter-idx1_italic">See</span> Lidocaine</p>
			<p class="em-only_endmatter-idx1">Y-&#173;shaped suture, 82</p>
			<p class="em-only_endmatter-idx1">Zaditor. <span class="endmatter-idx-alpha_italic">See</span> Ketotifen fumarate</p>
			<p class="em-only_endmatter-idx1">Zeaxanthin, 94</p>
			<p class="em-only_endmatter-idx1">Zidovudine, 432<span class="endmatter-idx1_italic">t,</span> 436</p>
			<p class="em-only_endmatter-idx1">Zinc, in aqueous humor, 274</p>
			<p class="em-only_endmatter-idx1">Zioptan. <span class="endmatter-idx1_italic">See</span> Tafluprost</p>
			<p class="em-only_endmatter-idx1">Zirgan. <span class="endmatter-idx1_italic">See</span> Ganciclovir sodium</p>
			<p class="em-only_endmatter-idx1">Zonulae adherentes, 98</p>
			<p class="em-only_endmatter-idx1">Zonulae occludentes, 98</p>
			<p class="em-only_endmatter-idx1">Zonular fibers</p>
			<p class="em-only_endmatter-idx2">of lens, 82–83, 83<span class="endmatter-idx2_italic">f,</span> 292</p>
			<p class="em-only_endmatter-idx2">ultrasound biomicroscopy of, 472<span class="endmatter-idx2_italic">f</span></p>
			<p class="em-only_endmatter-idx2">of vitreous, 298</p>
			<p class="em-only_endmatter-idx1">Zovirax. <span class="endmatter-idx1_italic">See</span> Acyclovir sodium</p>
			<p class="em-only_endmatter-idx1">Zygomatic bone, 6<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Zygomaticofacial artery, 25<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Zygomaticofacial foramen, 11</p>
			<p class="em-only_endmatter-idx1">Zygomaticotemporal artery, 25<span class="endmatter-idx1_italic">f</span></p>
			<p class="em-only_endmatter-idx1">Zygomaticotemporal foramen, 11</p>
			<p class="em-only_endmatter-idx1">Zygote, 215</p>
			<p class="em-only_endmatter-idx1">Zylet. <span class="endmatter-idx1_italic">See</span> Loteprednol etabonate/tobramycin</p>
			<p class="em-only_endmatter-idx1">Zymar. <span class="endmatter-idx1_italic">See</span> Gatifloxacin</p>
			<p class="em-only_endmatter-idx1">Zymaxid. <span class="endmatter-idx1_italic">See</span> Gatifloxacin</p>
		</div>
	</body>
</html>
